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Abstract 
 
 
 
This thesis is primarily concerned with the enzyme- catalysed synthesis of 
sulfoxides using reductase and dioxygenase enzymes. 
 
Chapter 1 provides an introduction to the topic of redox chemistry with particular 
emphasis on the application of reductase and dioxygenase enzymes in 
organosulfur chemistry. Earlier literature methods for the production of 
enantiopure sulfoxides are reviewed. A brief discussion of the methods used for 
the determination of enantiomeric excess and absolute configuration is provided. 
 
Chapter 2 contains results obtained using a range of whole-cell bacteria each 
using a dimethyl sulfoxide reductase enzyme. The synthesis of a series of racemic 
sulfoxides and the development of appropriate CSPHPLC analytical methods is 
discussed. Kinetic resolutions of a series of sulfoxides have been achieved. 
 
Chapter 3 contains a presentation of results using dioxygenase enzymes as 
biocatalysts for the asymmetric sulfoxidation of dialkyl sulfoxides including 
thioacetal sulfoxides. A new range of monosulfoxides, cis-dihydrodiols and cis-
dihydrodiol sulfoxides have been isolated in enantiopure form. 
 
Chapter 4 is focussed on the application of chiral sulfoxides in synthesis. A new 
chemoenzymatic route to diol sulfoxide enantiomers and the derived enantiopure 
phenols and catechols is discussed. The application of chemically synthesised 
sulfoxide enantiomers in the production of hydroxy sulfoxides is reported. 
 
Chapter 5 provides a full experimental section where the synthesis of sulfides and 
racemic sulfoxides is included. The methods used in the isolation and 
characterisation of bioproducts from the biotransformation are discussed and full 
experimental details given. 
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Chapter 1. Introduction. 
 
Enzymes have been utilised by man in the production of food and drink for 
thousands of years. Even before the industrial revolution, the use of enzymes, found 
in micro-organisms, had been refined and perfected in techniques such as brewing, 
baking and cheese manufacture to name but a few applications. Nowadays it is 
possible to manipulate a whole series of micro-organisms into metabolising a range of 
organic chemicals. What information and benefits will the study of enzyme 
metabolism of organic compounds provide? 
 
- it explains how nature can dispose of xenobiotic compounds, 
- it shows the potential of enzymes  in synthesis, 
- the chiral bioproducts provide a valuable addition to the ‘chiral pool’. 
 
This introductory chapter will discuss certain aspects of metabolism of 
xenobiotics and compare the synthetic potential of some metabolic enzymes with their 
chemical equivalents, in relation to the metabolism of mainly organosulfur and 
aromatic compounds. It will also highlight possible uses for the metabolites. 
 
1.1. Chemoenzymatic synthesis. 
Chemoenzymatic synthesis can be described as a synthesis, using both 
chemical and enzymatic steps. The enzyme-catalysed reactions involving the use of 
pure enzymes or whole cells. A common question is ‘What advantages have enzymes 
over the use of traditional chemical reagents?’ One important advantage nowadays is 
their use in green chemistry or clean synthesis. ‘The challenge for chemists and others 
is to develop new products, processes and services that achieve the societal, economic 
and environmental benefits that are now required. This requires a new approach which 
sets out to reduce the materials and energy intensity of chemical processes and 
products, minimise or eliminate the dispersion of harmful chemicals in the 
environment, maximise the use of renewable resources and extend the durability and 
recyclability of products in a way which increases industrial competitiveness'.
1
 For the 
synthetic chemist, this demands the development of a commercially viable process, 
where all steps are environmentally friendly. Enzymes fit this role perfectly because 
(i) normal enzymatic reactions are carried out in water, (ii) there are generally no 
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waste products produced, and (iii) as biocatalysts their productivity may be higher 
than any chemical catalyst and enzymes are therefore on the whole, reasonably 
inexpensive. A good example of the use of enzymes as an environmentally friendly 
option is provided by a review by H. Danner and R. Braun
2
 showing how certain 
commodity chemicals can be produced using microorganisms to metabolise sugars, as 
a renewable resource, thus further avoiding the consumption of fossil fuels, normally 
used to produce the same commodity chemicals.  
A further benefit of using enzymes in synthesis is that nature has supplied  the 
chemist with an amazing variety of biocatalysts that may catalyse a multitude of 
synthetic steps. It has often been found that a single type of enzyme-catalysed reaction 
would require a multistep chemical synthesis, at great cost and with considerable 
waste production. This is evident from the ability of some enzymes to catalyse 
asymmetric syntheses and kinetic resolutions with a remarkable degree of 
chemoselectivity, regioselectivity and enantioselectivity far exceeding any chemical 
reagent equivalents. 
 
1.2. The importance of chirality in chemistry. 
A large part of modern synthetic chemistry is devoted to chiral synthesis. This 
is mainly due to the needs of the pharmaceutical industry for therapeutic agents, 
containing chiral functionalities. In recent years there has been a growing need for 
single enantiomers of drugs. Perhaps the most infamous chiral drug is thalidomide 1. 
This tragedy occurred in the last century, where thalidomide was marketed as a 
racemate, for treatment of morning sickness.  
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Many thousands of children were born with limb deformities. It was only after 
this disaster that it was discovered that the different enantiomers of thalidomide (S)-1 
and (R)-1 produced completely different biological responses. Enantiomer (S)-1 was 
the main culprit, giving a teratogenic response while enantiomer (R)-1 showed the 
desired sedative effects. 
In organosulfur compounds, the sulfoxide group is often the sole chiral 
moiety. Chiral sulfoxides are becoming more frequently used as new drugs, e.g. the 
ACAT (acyl-CoA cholesterol acyltransferase) inhibitor RP73163
3
 2. In the quest for 
synthetic routes to optically pure sulfoxides, biological methods are becoming more 
widely used. The importance of chiral sulfoxides in synthesis will be discussed later 
in this chapter. 
 
 
1.3. Metabolic enzymes in animals. 
For centuries, and especially after the industrial revolution, humans have 
introduced a wide range of chemicals into the environment. These include medicines, 
herbicides, pesticides, industrial waste and volatile organic compounds, including 
mono- and poly-cyclic aromatic hydrocarbons (PAHs), which are released into our 
environment via the combustion of fossil fuels, oil spills etc. What happens to these 
compounds when they enter a human body?  Are they excreted, or are they absorbed? 
What damage is caused by xenobiotic compounds or their metabolites? 
In mammals (eukaryotes), they are transformed by various enzymes until they 
are sufficiently polar and water soluble to be excreted. Metabolism of this type can be 
considered as two stages, i.e. Phase I and Phase II metabolism. In Phase I metabolism, 
many types of biotransformation can occur to break up and polarise the molecules. 
These include oxidations, reductions or hydrolysis reactions, many of which introduce 
polar groups. Other water-soluble molecules or groups, e.g. monosaccharides and 
peptides, can be used to conjugate with the phase I metabolites (Phase II metabolism). 
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This further increases their solubility in water and therefore their chances of excretion. 
In Phase I mammalian metabolism, monooxygenases (cytochrome P-450 isozymes) 
are the most important enzymes. The cytochrome P-450 monooxygenases (CYP-
450s) are involved in oxidative metabolism and catalyse the addition of molecular 
oxygen to the substrate, with one of the dioxygen atoms going to the substrate and the 
other being reduced to water. The most common types of oxidation catalysed by 
monooxygenases (Scheme 1.1.) include heteroatom oxidation (e.g. sulfide, sulfoxide, 
phosphine and nitrogen oxidation to sulfoxides, sulfones, phosphine 
 
 
 
Scheme 1.1. Common oxidations catalysed by monooxygenases. 
 
oxides, hydroxylamines and N-oxides respectively, Scheme 1.2.), alkyl 
hydroxylation, dealkylation of heteroatoms (includes heteroatom release, Scheme 
1.3.), and Baeyer-Villiger oxidations (ketone to esters). When aromatic systems, such 
as PAHs, are metabolised, monooxygenases will oxidise the rings to epoxides (arene  
oxides) which isomerise to phenols.  
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Scheme 1.2. Heteroatom oxidation catalysed by monooxygenases. 
 
 
 
Scheme 1.3. Alkyl hydroxylation catalysed by monooxygenases. 
 
 
 
Scheme 1.4. Arene oxide formation and hydrolysis to trans-dihydrodiol 5. 
 
trans-Dihydrodiols are also obtained via the hydrolysis of unstable arene oxides 
(Scheme 1.4.). This was first demonstrated
4
 by the detection of naphthalene-1,2- 
oxide 3 from the metabolism of naphthalene 4 followed by enzyme-catalysed 
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hydrolysis to yield trans-1,2-dihydronaphthalene-1,2-diol 5. Arene oxides of 
quinoline
5 
6, methylbenzoate
6
 7 and more recently of methyl-2-
(trifluoromethyl)benzoate
7
 8 have been isolated. PAH arene oxides are known to be 
initial metabolites leading to diol epoxide carcinogens. 
 
1.4. Redox enzymes in synthesis. 
Applications of oxidoreductase enzymes are extremely important in 
metabolism.  Within this category, monooxygenases, dioxygenases, dehydrogenases 
and reductases have all been used as biocatalysts in chemoenzymatic synthesis. In the 
context of this thesis particular emphasis will be placed upon dioxygenases. 
 
1.4.1. Dioxygenases in nature. 
Due to the harmful biological effects of PAHs, found in our environment, 
there has been much interest in studying their metabolism. As cytochrome P-450 
systems are among the most important in animal metabolism, early studies focussed 
around these. Recently the study of metabolism by other oxidative enzymes has 
become more common.  
One of the primary processes for the removal of contaminating PAHs from our 
environment is thought to be via microbial degradation.
8
 The biodegradation of a 
wide range of xenbiotics by microorganisms, has been studied
9
 and it has been 
determined that dioxygenases play a major role in the bacterial catabolism of 
aromatics. Several biocatalytic steps, including the initial oxidation step of PAHs, 
involve dioxygenases. Thus, in the degradation of biphenyl 9 (see Scheme 1.5.) by 
the wild type strain Sphingomonas yanoikuyae B1, as described by Zylstra and Kim,
10
 
the initial step (step 1) involves dioxygenase attack, giving a cis-dihydrodiol 10. 
Dehydrogenation to a catechol 11 (step 2), followed by further dioxygenase-catalysed  
attack (step 3) giving ring cleavage. Subsequent catabolic steps, also involving 
dioxygenases are carried out on the fragments, ultimately leading to acetaldehyde 12 
and pyruvate 13 which then become involved in normal metabolic pathways in the 
bacterium. The initial steps in the metabolism of arenes are similar in some respect to 
the eukaryotic catabolic metabolism of aromatics. (Scheme 1.6.).  
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Scheme 1.5. The bacterial catabolism of biphenyl 9. 
 
Eukaryotic metabolism, involve arene oxide formation as the initial step followed by 
hydrolysis to yield a trans-dihydrodiol. Both arene oxides and trans-dihydrodiols can 
form phenols. The trans-dihydrodiols are also converted to catechols prior to further 
degradation. The initial step in prokaryotic metabolism involves cis-dihydrodiol 
formation, which may be again converted to phenols or catechols. 
 
 
 
Scheme 1.6. Prokaryotic and eukaryotic arene metabolism. 
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1.4.2. Catalytic mechanism of dioxygenases. 
Dioxygenases are known to be multicomponent enzymes, comprising several 
proteins involved in the transport of electrons to the active site, binding of substrate 
and actual biocatalytic oxygenation of the substrate at the active site.
11
 In the case of 
naphthalene dioxygenase (NDO) from Pseudomonas sp. NCIMB 9816-4, an X-ray 
crystal structure has been obtained
12
 (Fig 1.1.). The active part of the enzyme contains 
two domains. One containing an  [Fe2S2] cluster, called a Rieske centre, and the active 
site that is a mononuclear co-ordinated iron (Fig 1.2.). In the Rieske centre, one iron 
atom is co-ordinated by Cys 81 and Cys 101 residues, while the second iron atom is 
co-ordinated by His 83 and His 104 residues. The active site mononuclear iron atom 
is co-ordinated by His 208, His 213, bidentate Asp 362 residues and water. Electrons, 
originating from NADH are passed from the Rieske centre, through Asp 205 residue 
which is hydrogen bonded to both His 104 of the Rieske centre and His 208 of the 
active site, where it has been determined, from 
18
O2 labelling studies, that both atoms 
of molecular oxygen are incorporated into the substrate.
13,14
 The exact mechanism of 
the addition of dioxygen to the substrate is unknown. The mechanism was originally 
thought to involve a dioxetane intermediate
15,16 
(Scheme 1.7.), but there is no 
evidence to support this other than the incorporation of both atoms of O2 from the 
18
O2 studies. It is also now considered that the four membered dioxetane ring is 
unlikely to exist. It would be too unstable due to the ring strain involved, and also the 
loss of aromaticity of the arene substrate. There is now X-ray crystallographic 
evidence available for the existence of an acyclic peroxide intermediate.
14
 A refined 
crystal structure of naphthalene dioxygenase (NDO), obtained from Pseudomonas sp. 
NCIMB 9816-4, grown in the presence of indole 14 derived from the metabolism of 
tryphtophan 15, showed the presence of an indole substrate bound through a peroxide 
bond to an iron atom in the active site (Fig 1.3. & Scheme 1.8.). 
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Fig 1.1. Crystal structure showing active site and Rieske centre of NDO. 
 
 
 
Fig 1.2. Electron transport in NDO. 
Reiske [2Fe-
2S]         
centre 
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e -
site 
!  sub-
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Scheme 1.7. Proposed formation of dioxetane intermediate. 
 
 
Scheme 1.8. Formation of acyclic peroxide intermediate during indigo 16 production. 
 
 
 
Fig 1.3. X-ray structure showing a peroxide intermediate. 
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1.4.3. Types of dioxygenase enzymes.   
To date there have been as many as 40 different dioxygenases identified by 
protein purification and sequence analysis.
17,18
 Different strains of dioxygenase-
containing micro-organisms have been grown using single organic compounds as the 
sole carbon and energy sources. The most common method used for distinguishing 
different dioxygenases is to name them after the carbon source. In this study we have 
been using  TDO (Toluene DiOxygenase) grown on toluene,  NDO (Naphthalene 
DiOxygenase) grown on naphthalene and a BPDO (BiPhenyl DiOxygenase) grown 
on biphenyl as the sole carbon and energy source. TDO was initially purified, 
characterised and classified by Gibson.
13,19,20
 NDO was first isolated from a 
Pseudomonas sp. NCIMB 9816.
21
 Its X-ray structure was however determined from 
NDO isolated from strain NCIMB 9816-4
12
 (Fig 1.1). BPDO was isolated by Gibson 
in 1973
22
 from a Beijerinckia species (B1) and this strain has recently been 
reclassified as Sphingomonas yanoikuyae B1.
23
 For the biotransformations described 
herein Pseudomonas putida UV4 (TDO), Pseudomonas sp. 9816-11 (NDO) and 
Sphingomonas yanoikuyae B8/36 (BPDO) have been used. These strains are mutated 
forms of the wild type strains, where the mutation alters the genome of the micro-
organism in order to prevent the expression of the cis-diol dehydrogenase, in the 
catabolic sequence, thus giving an accumulation of cis-dihydrodiol bioproduct 
(Scheme 1.9.). The NDO and BPDO strains are single mutants which need to be fed 
on a growth medium but also require an inducer in the form of a small organic 
molecule such as salicylic acid or xylene, in order for the dioxygenase to be 
expressed. This inducer molecule binds to a repressor protein, causing it to stimulate 
the transcription and translation of the genetic code for the dioxygenase enzyme. The 
UV4 strain, a commercial strain, is a doubly mutated strain. The initial mutation 
caused the prevention of expression of cis- diol dehydrogenase.  
 
Scheme 1.9. Incomplete metabolism giving accumulation of a cis-dihydrodiol. 
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The second mutation promotes the continuous expression of the dioxygenase by 
altering the bacterial genetic code for the repressor protein so as to stimulate the 
expression of the dioxygenase permanently, without the need for an inducer. 
Therefore the UV4 strain requires only a growth medium and the substrate for a 
biotransformation. The best substrates for these dioxygenases are the carbon sources 
upon which the wild type strains are grown. The enzymes are not restricted to 
metabolising these substrates alone. Many arene substrates with similar shape and size 
to the initial carbon source can be metabolised by differing routes. This is 
demonstrated by the fact that dioxygenases are capable of catalysing benzylic 
hydroxylation, heteroatom oxidation (including chiral sulfoxidation) as well as 
producing many types of aromatic dihydroxylation products from the 
biotransformation of a range of substrates. 
 
1.4.4. Common dioxygenase-catalysed reactions. 
Over 300 cis-diols have been isolated as metabolites from arene substrates. 
These range from monosubstituted aromatics to pentacyclic PAHs, as summarised in 
two recent reviews.
24,25
 The majority of substrates studied are monosubstituted 
benzenes which on metabolism with P. putida UV4 (containing  TDO as biocatalyst) 
yield cis-diols after dihydroxylation- exclusively across the 2,3-bond (see Scheme 
1.10.).   
 
Scheme 1.10. Regiospecific attack by dioxygenases on monosubstituted benzenes. 
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There is only one example of cis-dihydroxylation occurring across the 1,2- bond
26,27
 
i.e. the metabolism of benzoic acid 17 by Alcaligenes eutrophus B9, containing 
BZDO (BenZoate DiOxygenase), to yield cis-cyclohexadiene-1,2-diol-1-carboxylic 
acid 18 (Scheme 1.11.). It has only recently been reported that a 3,4-diol is formed 
during the metabolism of biphenyl with site directed mutants containing NDO.
28 
3,4-
cis-Dihydrodiols have also been synthesised by chemoenzymatic methods from the 
corresponding 2,3-cis-diol bioproducts.
29
  
 
 
Scheme 1.11. Formation of  a 1,2-dihydrodiol 18 by A. eutrophus B9. 
 
1-Bromo-2-iodobenzene 19 was thus metabolised by P. putida UV4 giving (1S,2S)-4-
bromo-3-iodocyclohexa-3,5-diene-1,2-diol 20 in > 98% ee. This was hydrogenolysed 
using a palladium catalyst to give (1S,2R)-4-bromocyclohexa-3,5-diene-1,2-diol 21 in 
65% yield (Scheme 1.12.). 
 
Scheme 1.12. Chemoenzymatic synthesis of the 3,4-cis-diol 21 
 
In addition to aromatic dihydroxylation, dioxygenases have the ability to 
catalyse other reactions such as benzylic hydroxylations, and heteroatom oxidations. 
A good example of heteroatom oxidation by dioxygenases is the production of a range 
of chiral sulfoxides with high ee values from the corresponding sulfides. In several 
cases enantiocomplementarity was observed with different dioxygenases., e.g. 
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sulfoxidation of thioanisole 23 with NDO and TDO from Pseudomonas sp. NCIMB 
8859 and Pseudomonas putida UV4 respectively
30
 (Scheme 1.13.). From use of the 
NDO enzyme the (S) enantiomer of methyl phenyl sulfoxide 24 is formed with an ee 
of 91% and a 33% yield. However, with the TDO the (R) enantiomer is formed 
exclusively in 90% yield. 
 
Scheme 1.13. NDO- and TDO- catalysed sulfoxidation of thioanisole 23. 
 
1.4.5. Dehydrogenases and reductases. 
Dehydrogenases and reductases also play an important role in metabolism. 
They catalyse various reactions such as hydrogenation and dehydrogenation of 
multiple bonds, carbon-heteroatom bond cleavage (e.g. dehalogenation) and 
heteroatom deoxygenation (e.g. sulfoxide reduction to sulfide). 
 
1.4.5.1. cis-Dihydrodiol dehydrogenases. 
Dehydrogenase enzymes such as alcohol dehydrogenase, glyceraldehyde-3-
phosphate dehydrogenase, lactate dehydrogenase and soluble malate dehydrogenase 
are important in metabolism. These enzymes catalyse the oxidations of the 
appropriate alcohol to acetaldehyde, glyceraldehyde-3-phosphate to glyceric acid-1,3-
biphosphate, lactic acid to pyruvic acid and malic acid to oxaloacetic acid 
respectively. The best known alcohol dehydrogenase catalyses the oxidation of 
ethanol to acetaldehyde. In common with many of the well known alcohol 
dehydrogenases, e.g. those isolated from horse liver or yeast, it contains zinc at the 
active site. These enzymes catalyse the loss of 2 e
-
 and 2 H
+
 from an alcohol, 
involving a co-factor, usually NAD,
+
 and releasing an aldehyde  or ketone plus 
NADH + H
+
 (Scheme 1.14.). 
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Scheme 1.14. Enzyme-catalysed oxidation of an alcohol. 
 
An E. coli strain, which expresses the naphthalene cis-dihydrodiol 
dehydrogenase gene (narB) from Rhodococcus sp. NCIMB 112038 strain, has been 
used in the work presented in this thesis.
31
 As shown in Schemes 1.5, 1.6 and 1.9, cis-
dihydrodiol dehydrogenases are involved in prokaryotic arene catabolism. The new 
Escherichia coli strain (narB) has the ability to convert several  cis-dihydrodiols into 
catechols (see Scheme 1.15.). Previously Jeffrey et al
32
 had discovered that 
naphthalene cis-dihydrodiol dehydrogenase (cis-NDD) from P. putida 9816 oxidised 
the dihydrodiol 25 to the corresponding catechol 26 via a non-concerted mechanism, 
similar to the alcohol dehydrogenases, Scheme 1.14. This involves the oxidation of 
one of the hydroxyl groups to give an unstable ketoalcohol intermediate that 
spontaneously tautomerises to the catechol 26 (Scheme 1.16.). Preliminary work has 
shown that the 'narB' enzyme has the ability to dehydrogenate a range of monocyclic 
and polycyclic cis-dihydrodiols, such as naphthalene- cis-1,2-dihydrodiol 25 to 1,2-
dihydroxynaphthalene 26. trans-Dihydrodiols however are not dehydrogenatated by 
this enzyme. 
Scheme 1.15. Enzymatic dehydrogenation of cis-dihydrodiols. 
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Scheme 1.16. Non-concerted formation of a catechol 26 by cis-NDD. 
 
1.4.5.2. DMSO Reductases. 
Bacterial DMSO reductases found in nature play an important part in the 
regulation of dimethyl sulfoxide (DMSO) and dimethyl sulfide (DMS) in the global 
sulfur cycle
33
 (Fig 1.4.). Thus DMSO, formed mainly from photooxidation of volatile 
DMS in the atmosphere, is converted to DMS by means of a deoxygenation reaction, 
catalysed by DMSO reductases found in ocean-dwelling bacteria. 
 This deoxygenation reaction has to date been applied to a small range of 
dialkyl and alkyl aryl sulfoxides, by Hanlon et al.
34 
t-Butylmethyl sulfoxide 27, 
methionine sulfoxide 28 and the alkyl aryl sulfoxide methyl-p-tolyl sulfoxide 29, were 
reduced by whole-cell organisms and purified enzymes. The potential importance of 
reductase enzymes to the synthetic chemist lies in their ability to kinetically resolve a 
sulfoxide racemate. Some DMSO reductases have even been found to catalyse the 
deoxygenation of trimethylamine N-oxide. 
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Fig1.4. The global sulfur cycle. 
 
 The redox center of the enzyme, where the actual deoxygenation occurs is part 
of a cofactor containing a molybdenum atom that is co-ordinated by two pterin 
molecules (molybdopterin cofactor, Fig 1.5.). It is coordinated to the active site of the 
enzyme by an amino acid residue e.g. a serine residue, as observed in the X-ray 
crystal structure for DMSO reductase (Fig 1.6.) obtained from Rhodobacter 
capsulatus by McAlpine et al.
35
 Crystallography studies done on DMSO reductases 
from other strains of bacteria show similar structures.
36-38
 At the active site the 
molybdenum exists in two oxidative states. The reductive process begins with binding 
of DMSO to the reduced Mo
IV
 which is oxidised to Mo
VI 
releasing DMS and leaving 
the extra O + 2 e
-
 atom co-ordinated to the metal centre. The Mo
VI
 then receives 2 e
-
 
from an electron donor (specific cytochrome, differing for each enzyme), allowing the 
regeneration of the Mo
IV
 and releasing an oxygen atom in the form of H2O 
simultaneously. This then allows the binding of another DMSO and repetition of the 
cycle. 
In this study DMSO reductases from intact cells of Rhodobacter capsulatus, 
Escherichia coli, Proteus Vulgaris, have been evaluated. In particular a new 
bacterium, recently isolated from the North Sea, Citrobacter braakwi, as part of a 
collaborative study with the Department of Biological Sciences at the University of 
Warwick. 
 DMSO 
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Metal·molybdopterin cofactor  
(M = Mo;R = AMP, GMP, HMP) 
 
 
 
 
 
 
 
Fig 1.5. Molybdopterin cofactor. 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 1.6. Crystal structure for DMSO reductase from Rhodobacter capsulatus. 
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1.5. Applications of chiral sulfoxides, cis-dihydrodiols and catechols in 
synthesis. 
As this research programme has been directed towards using enzymes to 
create chirality in organosulfur compounds, and applications of the latter, a summary 
of potential uses for chiral sulfoxides and other types of  dioxygenase-derived 
bioproducts from these biotransformations is provided. 
 
1.5.1. Applications of chiral sulfoxides. 
As suggested earlier in the chapter, the chiral sulfoxide functionality can be 
found in many agrochemical and pharmaceutical compounds and improved, or 
alternative, synthetic methods are constantly being sought. 
Chiral sulfoxides themselves are very useful in synthesis and will facilitate 
such reactions as 1) carbanion formation with alkyl sulfoxides, 2) dienophile 
activation with vinyl sulfoxides and 3) pseudo-Michael additions. The sulfoxide is 
also easily converted to other functional groups. The presence of a chiral sulfoxide 
often provides strong stereodirecting power. This was demonstrated by the work 
carried out by Aggarwal et al
39
 where chiral vinyl sulfoxides were used as dienophiles 
in Diels Alder cycloadditions using a range of dienes. The products showed high 
diastereomeric excess values  (> 94% de) and were subsequently converted to ketones 
by reduction and cleavage of the organosulfur portion (Scheme 1.17.). This provides 
a useful  demonstration  of the application of  sulfoxides as chiral auxilaries in 
synthesis  
 
Scheme 1.17. Synthesis of chiral ketones. 
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Sulfoxides are also becoming more widely used as chiral ligands in organometallic 
reactions, such as diethylzinc-assisted alkylation reactions of aromatic aldehydes. 
Another example is the synthesis of a synthon 31 for hypocholestemic agents related 
to mevinic acid, from an optically pure sulfoxide.
40
 An !-carbon on a single 
enantiomer of alkyl aryl sulfoxide was deprotonated in two successive steps to create 
a single diastereoisomer 30 containing new chiral centres. Further steps, including 
cleavage of the sulfoxide, were carried out to give the lactone 31 with 2 new chiral 
centres (Scheme 1.18.).  
 
Scheme 1.18. Use of chiral sulfoxide carbanion in synthesis. 
 
1.5.2. Applications of cis-dihydrodiols. 
 The use of cis-dihydrodiols in the synthesis of natural products has become 
more common over the last decade, and several reviews have been published on the 
topic.
41-45
 Industrial applications of cis-dihydrodiols have also been explored, e.g. 
production of indigo dye. 
 The first reported biologically important molecule synthesised from a cis-
dihydrodiol was racemic pinitol (+/-)-32.
46
 Pinitol 32 was obtained from cis-
cyclohexa-3,5-diene-1,2-diol 33, the dioxygenase-catalysed oxidation product of 
benzene (Scheme 1.19.).  
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Scheme 1.19. Synthesis of racemic pinitol 32. 
 
Hudlicky et al
47
 synthesised pinitol 32 from cis-(1S,2S)-bromo-1,2-dihydrobenzene-
1,2-diol 34 but in enantiopure form. The cis-dihydrodiol metabolites from 
monosubstututed benzenes can be applied to many types of reaction, including 
transfer of chirality to new exocyclic centres. They can undergo reactions such as 
epoxidation of double bonds, cycloadditions, selective hydrogenation of double 
bonds, hydrogenolysis of C-halogen bonds, protection/deprotection of diol 
functionality, osmylation of double bonds, reductive/oxidative ozonolysis of C=C 
bonds, carbene addition, formation of organometallic complexes and substitution of 
halogen atom (Fig 1.7.). 
 
Fig 1.7. Reactions of cis-dihydrodiols. 
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Scheme 1.20. Synthesis of pinitol 32 enantiomers. 
 
These reactions have allowed the synthesis of many natural products, natural product 
analogues, or compounds of pharmacological and biological importance. Pinitols, 
inositiols,
48-51
 conduritols
41,52-54
  and their analogues, e.g. L-chiro-inositol 35 and (-)-
conduritol E 36, are some typical examples which have been synthesised from 
enantiopure cis-diols. 
 
1.5.2.1. Potential applications of cis-dihydrodiols in industry. 
Some cis-dihydrodiols are now commercially available in multigram 
quantities. Inositols synthesised from cis-dihydrodiols are also commerically available 
on a medium scale for natural product research. On a larger scale indigo dye 16 has 
been produced by Genencor International from the NDO-catalysed oxidation of indole 
14 as shown in Scheme 1.8. In the pharmaceutical industry, Indinivir (crixivan) 37, an 
important HIV protease inhibitor developed by Merck, has been synthesised,
55
 by a 
method involving the dioxygenase-catalysed cis-dihydroxylation of indene
56
 38 to 
give (1S,2R)-dihydroxyindan 39. This is converted, by the Ritter reaction, into the 
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amino alcohol (1S,2R)-1-amino-2-hydroxyindan 40, and is then used to construct 
indinavir 37, containing the aminoalcohol moiety. The alternative to this process is 
the Jacobsen epoxidation of indene 38 to give the indene oxide 41 followed by the 
Ritter reaction to give the amino alcohol 40. The advantage of the biological method 
is that the Jacobsen epoxidation
57
 only gives ca: 86% ee whereas the biological 
method produces the enantiopure diol 39 (Scheme 1.21.). 
 
 
 
Scheme 1.21. Industrial synthesis of Indinivir 37. 
 
1.5.3. Catechols. 
Catechols and substituted catechols are components of many natural products 
found in the environment and biologically active molecules in animals. 
Neurotransmitters such as dopamine 42, norepinephrine (noradrenaline) 43 and 
epinephrine (adrenaline) 44 all contain catechol functionalities. 
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Drugs such as the narcotic painkiller morphine 45 or Entacapone 46, marketed 
by Novartis for the treatment of Parkinson's disease, also contain catechol moieties. 
Drugs of abuse such as methylenedioxy methamphetamine (MDMA) 47 also known 
as 'Ecstasy', often contain catechols. 
 
 
  
 
 
A catechol precursor has also been used,
58,59
 in approaches to the syntheses of 
morphine 45. In this approach, catechol 48, and its monomethyl ether derivative 
bromoguiacol 49, were used as synthetic precursors. Catechol 48 has been derived 
from bromobenzene 22 using a tandem biotransformation, i.e. two enzymes in the one 
pot.
60
 This process involves (i) a dioxygenase-catalysed  oxidation of bromobenzene 
22 to give the cis-diol 34, (ii) dehydrogenation with a cis-dihydrodiol dehydrogenase 
enzyme to yield 2,3-dihydroxybromobenzene 48, followed by mono-methylation to 
give the substituted catechol 49 (Scheme 1.22.). 
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Scheme 1.22. Synthesis of morphine 45. 
 
1.6. Synthetic approaches to chiral sulfoxides. 
Non-racemic chiral compounds can be obtained by methods involving 
asymmetric synthesis or various resolution techniques. The asymmetric synthesis 
route involves preferential attack by a reagent on a prochiral face, atom or group to 
give an excess of a single enantiomer. The chirality may be induced by the chiral 
reagent, or by an existing chiral centre on the substrate, forming diastereoisomers in 
varying proportions, which may be separable by chromatographic techniques. The 
kinetic resolution method involves the chemical transformation of enantiomers of a 
racemic mixture at differing rates, leaving an excess of one enantiomer. This will be 
discussed  in greater detail in Chapter 2. 
There are several methods in the literature for the synthesis of chiral 
sulfoxides involving asymmetric synthesis and kinetic resolution. The best known 
methods are those developed by Kagan
61,62
 and Andersen.
63
 
 
(i) The ‘Kagan method’ is an extension of the ‘Sharpless method’ for epoxidation 
of allylic alcohols. It provides a good general method for asymmetric synthesis of 
chiral sulfoxides from prochiral sulfides. Like the Sharpless method, it involves use of 
Ti(OPr
i
)4, tert. butyl hydroperoxide and diethyltartrate. The main difference involves 
addition of 1 mol of H2O to co-ordinate to the Ti atom, replacing the co-ordinating 
hydroxyl in allylic alcohols. The best ee values were obtained using cumene 
hydroperoxide, instead of t-butyl hydroperoxide
64
 (Scheme 1.23.). This method has 
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been successful and is used in the synthesis of the ACAT inhibitor RP 73163
3
 2 and 
potassium channel opener RP 52891
65,66
 50 by Rhône-Poulenc Rorer giving high ee 
values. 
 
 
Scheme 1.23. The Kagan method. 
 
 
 
 
 
 
 
(ii) A second method developed by Kagan, involves formation of cyclic sulfites 
from a chiral diol and SOCl2. This is followed by organometallic addition (usually a 
Grignard reaction) to give sulfinate diastereoisomers that are used in turn to obtain 
enantiomerically pure sulfoxides. Advantages of this method include the possible use 
of different organometallic reagents and the formation o dialkyl sulfoxides. Both 
enantiomers can often be produced since the diastereoisomers are readily separable in 
many cases (Scheme 1.24.). 
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Scheme 1.24. Synthesis of sulfoxide enantiomers from cyclic sulfites. 
 
(iii) The ‘Andersen method’ was the first route available for the synthesis of 
enantiopure sulfoxides and also involves the formation and separation of a mixture of 
diastereoisomers. These were formed by reacting a sulfinyl chloride with a chiral 
alcohol (usually menthol), followed by an organometallic addition to the separated 
diastereoisomers, to give each enantiomer (Scheme 1.25.). 
 
Scheme 1.25. The Andersen method. 
 
 A number of biological methods for the synthesis of chiral sulfoxides are 
available. Enzymes that will catalyse the asymmetric addition of an oxygen atom to 
thioethers include monooxygenases, dioxygenases, chloroperoxidases, and 
bromoperoxidases and the topic has been reviewed in a recent paper by Holland
67
. 
These may be found in whole cell organisms or as purified enzymes requiring co-
factor addition and dioxygen or hydrogen peroxide. Enzymes are also available that 
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will kinetically resolve racemic mixtures of sulfoxides either by reduction to sulfide 
(deoxygenation) or oxidation to sulfone (oxygenation), with one enantiomer being 
removed faster than another. 
 
1.7. Methods for determination of enantiomeric excess (ee). 
1.7.1. Sulfoxides. 
1.7.1.1 Chiral stationary phase HPLC. 
Over the past 20 years a range of chiral stationary phases (CSPs) have been 
developed for the resolution of sulfoxide enantiomers. Among the most useful 
stationary phases used for the resolution of sulfoxides were those based on ester and 
carbamate derivatives of long chain carbohydrates (amylose or cellulose, see Fig 
1.8.), hydrogen bonded on to a silica support. The instability of these columns, e.g. 
Chiralcel OB, has however been a major problem. An alternative superior type of 
column has the CSP covalently bonded to a silica support (Fig 1.9.). 
 
 
 
Fig 1.8. Carbohydrate based stationary phases. 
 
In this category the (S,S)-Whelk-O1 column, with spherical Kromasil silica, is a chiral 
#-electron acceptor / #-electron donor phase, covalently bonded to the silica support. 
The major advantage of this covalently bonded support being that many solvent 
systems can be used with the column and the chiral phase will not normally be 
removed by the solvent. 
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Fig 1.9. (S,S)-Whelk-O1 chiral stationary phase. 
 
 
 
1.7.1.2. NMR spectroscopy involving addition of chiral reagents. 
 
Enantiomerically pure compounds which can complex with chiral sulfoxides 
may show distinguishable 
1
H-NMR “diastereoisomeric”signals for each enantiomer. 
The most widely used reagent in this category is “Pirkle solvent”, (+)-(S)-1-(9-
anthryl)-2,2,2-trifluoroethanol 51. When one equivalent of this reagent is added to an 
NMR sample of racemic sulfoxide in CDCl3 solution, two hydrogen bonded transient 
diastereoisomeric complexes can be formed (Fig 1.10.), which have different physical 
properties, including NMR chemical shift positions. 
 
 
 
 
(+)-(S)-1-(9-anthryl)-2,2,2-trifluoroethanol 51 
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In order to achieve baseline resolution of peaks in the NMR spectrum, the alkyl R1 
and R2 groups should preferentially exist as a singlet.  
 
 
 
Fig 1.10. Pirkle solvent/sulfoxide complexes. 
 
1.7.2. cis-Dihydrodiols. 
1.7.2.1. MTPA Derivative formation. 
The most widely used method for determination of enantiomeric purity of 
alcohols involves reacting one equivalent of either (+)- or (-)-methoxytrifluoromethyl 
phenyl acetyl (MTPA) chloride (+)- or (-)-52 to the chiral alcohol (Scheme 1.26.) 
Formation of the MTPA (Mosher) ester followed by analysis using NMR 
spectroscopy and HPLC has been used in the determination of ee values. Three 
different NMR singlet signals associated with the MTPA group (
19
FCF3, 
1
HOMe, 
1
HHA) 
are widely used as a measure of the ee values. Unfortunately due to the instability of 
cis-dihydrodiols and derivatised diols which readily aromatize, the MTPA method 
cannot be employed directly.  
 
Scheme 1.26. MTPA derivatisation. 
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Stable MTPA esters can however be formed after selective hydrogenation of one C=C 
bond, or formation of cycloadducts. One method that has been used widely is the 
addition of Cooksons reagent (4-phenyl-4,5-dihydro-3H-1,2,4-triazole-3,5-dione) 53 
to the cis-dihydrodiols (Scheme 1.27.). The addition of this reactive dienophile readly 
forms a cycloadduct exclusively cis to the diol groups, preventing premature 
decomposition and allowing derivatisation with the MTPA-Cl 50. 
 
 
Scheme 1.27. Enantiomeric excess determination with Cooksons reagent 53. 
 
1.7.2.2. Chiral boronate formation. 
cis-Dihydrodiols can also be derivatised using chiral boronic acids, such as 2-
(1-methoxyethyl)benzene boronic acid (MEBBA) 54, Unlike the MTPA esters, the 
MEBBA esters can be formed in a single step and are stable in CDCl3, thus allowing 
direct NMR analysis. The sample can simply be dissolved in CDCl3 in an NMR tube 
with addition of one equivalent of (R)- or (S)- chiral boronic acid to form a boronate 
ester (see Scheme 1.28.). 
 
Scheme 1.28. Boronate ester formation. 
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1.8. Methods for determination of absolute configuration. 
Throughout this thesis the absolute configurations of many compounds have 
been rigorously determined by X-ray diffraction methods. This technique is generally 
used if there is no more convenient way to determine the absolute configuration of a 
chiral compound. Excluding X-ray crystallography, the two most commonly used 
alternative methods, for the determination of absolute configurations are 
stereochemical correlation and circular dichroism (CD) spectroscopy. Empirical 
methods have also been used for the determination of absolute configuration of cis-
dihydrodiols. These include cycloadduct-diMTPA formation or chiral boronate 
derivatisation followed by NMR analysis. 
 
1.8.1. Stereochemical correlation methods. 
In cases where the absolute configuration of known chiral compounds are 
being determined, a simple specific optical rotation ([!]D) measurement or chiral 
HPLC analysis may be sufficient. This involves correlating the correct configurations 
with sign and magnitude of rotation or enantiomer elution sequence on a CSP HPLC 
trace. This may also be extended to compounds of unknown absolute configuration. If 
a trend can be established for enantiomers of compounds from a topological series, 
giving similar signs of rotation ([!]D) or peak elution order via CSP HPLC, it may be 
possible to predict the absolute configuration of an enantiomer of an unknown 
compound of similar topology. It may also be possible to determine the 
stereochemistries of unknown compounds by chemically changing a functional group 
on a chiral molecule, without racemising or destroying the chiral centre, to produce a 
fully characterised compound of known absolute configuration; or by synthesising 
that molecule from one with known stereochemistry, using chemical steps which 
either do not affect the chiral centres involved, or alter them in a predictable fashion. 
 
1.8.2. Circular dichroism spectroscopy. 
 CD spectroscopy can be used to determine the absolute configurations of 
members of a series of non-racemic chiral compounds. This technique is generally 
used if the absolute stereochemistry of one member of the series has already been 
established. 
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 Linear polarised light consists of left [L] and right [R] circularly polarised 
components. When this light is not absorbed, e.g. at 589nm, but passed through a 
solution of a chiral enantioenriched compound, the plane of polarisation may be 
rotated to the left or right, depending on the configuration of the chiral compound, 
thus giving rise to positive and negative !- values. When an enantioenriched chiral 
compound, containing a chromophore, absorbs light, the absorption of the left and 
right components of polarised light are different. The difference in absorption ("L - 
"R), represented by #" (absorption coefficient) changes over a range of wavelengths, 
giving positive and negative values. This is measured by $, which can be used to 
determine #" by the equation: $ ÷ 33  =  #" $ c $ l (c = concentration, l = path 
length). A CD spectrum contains a plot of #" v % (wavelength) and will give both 
positive and negative curves. For similar types of compounds having the same 
configuration, the curves take a similar shape. Compounds of opposite configuration 
will have the same shape of CD curve but having opposite signs.  
 A strong positive or negative CD absorption is called a 'Cotton effect', and it 
has been observed that chiral centers, in conjunction with a certain chromophores, can 
produce predictable Cotton effects. In relation to sulfoxides, Andersen and Mislow 
63,68-71 
have observed that alkylaryl sulfoxides gave a strong Cotton effect at around 
230 - 255nm (positive for R and negative for S configuration) and with dialkyl 
sulfoxides, Ohta et al
72
 have observed a strong Cotton effect in the 215 - 225nm 
region which was positive for S and negative for R configurations. In the case of cis-
dihydrodiols, a strong positive Cotton effect is usually located around 265 - 275nm, 
due to the interaction between the diene chromaphore and the C-1 and C-2 chiral 
centres; this is commonly associated with cis-(1S,2R)-dihydrodiols. 
 
1.8.3. Chiral boronate Derivative formation. 
 The formation of chiral boronate derivatives can also be used in the 
determination of absolute configuration of cis-dihydrodiols, as well as in ee 
measurements (see 1.7.2.2.). Initial work, carried out by Burgess and Porte
73
 and later 
by Resnick et al
74
 involved the derivatisation of a range of diols with chiral boronic 
acids. An empirical rule has been developed that enables the determination of absolute 
configuration of a cis-dihydrodiol boronate ester, from a comparison of the relative & 
values of the 
1
H-NMR signals of the two boronate diastereoisomers.  
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A range of alternative chiral boronic acids has been synthesised by Harrison 
and McConville in these laboratories.
75,76
 These new chiral boronic acids were 
designed to suit diols of varying structures. These include 2-(1-
Methoxyethyl)Benzene Boronic Acid (MEBBA) 54, 2-(1-Methoxy-2-
Methylpropyl)Benzene Boronic Acid (MMBBA) 55, 2-(1-Methoxy-2,2-
Dimethylpropyl)Benzene Boronic Acid (MDBBA) 56, 2-(1-Methoxy-1-
Phenylmethyl)Benzene Boronic Acid (MPBBA) 57 and 2-(1-Methoxy-2,2,2-
Trifluoroethyl)Benzene Boronic Acid (MTBBA) 58. 
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Chapter 2   Enzyme-catalysed enantioselective deoxygenation of chiral 
sulfoxides. 
 
As the research programme in this thesis was mainly directed towards 
synthesis of chiral sulfoxides, the two different approaches of asymmetric synthesis 
and kinetic resolution, involving different sets of enzymes, have been used. The most 
appropriate method would then be used for the synthesis of specific types of 
sulfoxide. 
 
2.1. Available biological approaches to chiral sulfoxides. 
2.1.1. Asymmetric synthesis. 
Whole cell fungal and bacterial systems have been used to enantioselectively 
oxidise sulfides to chiral sulfoxides.
77-92
 Recent work carried out by this research 
group
30,90,93
 into the TDO- and NDO- catalysed metabolism of a range of alkyl aryl 
and diaryl sulfides has shown that dioxygenases have the ability to introduce chirality 
not only by cis-dihydroxylation, but also by enantioselective sulfoxidation. A few 
typical examples illustrate the range of products from dioxygenase-catalysed 
oxidation (Table 2.1.). Methyl phenyl sulfide 23 when metabolised by P. putida UV4 
(TDO) gave the sulfoxide (R)-24 as a single product (> 98% ee and 90% yield), from 
oxidation at a position !-to the aromatic ring. (2-Fluorophenyl)methyl sulfide 59 
when metabolised by P. putida UV4 gave sulfoxide (R)-60 in (> 98% ee and 43% 
yield) and also a cis-dihydrodiol 61 (> 98 % ee and 7% yield), due to attack at the !-
position and at the arene ring.  2,3-Dihydrobenzo[b]thiophene 62 was a substrate with 
P. putida UV4 and gave sulfoxide (R)-63 (26% ee, 5% yield) and hydroxysulfide (S)-
64 (90% ee, 8% yield) both from attack at positions !- to the ring. Phenyl(2-thienyl) 
sulfide 65, containing both a heterocyclic and an acyclic sulfur atom, gave the diaryl 
sulfoxide 66 (66% ee, 15% yield) and the unstable thiophene sulfoxide 67 as a minor 
metabolite from S. yanoikuyae B8/36 (BPDO). These bioproducts demonstrate the 
different scope of reactions catalysed by dioxygenases but also show the limitations of 
the enzymes. Attack occurred mainly at positions !- to the aromatic ring, but also at 
the ring itself. In all cases sulfoxidation was observed but with variable ee values 
(often > 98%). Enantiocomplementarity was observed using different dioxygenase-
containing strains. One disadvantage of using dioxygenases for sulfoxidation was that 
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this type of enzyme could not normally oxidise sulfur atoms unless they were directly 
attached to an aromatic ring, or formed part of an aromatic heterocyclic ring.  
 
SUBSTRATE STRAIN 
(ENZYME) 
BIOPRODUCT 1 BIOPRODUCT 2 
 
 
23 
 
P. putida 
UV4 
(TDO) 
 
 
(R)-24 > 98% ee 
 
 
n/a 
 
 
59 
 
 
P. putida 
UV4 
(TDO) 
 
 
(R)-60 > 98% ee 
 
 
(+)-61 > 98% ee 
 
 
62 
 
 
P. putida 
UV4 
(TDO) 
 
 
(S)-63 26% ee 
 
 
(S)-64 90% ee 
 
 
65 
 
 
S. yanoikuyae 
B8/36 
(BPDO) 
 
 
66 
 
 
67 
 
Table 2.1. Dioxygenases-catalysed oxidation of aryl sulfides 23, 59, 62 and 65. 
 
Dioxygenases have also failed to oxidise aromatic compounds containing  
hydroxyl (phenols) or amino (anilines) groups. For example, while methyl phenyl 
sulfide 23 was oxidised to sulfoxide 24 in a dioxygenase-mediated process, (2-
hydroxyphenyl)methyl sulfide 68 was not. These deficiencies prompted the current 
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investigation into other methods for creating enantiopure chiral sulfoxides. A main 
focus was thus directed towards the kinetic resolution of racemic mixtures of 
sulfoxides. 
 
 
 
2.1.2. Kinetic resolution of sulfoxides. 
Kinetic resolution of sulfoxides using enzymes may involve different 
approaches including hydrolysis of esters, reduction of ketones and oxidation to 
sulfones. One literature example of enzymatic kinetic resolution of a series of chiral 
organosulfur compounds (Colonna et al
94
) involves the resolution of cyclic sulfites by 
enantioselective oxygenation to the sulfates catalysed by cyclohexanone 
monooxygenase (CMO). In this paper,
94
 a series of 5- and 6-membered cyclic sulfite 
rings were enantioselectively oxygenated, giving ee values up to > 99% in two cases 
and > 90% in four cases.  
Sulfoxide deoxygenation provides a further method and has been used in the 
current study. Enzymatic deoxygenation of sulfoxides has been known to occur for 
more than thirty years. A paper published in 1981 by Auret et al
95
 demonstrated that 
the enzymatic deoxygenation of both 1,3-dithiane-1-oxide and 1,3-dithiane-1,3-
dioxide to yield 1,3-dithiane could be achieved using reductase enzymes present in the 
fungus Mortierella isabellina NRRL 1757. This fungal species, normally associated 
with asymmetric sulfoxidation of sulfides, was thus also capable of asymmetric 
deoxygenation of sulfoxides. When racemic 1,3-dithiane-oxide was used as substrate, 
the recovered material was found to have a low ee value. The kinetic resolution of a 
racemic sulfoxide through biotransformation at the sulfoxide centre, can be achieved 
either by a process of enantioselective oxygenation to yield sulfone, or deoxygenation 
of the sulfoxide to yield sulfide. In the present study DMSO reductases were used to 
catalyse the enantioselective deoxygenation reaction. Two previous examples in the 
literature of kinetic resolution of chiral sulfoxides, using reductase enzymes were 
Chapter 2.  38 
provided by Abo et a.l
96,97
 The earlier reference
96
 described the preparation of 
enantioeriched sufoxides from strains of Rhodobacter sphaeroides . This strain was 
obtained from the waste water of a ‘tofu’ factory and contained DMSO-reductases 
capable of enantioselectively reducing racemic sulfoxides.  The later reference
97
 
describes the electrochemical enzymatic deoxygenation of chiral sulfoxides using 
purified DMSO reductase from Rhodobacter sphaeroides. This method allowed 
greater control over the reduction of various functionalised sulfoxides, which gave 
poor yields with the whole-cell organism, by avoiding undesirable side reactions.  
The kinetic resolution technique, utilising DMSO reductase enzymes involves 
the selective removal of a single sulfoxide enantiomer from a racemic mixture leaving 
the residual sulfoxide enriched in one enantiomer and giving the corresponding 
sulfide. The reductase enzymes can achieve this enrichment when one of the 
enantiomers is more reactive to deoxygenation than the other (Fig 2.1.). It is also 
assumed that no oxygenation (sulfoxidation) of the product sulfide can occur. 
 
 
 
Fig 2.1. Kinetic resolution of racemic sulfoxides with DMSO-reductase. 
 
Ideally the reaction should be monitored by HPLC and stopped at approximately 50% 
conversion. Depending on the relative reactivities of each enantiomer to 
deoxygenation, a longer biotransformation period may be required for some 
racemates. This however is undesirable as the yields are already at best 50%. A 
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typical reverse phase HPLC trace of the crude culture medium from the 
biotransformation, shows the appearance of the sulfide  peak and the disappearance of 
the sulfoxide peak during the resolution of racemic methyl-p-tolyl sulfoxide 
(MPTSO) 29 using Proteus vulgaris (Fig 2.2.). This biotransformation was  carried 
out at the University of Warwick as part of a collaborative study. Prior to this 
biotransformation study, suitable analytical CSP HPLC systems were developed 
which allowed the estimation of the  % ee  of the residual sulfoxides (Table 2.2. & 
Appendices).  
 
 
 
 
Fig 2.2. C-18 reverse phase HPLC trace of the biotransformation media from 
MPTSO resolution with Proteus vulgaris. 
 
In principle, synthesis of chiral sulfoxides by selective deoxygenation of 
sulfones would be synthetically useful as this process would be an asymmetric 
synthesis rather that a kinetic resolution with a theoretical yield of 100% for a single 
sulfoxide enantiomer. Unfortunately this deoxygenation reaction did not occur when 
tested on methyl-p-tolyl sulfone 69 (Scheme 2.1.); virtually all of the sulfone was 
recovered. 
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Peak Elution / min Compound 
S-sulfoxide R-sulfoxide 
Column / 
Conditions 
!-value 
 
70 
 
36 
 
46 
Chiracel OB 
10% IPA/Hex 
0.5cm
3
/min 
 
1.32 
 
71 
 
30 
 
35 
 
As above 
 
1.17 
 
72 
 
28 
 
30 
 
As above 
 
1.07 
 
73 
 
27 
 
 
29 
 
As above 
 
1.06 
 
74 
 
32 
 
36 
 
As above 
 
1.13 
 
29 
 
20 
 
60 
 
As above 
 
3.1 
 
75 
 
19 
 
37 
 
As above 
 
1.95 
 
76 
 
34 
 
50 
 
As above 
 
1.47 
 
77 
 
19 
 
30 
 
As above 
 
1.58 
 
78 
 
15 
 
13 
Chiralcel OJ 
10% IPA/Hex 
0.7cm
3
/min 
 
1.15 
 
Table 2.2. CSP HPLC separation and retention times of sulfoxide enantiomers. 
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Scheme 2.1. Inability of DMSO reductase to catalyse the deoxygenation of sulfone 
69. 
 
On hindsight this result was not suprising since it is established that chemical 
deoxygenation reactions are much slower on sulfones compared with sulfoxides. 
Furthermore, a comprehensive search of the literature failed to provide any evidence 
of this reaction having occurred under enzyme catalysis. 
 
2.2. Selection and synthesis of substrates, for DMSO reductase enzymes. 
As the whole-cell reductase-catalysed biotransformations were carried out in 
the Department of Biological Sciences at the University of Warwick (Drs C. Walker 
and H. Luckarift), there was a limit to what control could be exercised over the 
monitoring of the biotransformations from these laboratories. HPLC, using a reverse 
phase C-18 column, was found to be the most convenient method for monitoring the 
progression of the reactions from direct analysis of the culture medium. This method 
was not completely satisfactory as both the substrates and products have differing 
solubilities in the aqueous reaction media. The less water-soluble sulfide products 
were more likely to precipitate from solution and could thus appear to be present in 
lower concentrations in the culture medium. Volatile sulfide products (e.g. 
thiophenes) also had the potential to be removed from solution by evaporation, while 
some sulfide bioproducts were unstable (e.g. 1,2-disulfides). For these reasons, a 
completely accurate measure of the reaction progress was difficult to obtain. In view 
of these experimental difficulties, it was decided to screen a range of substrates using 
several reductase enzymes, and to determine the potential of this method for the 
synthesis of chiral sulfoxides. Of particular interest in this project, was the possible 
application of these enzymes in the synthesis of functionalised chiral sulfoxides, 
which have proved difficult to obtain using other enzyme systems, e.g. dioxygenases. 
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 Representative substrates were chosen ranging from dialkyl sulfoxides, alkyl 
aryl sulfoxides, diaryl sulfoxides, thiophene sulfoxides, hydroxy sulfoxides and a 
sulfinate.  
 
2.2.1. General procedures for the synthesis of sulfoxides. 
 Several sulfides and sulfoxides were commerically available or had been 
previously synthesised. These included methyl-p-tolyl sulfide 79, ethyl-2-pyridyl 
sulfide 80, benzylmethyl sulfide 81, o-hydroxythioanisole 68, dibenzo[b,d]thiophene 
82 and phenylvinyl sulfoxide 76. The sulfides were then converted to the sulfoxides 
using one of the several available oxidation procedures. These methods included 
sodium periodate, NaIO4, which was used for oxidising the alkylbenzyl sulfides, 
phenyl-o-tolyl sulfide 83, ethyl-2-pyridyl sulfide 80 and methyl-p-tolyl sulfide 79. 
This was the favoured oxidation method for these sulfides, which were methanol 
soluble. Furthermore, the reagent was neutral, the workup was simple, the yields were 
good (> 75%) and no sulfone was produced, simplifying their purification (Scheme 
2.2.). 
 
  
Scheme 2.2. Sodium periodate oxidation to sulfoxides 29, 70-73, 75 and 78. 
 
Meta-Chloroperoxybenzoic acid (MCPBA) and dimethyldioxirane (DMD) 
provided convenient oxidation procedures for sulfides requiring stronger oxidants. 
DMD was a particularly useful oxidant since the reaction occurred rapidly at ambient 
temperature giving almost quantitative yields. The byproduct was acetone which was 
also the solvent allowing for a simple workup procedure. This was important in cases 
where the sulfoxides produced were unstable under acidic conditions or elevated 
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temperatures. For reactions where MCPBA overoxidation to the sulfone was possible, 
mixtures of MCPBA with borontrifluoride etherate  (BF3-Et2O) or MCPBA with hexa 
fluoroisopropanol (HFIP) mixtures were used. The yields obtained were close to 
quantitative and no sulfone was produced. These methods were used to oxidise  
thiophenes to the corresponding thiophene oxides. Sulfoxidation of the thiophene is 
generally slow since formation of the sulfoxide will result in a considerable loss of 
resonance energy. The non-aromatic thiophene sulfoxide can then be readily oxidized 
to the corresponding thiophene sulfone without any further significant decrease in 
resonance energy. The use of particular oxidants will be discussed in the context of 
the synthesis of individual sulfoxides. 
 
2.2.2. Synthetic routes to dialkyl sulfoxides. 
The dialkyl sulfoxides selected were benzylmethyl sulfoxide (70), benzylethyl 
sulfoxide (71), benzylpropyl sulfoxide (72), benzylisopropyl sulfoxide 73, (2-
hydroxybenzyl)methyl sulfoxide 84 and (3-hydroxybenzyl)methyl sulfoxide 75.  
 
 
The inclusion of an aromatic ring in each case resulted in decreased problems 
with the volatility of the sulfoxides or sulfides. The presence of a benzene 
chromophore also made the extraction, analysis and purification of the 
enantioenriched sulfoxide easier. The use of dioxygenases for the synthesis of 
enantiopure alkylbenzyl sulfoxides had previously proved to be very inefficient, 
giving low yields and ee values. In the case of the biotransformation of benzylmethyl 
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sulfide 81 using the NDO-containing strain, E. coli JM109 (pDTG141) Holland et al
83
 
isolated racemic sulfoxide in 20% yield and with a very low ee (< 5%, Scheme 2.3.).   
 
 
 
 
Scheme 2.3. Biotransformation of benzylmethyl sulfide 81 with E. coli 
JM109(pDTG141). 
 
From an earlier biotransformation of benzylmethyl sulfide 81 with P. putida UV4,
86
 
several bioproducts were reported including racemic sulfoxide 70 ( Scheme 2.4.). The 
other bioproducts were cis-(1S,2S)-3-(methylthio)methyl cyclohexa-3,5-diene-1,2-diol 
85, a dihydroxylation product and cis-(1S,2S)-3-(hydroxy)methyl cyclohexa-3,5-
diene-1,2-diol 86, a trihydroxylation product. 
 
 
Scheme 2.4. Biotransformation of benzylmethyl sulfide 81 with P. putida UV4. 
 
The synthesis of sulfoxide substrates 70-73 was completed using the literature 
methods. Thus, the sulfides 87, 88, and 89 were synthesised by deprotonation of 
benzyl thiol 90 using sodium ethoxide, followed by alkylation using the appropriate 
alkyl halide. The sulfides were then purified by column chromatography or distilled 
and sulfoxidised using NaIO4 (Scheme 2.4.).  
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Scheme 2.4. Synthesis of alkylbenzyl sulfoxides 70-73. 
 
The CSP HPLC peaks corresponding to individual enantiomers present in 
racemic sulfoxides 70-73 were separated using a Chiralcel OB column (10% 
IPA/Hex, flow 0.5cm
3
/min). The separation was indicated by the ! values of 1.32 for 
benzylmethyl (70), 1.17 for benzylethyl (71), 1.07 for benzylpropyl (72) and 1.06 for 
benzylisopropyl sulfoxides 73. The efficiency of the enantiomer separation was thus 
found to decrease with increasing size of the alkyl chain (Appendicies 2.1.-2.4.). 
 The synthesis of racemic samples of the phenolic dialkyl sulfoxides 84 and 74 
was attempted using several different approaches. Unfortunately these methods were 
unsuccessful. However, small samples of enantioenriched sulfoxides 74 and 84 were 
obtained by aromatisation of the corresponding cis-diol sulfoxide metabolites (See 
later). Partial enantiomer separation by CSP HPLC analysis has been observed for 
sulfoxide 74 using a Chiralcel OB column (10% IPA/Hex, flow 0.5cm
3
/min, !  1.13). 
 
2.2.3. Alkylaryl sulfoxides. 
The alkylaryl sulfoxides selected for kinetic resolution studies were methyl-p-
tolyl sulfoxide 29, ethyl-2-pyridyl sulfoxide 75, methyl-o-hydroxyphenyl sulfoxide 77 
and benzyl-p-tolyl sulfoxide 91. These sulfoxides were chosen as they contain 
differing functionalities, including a pyridyl ring in sulfoxide 75, and a phenolic group 
in sulfoxide 77. Compound 91, a slightly larger bicyclic sulfoxide, was selected as a 
substrate since it will later be used in a chiral synthesis (Chapter 3). Sulfoxide 29 was 
selected as a model since it had previously been used as a substrate enzyme-catalysed 
deoxygenation reaction. It would also allow a comparison to be made with all the 
DMSO reductase-containing strains or pure enzymes. 
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 Methyl-p-tolyl sulfoxide 29 was synthesised by NaIO4 oxidation of the 
commerically available sulfide 79  and gave the racemic sulfoxide in a 90% yield 
(Scheme 2.5.).  
 
Scheme 2.5. NaIO4 oxidation of a sulfide 79. 
  
 A CSP HPLC separation of racemic sulfoxide enantiomers 29 was achieved 
using a Chiralcel OB column (10% IPA/Hex, flow 0.5cm
3
/min, ! 3.11)  (Appendix 
2.6.). 
Ethyl-2-pyridyl sulfoxide 75 was also synthesised by NaIO4 oxidation of the 
sulfide 80 giving the sulfoxide in an 81% yield. (Scheme 2.6.) Separation of the 
enantiomers of sulfoxide 80  was again observed using a Chiralcel OB column (10% 
IPA/Hex, flow 0.5cm
3
/min, ! 2.33) (Appendix 2.7.). 
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Scheme 2.6. NaIO4 oxidation of a sulfide 80. 
 
 Benzyl-p-tolyl sulfoxide 91 was synthesised from isopropyl-p-tolyl sulfinate 
92. This was obtained in a 98% yield from the sodium salt of p-tolyl sulfinic acid 93 
using thionyl chloride and triethylamine in IPA. A Grignard reaction was then carried 
out on sulfinate 92 using benzyl magnesium bromide (generated from benzyl bromide 
94) giving the sulfoxide 91 in a 97% yield (Scheme 2.7.). 
 
Scheme 2.7. Synthesis of benzyl-p-tolyl sulfoxide 85. 
 
 The sodium periodate sulfoxidation method was not suitable for o-
hydroxythioanisole 68 as this oxidant has been found to oxidise phenols. In this case 
DMD was the best oxidant. This oxidant was formed from the reaction of acetone 
with sodium bicarbonate and oxone (potassium peroxymonosulfate), was used to 
oxidise the commerically available sulfide 68 to yield sulfoxide 77 in a 95% yield 
(Scheme 2.8.). 
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Scheme 2.8. DMD oxidation of a sulfide 68. 
 
 CSP HPLC analysis of the racemic sulfoxide 77 was carried out using a 
Chiralcel OB column (10% IPA/Hex, flow 0.5cm
3
/min,  ! 1.58, Appendix 2.8.). 
 
2.2.4. Thiophene oxides. 
Due to the instability of most  monocyclic thiophene oxides and unsubstituted 
benzo[b]thiophene oxides (which undergo cycloaddition reactions), more stable 
substituted benzothiophene and dibenzothiophene oxides were used. Three 
configurationally stable thiophene oxides, 2-methylbenzo[b]thiophene oxide 95, 2-
ethylbenzo[b]thiophene oxide 96 and dibenzo[b,d]thiophene oxide 97 were used. 
Although the tricyclic sulfoxide 97 was not chiral, it was considered to be a good 
model thiophene since it was also chemically stable but was more readily 
deoxgenated. It would also test if larger substrates of this type could be accepted into 
the active site and reduced by these enzymes. Sulfoxides 95 and 96 were the smallest 
stable chiral thiophene oxides that could be used for these studies. 
 
The 2-substututed benzo[b]thiophenes 98 and 99 were formed by reacting 
benzo[b]thiophene 100 with Bu
t
Li forming a carbanion exclusively at the 2- position. 
This nucleophile was then reacted with the corresponding alkyl halide to give the 
products 98 and 99  in 94% and 91% yields respectively (Scheme 2.9.). 
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Scheme 2.9. Synthesis of alkylbenzo[b]thiophenes 98 and 99. 
 
Neither NaIO4 nor DMD were suitable oxidants for the sulfoxidation of the 
thiophenes 98, 99 or dibenzo[b,d]thiophene 82. The periodate reagent was not strong 
enough to oxidise thiophene rings while DMD was too powerful and sulfone 
formation was also observed. The best reagent for thiophene sulfoxidation this was a 
mixture of MCPBA/BF3-Et2O in CH2Cl2 at - 20
o
C which had been used earlier
98
 
giving > 90% yields (Scheme 2.10.). The formation of a complex between the sulfur 
atom of the thiophene and BF3 appeared to allow sulfoxidation but also prevented 
further oxidation to the corresponding sulfone. 
 
 
 
Scheme 2.10. Sulfoxidation of thiophenes 82, 98 and 99. 
 
  Thiophene oxide 95 was found to have sufficient configurational stability to 
allow separation into enantiomers by CSP HPLC using an (S,S)-Kromasil Whelk-01 
column (50% MeOH/Water, flow 1.0cm
3
/min, ! 1.14, Appendix 2.9.). 
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2.2.5. Diaryl sulfoxide 78 and sulfinate 101. 
The racemic diaryl sulfoxide 78 was used to determine the enantioselectivity 
of the DMSO reductase where there was little difference between the size and shape 
of the phenyl and o-tolyl substutuents. The racemic sulfinate chosen as a potential 
substrate was benzo[d]-1,2-oxithian-1-oxide 101.  
 
 
As discussed in Chapter 1, chiral sulfinates can be used in the synthesis of 
single enantiomer sulfoxides. This approach was applied during the Andersen and 
Kagan methods (Chapter 1), where the sulfinate reacted with an alkylating 
organometallic reagent (Scheme 2.11.). Sulfinate (101) was chosen as it was stable 
under the biotransformation conditions and had an additional chromophore with the 
inclusion of the aromatic ring. 
 
 
 
Scheme 2.11. Synthesis of hydroxy sulfoxides from  sulfinate 101. 
 
Sulfide 83 was synthesised by reacting diphenyldisulfide with a Grignard 
reagent formed from o-bromotoluene 102. Sulfide 83 was then oxidised using NaIO4 
to yield phenyl o-tolyl sulfoxide 78 (Scheme 2.12.). 
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Scheme 2.12. Synthesis of phenyl-o-tolyl sulfoxide 78. 
 
 
A separation of the enantiomers of sulfoxide 78 was achieved by CSP HPLC 
analysis using a Chiralcel OJ column (10% IPA/Hex, flow 0.7cm
3
/min,  ! value 1.10, 
Appendix 2.10.). 
 The sulfinate 101 was synthesised from 1,2-dibromomethylbenzene 103 with 
2-hydroxymethyl sodium sulfinate and tetrabutylammonium bromide (TBAB) in 
DMF (Scheme 2.13.). 
 
 
 
 
 
 
 
 
Scheme 2.13. Synthesis of  sulfinate 101. 
 
CSP HPLC analysis using a Kromasil (S,S)-Whelk-01 semi-prep column 
(Bu
t
OMe, flow 2.5cm
3
/min) provided a separation of enantiomers of the sulfinate 101, 
with an ! value of 1.67 (Appendix 2.11.). 
 
2.3. Biotransformations using DMSO reductase enzymes. 
DMSO reductase-containing bacteria that were used in the biotransformation 
of racemic sulfoxides included Rhodobacter capsulatus, Proteus vulgaris, E. coli 
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HB101 and three strains of Citrobacter braakwi (DMSO-7, DMSO-10 and DMSO-
11).  
 When the biotransformations were carried out the first steps involved 
monitoring the reaction by HPLC, until about 50% conversion of the sulfoxide had 
occurred. At this point the reaction was terminated by centrifugation and addition of 
EtOAc. The reductase biotransformation  work was carried out at the University of 
Warwick. Both the initial synthetic work and the development of CSP HPLC systems 
were carried in Belfast as part of the current programme. The final steps in the process 
were also carried out at Belfast, and involved the extraction, purification and 
stereochemical analysis. The bioproducts were isolated from the aqueous media, 
either by removal of the water and extraction of the residue with organic solvent 
(EtOAc), or by saturation of the aqueous culture medium with salt and solvent 
extraction. The method involving removal of water under vacuum at 35-40 °C gave 
better yields. However if the bioproducts were unstable or volatile the second 
procedure was preferred. 
1
H-NMR and TLC analysis of the crude extract were good 
indicators of the progress of the reaction. The presence of sulfide bioproduct was 
detected in the 
1
H-NMR spectrum and by TLC analysis as the less polar  metabolite. 
The more polar sulfoxide substrate was pre-purified before CSP HPLC analysis, as 
the crude extract often contained impurities that could diminish the column efficiency. 
PLC  (silica-gel) was used to purify the sulfoxide prior to CSP HPLC separation of 
enantiomers which was then used to confirm if resolution had occurred, to determine 
the ee value and to identify the residual enantiomer. Absolute configurations of 
sulfoxides were determined using CSP HPLC, by comparison with known literature 
CSP HPLC separations
90,97,99,100
 or by comparison with enantiopure samples of 
sulfoxide of known configuration (Appendices).  
 From a total of fifteen racemic sulfoxides (29, 70-78, 84, 91 and 95-97) and a 
sulfinate 101 synthesised for this study, five (71-73 and 76) showed little evidence of 
kinetic resolution or production of sulfide, with one (84) showing complete 
conversion to sulfide, when a Citrobacter strain (DMSO-11) was used. Enantiomers 
of sulfinate 101, which had never been produced in enantiopure form before, were 
resolved  using a semi-prep. Kromasil (S,S)-Whelk-01 column. Unfortunately it has 
not yet been possible to determine the configurations of the enantiomers. The [!]D 
values (+ 68, CHCl3 for the early peak and – 70, CHCl3 for the later peak) were,   
Chapter 2.  53 
within experimental error, of equal magnitude and of opposite sign. The CD spectra 
of these compounds were also recorded (Fig 2.3.) showing absorption peaks at 205nm 
and 226nm. 
 
 
 
 
Fig 2.3. CD spectra corresponding to (+)- and (-)-enantiomers of  sulfinate 101. 
 
 To assess the enantioselectivity of the available DMSO reductase-containing 
strains, the alkylaryl and dialkyl sulfoxides methyl p-tolyl sulfoxide 29 and 
benzylmethyl sulfoxide 70 were chosen. The results obtained with the R. capsulatus, 
P. vulgaris, E. coli, C. braakwi (DMSO-7, DMSO-10 and DMSO-11) strains are 
shown in Table 2.2.. These results indicated that (i) using sulfoxides 29 and 70, a 
degree of kinetic resolution has been achieved with all strains, (ii) the most efficient 
total kinetic resolution of sulfoxide 29 has been found with strains P. vulgaris and C. 
braakwi DMSO-10 giving the (S)-methyl-p-tolyl sulfoxide (S)-29, (iii) the E. coli and 
C. braakwi DMSO-11 strains also gave an excess of (S) enantiomer of sulfoxide 29 
with the remaining R. capsulatus, and C. braakwi DMSO-7 strains produce the (R)-
sulfoxide (R)-29, and (iv) using sulfoxide 70, all strains showed the same 
enantioselective preference giving (S)-benzylmethyl sulfoxide (S)-70 with the best 
results (77% ee) from the P. vulgaris strain. The results in Table 2.2. provide only a 
preliminary survey of the potential of the different bacterial strains, but it is clear that 
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the degree of enantioselectivity associated with deoxygenation using different DMSO 
reductases can change with different substrates. 
Sulfoxides 74, 75, 77, 78 and 84 were metabolised with the DMSO-11 strain 
of C. braakwi in an attempt to assess the applicability of this DMSO reductase in the 
kinetic resolution of functionalised sulfoxides, containing phenolic (74, 77, and 84),  
and pyridyl substituents (75). 
 
C. braakwi  
Sulfoxide 
 
 
R. 
capsulatus 
 
P. 
vulgaris 
 
 
E. coli DMSO-
7 
DMSO-
10 
DMSO-
11 
 
29 
58% ee 
 
(R) 
98% ee 
 
(S) 
60% ee 
 
(S) 
54%ee 
 
(R) 
98%ee 
 
(S) 
32% ee 
 
(S) 
 
70 
 
_ 
77% ee 
 
(S) 
68% ee 
 
(S) 
44% ee 
 
(S) 
37% ee 
 
(S) 
26% ee 
 
(S) 
 
Table 2.2. Enantiomeric excess values and absolute configurations of residual 
sulfoxides 29 and 70 obtained from DMSO reductase-containing strains. 
 
  Phenolic sulfoxides 74, 77 and 84 were metabolised, on a small scale, 
using DMSO-11. In the case of sulfoxide 84, 100% conversion was observed, with 
recovery of the sulfide. This result indicates that sulfoxide 84 is an excellent substrate 
for DMSO reductase. Phenol sulfoxide 74 (30% ee, R) was added as substrate to 
bacterial culture of DMSO-11. The residual sulfoxide was mainly (S)-3-
methylsulfinylmethyl phenol (S)-74 with an ee of 55% indicating a stereopreference 
for the R enantiomer (Scheme 2.14.). 
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Scheme 2.14. Kinetic resolution of sulfoxide 74. 
 
Sulfoxide 78 was metabolised using C. braakwi DMSO-11, giving sulfide 83 and 
residual sulfoxide (S)-78 with an ee value of 76%, showing that the new DMSO-11 
strain has the ability to distinguish between substituents of only slightly differing 
sizes. 
On a larger scale, racemic sulfoxides 75 (2g) and 77 (0.5g) were metabolised 
with P. vulgaris and DMSO-11 respectively. Sulfoxide 77 was biotransformed using 
DMSO-11 and the reaction was terminated at ~ 55% conversion. The sulfide 
bioproduct 68 was isolated and the residual enantiopure (> 98%ee) 2-methylsulfinyl 
phenol 77 was recovered in 27% yield  (Scheme 2.15.). An optical rotation of was 
recorded ([!]D – 189, CHCl3) which confirmed the enantiopurity of the sulfoxide 
stereocentre as S, by comparison to the literature value
101
. The stereochemistry, which 
was previously unknown, at the sulfoxide centre was confirmed through CD 
correlation of the purified residue with a sample of enantioenriched (R)-methylphenyl 
sulfoxide (R)-24 (Fig 2.4.), obtained from the P. putida UV4 metabolism of sulfide 
23. The CD spectra show strong, and opposite absorbtions at ca: 235-240nm and 
215nm, showing the sulfoxide residue from DMSO-11 to be (S)-77. 
 
 
 
 
Scheme 2.15. Synthesis of enantiopure phenol sulfoxide (S)-77. 
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Fig 2.4. Determination of the stereochemistry of (-)-(S)-2-methylsulfinyl phenol (S)-
77 by CD spectroscopy. 
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Ethyl-2-pyridyl sulfoxide 75 was metabolised using P. vulgaris. The reaction was 
stopped at ~ 55% conversion. The sulfide bioproduct 80 was isolated after 
chromatography. Enantiopure (> 98%ee) (-)-(S)-ethyl-2-pyridyl sulfoxide (S)-75 was 
recovered (45% yield) (Scheme 2.16.). The optical rotation of the residual sulfoxide 
was recorded ([!]D -157, MeOH) and this confirmed the configuration of the  
sulfoxide stereocentre as (S). 
 
 
 
Scheme 2.16. Synthesis of enantiopure pyridyl sulfoxide (S)-75. 
 
 The P. vulgaris and C. braakwi DMSO-11 strains were chosen for 
biotransformation of substrates 75 and 77, as they had previously been shown to 
produce these enantiopure sulfoxides on a small scale. These particular substrates 
were selected due to their potential as chiral synthons. They also provide a good 
demonstration of the value of DMSO reductases in the synthesis of functionalised 
chiral sulfoxides in comparison with other enzyme systems. 
 
2.4. Synthetic applications of sulfoxides obtained by DMSO reductase 
biotransformations. 
 The enantioselective addition of diethylzinc (Et2Zn) to carbonyl compounds 
has been catalysed by a range of chiral ligands including aminoalcohols,
102
 
diamines,
103
 diols
104
 and aminothiols.
105
 As hydroxy sulfoxides have the ability to 
coordinate as bidentate ligands due to the availibility of lone pairs on each of the 
oxygen atoms, they have previously been reported to catalyse this reaction.
106
 In this 
context, Et2Zn was postulated to coordinate with the alcohol sulfoxide catalyst to 
form a complex, which was capable of catalysing enantiospecific addition of Et2Zn to 
benzaldehyde 104 (Scheme 2.17.). 
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Scheme 2.17. Catalytic addition of Et2Zn to benzaldehyde 104. 
 
The highest ee values (55%) reported for alcohol 105 was obtained by using a 
hydroxysulfoxide.
106
 Other chiral ligands such as aminoalcohols have proved to be 
more successful as catalysts, although it seems that the best yields are always obtained 
using benzaldehyde 104 as substrate. Other aldehydes and ketones were alkylated 
with lower ee values. From this earlier study it is clear that there is potential for 
considerable improvement in this asymmetric alkylation reaction, especially in the 
synthesis of efficient catalysts containing enantiopure sulfoxide ligands. 
 To assess the potential of sulfoxides 75 and 77, in this reaction, samples of the 
enantiopure sulfoxides (S)-75 and (S)-77 were studied. The experiments were carried 
out according to the procedures reported by Ogumi et al,
102
 with a comparison of the 
sulfoxide catalysts (S)-75, (S)-77 and the amino alcohol, (S)-valinol 106 (Table 2.3.), 
which had previously been used for this reaction giving (R)-phenylpropan-1-ol 105 
with a 47% ee. 
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Isolated Yield (%) Ligand Ee (%) of 
105 107 108 104 109 
 
(S)-75 
 
 
0 
 
 
47 
 
 
5 
 
 
26 
 
 
_ 
 
(S)-77 
 
 
27.0 
 
 
30 
 
 
21 
 
 
17 
 
 
10 
 
(S)-106 
 
 
8.7 
 
 
79 
 
 
8 
 
 
0.5 
 
 
_ 
 
 
 
Table 2.3. Enantioselective addition of Et2Zn to benzaldehyde 104. 
 
The results in Table 2.3. show that the ee values obtained are generally low, with 
sulfoxide 75 giving no enantiomeric excess. There is also a greater tendency towards 
side reactions with the yields of compounds 107, 108 and 109 increasing compared to 
those for catalyst (S)-106. This however is not surprising as the conditions have not 
been optimised for chiral ligands of this type (i.e. containing alcohol and sulfoxide 
groups). In comparison to compound (S)-106, which was reported in the literature as 
giving a much higher ee value, the value obtained for sulfoxide (S)-77 (27%) seems to 
be more promising. 
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2.5. Conclusion. 
 This study has demonstrated that using various strains of bacteria containing 
DMSO reductase, it is possible to kinetically resolve sulfoxides with 
enantiocomplementarity being evident, using different strains. New strains of 
Citronella braakwi (DMSO-7, DMSO-10 and DMSO-11) have been isolated and 
found to (resolve or partially resolve) functionalised sulfoxides such as phenolic 
sulfoxides, that are difficult to synthesise via the dioxygenase-catalysed sulfoxidation 
route. A hydroxy sulfoxide (S)-77 obtained by kinetic resolution of the racemic 
sulfoxide using Citronella braakwi DMSO-11, has been demonstrated to have 
potential as a chiral ligand in the enantioselective alkylation of benzaldehyde 104. 
using Et2Zn. 
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Chapter 3.  Chemoenzymatic asymmetric synthesis of chiral sulfoxides. 
 
 Chapter 2 demonstrated the potential for the synthesis of chiral sulfoxides by 
kinetic resolution of sulfoxide racemates using DMSO reductases. This approach has 
proved to be particularly useful for functionalised sulfoxides, which are difficult to 
synthesise by the dioxygenase-catalysed oxidation route. Functionalised sulfoxides 
have also been shown to catalyse enantioselective diethylzinc alkylations of 
benzaldehyde 101. A major objective of this chapter will be to show that alternative 
chemoenzymatic methods are available for synthesising ligands that could catalyse 
this type of reaction. A further objective will be to synthesise new chiral sulfoxides 
using dioxygenases.  
 
3.1. Asymmetric synthesis of chiral dialkyl sulfoxides using dioxygenases. 
Dioxygenases have been found to catalyse the enantioselective sulfoxidation 
of a range of sulfides, generally where the sulfur atom is !- to an aromatic ring 
(alkylaryl and diaryl sulfides).  Few examples have been reported of dialkyl sulfides 
undergoing dioxygenase-mediated sulfoxidations. One study into biological oxidation 
of dialkyl sulfides, by Colonna et al,
107
 has evaluated the use of purified 
cyclohexanone monooxygenase (CMO)  and chloroperoxidase (CPO) enzymes in the 
synthesis of enantioenriched chiral dialkyl sulfoxides. These methods give a range of 
chiral dialkyl sulfoxides with high enantiopurity values and enantiocomplementarity 
between enzymes, although there are restrictions on the size of substrates, showing 
decreased yields and enantiopurity with increasing size and chain length. Perhaps 
dioxygenase-mediated metabolism can provide alternatives for certain substrates.  
To investigate whether dioxygenase-catalysed sulfoxidations can occur on 
dialkyl sulfides, a range of alkyl benzyl sulfides 81, 87-89, 2-phenyl-1,3-dithiane 110 
and 2-phenyl-1,3-dithiolane 111 were studied.  
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These substrates were selected as the benzene ring may satisfy the 
requirements for binding to the active site, and may facilitate sulfoxidation. The 
chromophore also assists in the identification  and purification of any possible 
bioproducts. 
The selected organosulfur substrates (alkylbenzyl sulfides and thioacetals) 
have also previously been metabolised by a range of microorganisms in some cases 
giving mixtures of cis and trans sulfoxides (Table 3.1.). From Table 3.1. it is clear 
that while the yields are moderate to good, the ee values obtained are low. There are 
only three examples with ee values > 90% which can be compared with dioxygenase-
mediated metabolism of alkylaryl and diaryl sulfides
30,90
 where there are many cases 
of high yields and ee values, with enantiocomplementarity between strains. 
 
 
 
  
 
R = Me 
97% yld, 54% ee (R) 
R = Me 
90% conv. 95% ee 
trans-(1R,2R) 
R = Me 
100% conv. 50% ee 
trans-(1R,2R) 
R = Et 
80% yld, 67% ee (S) 
R = Ph 
98% conv. 28% ee 
trans-(1R,2R) 
 
R = Pr 
90% yld, 96% ee (S) 
  
Acinetobacter 
calcoaceticus NCIMB 
9871 
 
Ref. 107, 108, 100 
R = Pr
i
 
95% yld, 80% ee (S) 
  
R = Hex 
82% ee (S) 
R = Me 
28% yld, 33.5% ee 
trans-(1S,2S) 
2% yld, 36% ee cis-
(1S,2R) 
 Helminthsporium sp. 
NRRL 4671 
 
Ref. 109, 110 
R = Hept 
>95% ee (S) 
R = Bu
t
 
20% yld, 72% ee trans-
(1S,2S) 
2% yld, 35% ee cis-
(1S,2R) 
 
Mortierella isabellina 
NRRL 1757 (ATCC 
42613) 
 
Ref. 111 
 R = Me 
20% yld, 32% ee trans-
(1R,2R) 
 
 
Table 3.1. Biological sulfoxidation of some benzylalkyl sulfides and thioacetals. 
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All of the sulfides 81, 87-89, 110 and 111 have the same benzyl sulfide moiety 
(PhCHRSR) in common. Single enantiomer sulfoxides containing this group have 
potential as chiral auxiliaries in asymmetric synthesis as the benzylic protons are 
doubly activated by the aromatic ring and the sulfoxide, making them easily 
derivatised via a stabilised carbanion (Scheme 3.1.). 
 
 
Scheme 3.1. Derivatisation of a benzyl sulfoxide. 
 
3.2. Dioxygenase-mediated oxygen incorporation. 
In the literature there have been cases of dioxygenases catalysing mono-, di-, 
tri- and even tetra-oxygenation of substrates
24,30,112
 Asymmetric monooxygenation of 
a range of alkylaryl sulfides to sulfoxides having variable ee values and 
configurations were found using different dioxygenases present in whole-cell bacterial 
cultures. Dioxygenation of a wide range of aromatic substrates has resulted in > 350 
known cis-dihydrodiols.
24
  
In relation to organosulfur compounds, dioxygenases can catalyse mono- and 
di-oxygenation processes with the incorporation of either one or both oxygen atoms 
from molecular dioxygen into the substrate. During cis-dihydrodiol production both 
oxygen atoms are incorporated and only one oxygen atom incorporated in the case of 
sulfoxidation, with the other atom being converted to a molecule of water. Literature 
examples of tri- and tetra-oxygenation are discussed below. 
 
3.2.1. Trioxygenation of substituted benzene substrates. 
 Examples of trioxygenation of substrates have been reported in the 
literature where substituted benzenes were biotransformed by P. putida UV4 to 
triols
113 
(Scheme 3.2).  
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Scheme 3.2. Trioxygenation of substututed benzenes. 
 
In this study a range of benzylic substrates having, for example, alkyl, vinyl 
and ether substituents, were metabolised by P. putida UV4. In addition to the 
expected cis-dihydrodiol metabolites, triols were also formed due to the !-carbon 
being hydroxylated. The reaction sequence has been found to be due to both 
dihydroxylation and monohydroxylation steps followed by either of two pathways. 1) 
Dihydroxylation of the benzylic alcohol metabolite or 2) cleavage of the acetal side 
chain giving benzaldehyde 104. Reduction of the aldehyde 104 to benzyl alcohol 108 
was catalysed by an alcohol dehydrogenase enzyme present in P. putida UV4. Benzyl 
alcohol 108 was finally dihydroxylated to yield triol 86. These two metabolic 
sequences were confirmed by addition of a range of parent cis-dihydrodiol 
metabolites as potential substrates, without  observing any triol metabolites.  
Benzylmethyl sulfide 81 has previously been metabolised by P. putida UV4 
yielding trio 86 as a minor product and an equivalent yield of sulfoxide.
113
 This can be 
attributed to benzylic hydroxylation leading to an unstable hemithioacetal. It was 
assumed to hydrolyse to benzaldehyde 104, which has previously been converted to 
triol 86 by P. putida UV4.
104
 These results suggest that in P .putida UV4 an alcohol 
dehydrogenase enzyme is present, in addition to a dioxygenase responsible for the cis-
dihydroxylation to triol 86 (Scheme 3.3.). 
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Scheme 3.3. Trioxygenation of benzylmethyl sulfide 81. 
 
A similar example of heteroatom / alkyl cleavage of the benzene substituent, 
through benzylic hydroxylation, has been observed before in a biotransformation 
carried out with P. putida UV4 on 2-phenyl-1,3-dioxane 112 as substrate. This 
substrate was first metabolised using P. putida F39/D (TDO source) by Wackett et 
al
115 
yielding only the cis-dihydrodiol 113. When carried out in these laboratories
116
 
with P. putida UV4, three bioproducts were observed, i.e. the cis-dihydrodiols 113, 
114 and the ester 115  (Scheme 3.4.) 
  
 
 
Scheme 3.4. Biotransfomation of acetal 112. 
 
The bioproduct 115, although not a trioxygenated product, is thought to be produced 
by benzylic hydroxylation of the acetal 112 to yield  an unstable product which 
decomposes by cleavage of a C-O bond giving the ester 115 (Scheme 3.5.). 
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Scheme 3.5. Benzylic hydroxylation of acetal substrate 112. 
 
Metabolite 114 is thought to be a decomposition product of cis-dihydrodiol 113. This 
is due to the fact that when benzaldehyde 104 is metabolised by P. putida UV4 the 
triol 86 is produced, rather than the bioproduct 114.  
The dioxygenase-catalysed benzylic hydroxylation can perhaps be considered 
to be analogous to the heteroatom oxidation found when substrates such as 
phenylmethyl sulfide 23 is metabolised by dioxygenases, giving sulfoxide 24. This 
could be attributed to a preferred oxidation at positions !- to an aromatic ring or other 
conjugated systems. This regioselective benzylic hydroxylation may explain why 
there is little sulfoxide produced with the dioxygenase-mediated metabolism of 
benzylmethyl sulfide 81,
113
 despite sulfur being much easier to oxidise than an alkyl 
chain or an aromatic ring.  
 
3.2.2. Tetraoxygenation of substrates. 
The first examples of dioxygenase-catalysed tetraoxygenation of substrates 
have recently been reported in the literature.
112
 The production of tetraol derivatives 
of the polycyclic arenes acridine 116 and phenazine  117 was observed in cultures of 
Sphingomonas yanoikuyae B8/36 in these laboratories (Scheme 3.6.). The reaction 
sequence in these cases involving two consecutive dihydroxylation steps. The initially 
formed cis-dihydrodiols 118 and 119 were found to undergo a second dihydroxylation 
step leading to the corresponding  bis-cis-dihydrodiol (cis-tetraols) products 120 and 
121. 
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Scheme 3.6. Tetraoxygenation of substrates 116 and 117. 
 
3.3. Metabolism of alkylbenzyl sulfides 81, 87-89 with P. putida UV4. 
 The metabolism of benzylmethyl sulfide 81 by P. putida UV4 was previously 
reported
113
 yielding the cis-dihydrodiol 85 as the major product, from a 
dioxygenation. Traces of sulfoxide 70 and triol 86 were obtained from 
monooxygenation and trioxygenation processes. The diol 85 and triol 86 were found 
to be enantiomerically  pure, but the sulfoxide 70 was racemic (Scheme 3.7.).  
 
 
 
Scheme 3.7.Reported biotransformation of benzylmethyl sulfide 81. 
 
When repeated during the current research programme, results were slightly 
different, with the formation of a new diol sulfoxide trioxygenation product 122 of 
unknown configuration and ee value, and the absence of any sulfoxide 70 (Scheme 
3.8.).  
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Scheme 3.8. Biotransformation of benzylmethyl sulfide 81. 
 
Metabolism of alkylbenzyl sulfides 87-89, yielded only the cis-dihydrodiols 123 and 
124 of unknown configuration and ee values, with benzylisopropyl sulfide 89 giving 
no bioproduct (Scheme 3.9.). Trioxygenation products analogous triol 86 and diol 
sulfoxide 122 were thus not isolated using P. putida UV4 metabolism of benzylalkyl 
sulfides 88 and 89. 
 
 
 
Scheme 3.9. Diol bioproducts from the biotransformation of alkylbenzyl sulfides 81 
and 87-88. 
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3.3.1. Determination of absolute and  relative configurations and enantiopurity 
values of metabolites from alkylbenzyl sulfides. 
3.3.1.1. Enantiopurity determination of the diol sulfides 123 and 124. 
The enantiopurity of the diols from the metabolism of alkylbenzyl sulfides 123 
and 124 was determined by the ‘chiral boronate method’, with the formation of 
boronate derivatives using (-)- and (±)-2-(methoxyphenylmethyl)benzene boronic acid 
(MPBBA) 57, and (-)- and (±)-2-(1-methoxyethyl)benzene boronic acid (MBBA) 54. 
No diastereoisomer peak resolution was observed using the (-) MPBBA. Comparison 
of the NMR spectra obtained with racemic MEBBA did however differentiate 
between 
1
H-NMR signals for the diastereoisomers. Enantiopure MEBBA showed no 
splitting of the 
1
H-NMR signals due to the presence of a single diastereomer. This 
observation indicates that the diol sulfides 123 and 124 were enantiopure (> 98% ee), 
in common with virtually all earlier examples of cis-dihydrodiol metabolites of 
monosubstituted benzene substrates. 
 
3.3.1.2. Absolute configuration determination of the diol sulfides 123 and 124. 
The configurations of the diol sulfides 123 and 124, with optical rotations of  
+ 69 (CHCl3) and + 73 (CHCl3) respectively, were correlated by CD spectral 
comparison of enantiopure (+)-cis-(1S,2R)-3-(methylsulfanylmethyl)cyclohexa-3,5-
diene-1,2-diol 85, of known enantiopurity, obtained from the biotransformation of the 
parent sulfide 81 (Fig 3.1.) The CD spectra all had  a common positive CD absorption 
at ca: 275nm and weaker positive absorption at ca: 230nm consistent with identical 
(1S,2R) absolute configurations.  This established the metabolites to be (+)-cis-
(1S,2R)-3-(ethylsulfanylmethyl)cyclohexa-3,5-diene-1,2-diol 123 and (+)-cis-(1S,2R)-
3-(propylsulfanylmethyl)cyclohexa-3,5-diene-1,2-diol 124. 
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Fig 3.1. CD correlation of absolute configurations of diol sulfides 85, 123 and 124. 
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Using the MEBBA boronate method also confirmed the configurations of the 
diols 123 and 124, showing "OMe to be upfield and "Me to be downfield from the other 
diastereomers,  using the (-)-MEBBA ; the " values for the (-)-MEBBA derivatives  
123 and 124 were 3.152ppm (OMe) and 3.151ppm (OMe) respectively. For the other 
(+)-MEBBA diastereoisomer, " values for 123 and 124, were 3.158ppm (OMe) and 
3.158ppm (OMe) respectively. The "Me values were not reported as they were ill-
defined. 
 
3.3.1.3. Determination of absolute configuration and enantiopurity of triol 86 and 
diol sulfoxide 122. 
The triol 86 produced from trioxygenation of sulfide 85 was enantiopure, [!]D 
+ 35 (MeOH), as found in the earlier studies
113
  
It is unclear whether the tandem oxidation, to yield diol sulfoxide 122 occurs via the 
sulfoxide 70 (analogous to the sequence found with the triol formation
113
), or the 
sulfoxidation of the cis-dihydrodiol 85 (Scheme 3.10.). It was anticipated that 
reintroduction of dihydrodiol sulfide 85 and racemic sulfoxide 70 as substrates for P. 
putida UV4 could identify the pathway; unfortunately both the substrates afforded 
diol sulfoxide 122 albeit in trace amounts.  In addition to the isolation of 122, a small 
quantity of the diol sulfide 85 was isolated, Thus a minor pathway of enzymatic 
deoxygenation, followed by dihydroxylation was discovered. Recent results, carried 
out in these laboratories,
117
 involving the metabolism of racemic methylphenyl 
sulfoxide 24 by P. putida UV4 showed the formation of diastereoisomeric diol 
sulfoxide metabolites 126 and 127 in significant yields (Scheme 3.11.). This has 
demonstrated that, in this case (from alkylaryl sulfoxide), the sequence involving 
sulfoxidation, followed by dihydroxylation (consistant with the triol formation 
analogy) is the major pathway.  
The enantiopurity and configuration of the diol sulfoxide 122 was determined 
by chemoenzymatic synthesis (DMD oxidation) and separation of the two possible 
diastereoisomers from the initially formed enantiopure cis-dihydrodiol 85, obtained 
from the biotransformation of the parent sulfide 81 (Scheme 3.12.). 
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Scheme 3.10. Dioxygenase-catalysed synthesis of the cis-dihydrodiol sulfide 85, triol 
86 and cis-dihydrodiol sulfoxide 122. 
 
 
 
Scheme 3.11. Formation of diol sulfoxide diastereoisomers 126 and 127. 
 
The diastereoisomers 122 and 125 were separated and purified by PLC. X-ray 
crystallographic analysis, using the anomalous dispersion method (Fig 3.2.), of the 
less polar diastereoisomer 125 ([!]D + 56.2, MeOH) showed it to be (+)-cis-(1S,2R)-
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3-(R-methylsulfinylmethyl)cyclohexa-3,5-diene-1,2-diol 125. The –OH group at C-2 
was found to be pseudoaxial due to steric interaction with the C-3 substituent. The C-
1 –OH group adopted a pseudoequatorial conformation in the crystalline state. No 
evidence of intramolecular hydrogen-bonding between the sulfoxide and –OH groups 
was observed. As the absolute configuration of the less polar diastereoisomer 125 was  
known, the structure of the more polar bioproduct was deduced to be (+)-cis-(1S,2R)-
3-(S-methylsulfinylmethyl)cyclohexa-3,5-diene-1,2-diol 122. 
 
 
Scheme 3.12. DMD oxidation of  cis-dihydrodiol 85. 
 
 
 
 
 
Fig 3.2. X-ray crystal structure of cis-(1S,2R)-3-(R-methylsulfinylmethyl)cyclohexa-
3,5-diene-1,2-diol 125 (Dr J. F. Malone). 
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3.4. Metabolism of 2-phenyl-1,3-dithiane 110 and 2-phenyl-1,3-dithiolane 111 
with P. putida UV4. 
The thioacetals 2-phenyl-1,3-dithiane 110 and 2-phenyl-1,3-dithiolane 111 
have previously been metabolised on a small scale by P. putida UV4 in these 
laboratories,
90,99
 giving a mixture of oxidation products which were not fully 
identified or characterised. As part of the current programme this biotransformation 
was revisited but using a larger scale. The products, like those found using 
benzylmethyl sulfide 81 as substrate, were mixtures of mono-, di- and trioxygenation 
products.  
 
3.4.1. Assignment of the relative stereochemistry of 1,3-dithiane and 1,3-
dithiolane sulfoxides. 
 NMR analysis has previously been applied to the determination of the relative 
stereochemistry of cis- and trans-2-substituted-1,3-dithiane
118 
and 1,3-dithiolane 
sulfoxides.
119,120
 Cis and trans configurations are possible with respect to the 
sulfoxide oxygen atom and substituent R at C-2. Earlier assignments of the cis- or 
trans-geometry of 1,3-dithiane-1-oxides were based on crystallographic and NMR 
evidence obtained by Carey et al.
120
 It was observed that "2-H  values for cis 
sulfoxides were upfield relative to those for the trans sulfoxides. This was due to the 
1,3-dithiane and 1,3-dithiolane rings adopting chair and envelope conformations 
respectively. The anisotropic effect of the sulfoxide group (equatorial) was found to 
deshield 2-H, which was in a cis position relative to the sulfoxide group (axial), 
causing it to move downfield.  
 
Fig 3.2. The effect of deshielding by the sulfoxide group on adjacent axial protons in 
the 1,3-dithiane ring. 
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This anisotropic effect is similarly observed for the H-6 proton in the axial opsition, 
with the trans-sulfoxide configuration. In the absence of X-ray crystallography, this 
method has been of considerable value in determining relative configurations. 
 
3.4.2. Biotransformation of 2-phenyl-1,3-dithiane 110 with P. putida UV4. 
 In a preliminary study by McMurry,
99
 biotransformation of 2-phenyl-1,3-
dithiane 110 by P. putida UV4, gave three bioproducts. The sulfoxide 128 
(monooxygenation product) and the diol 129 (dioxygenation product) were 
stereochemically assigned. However in the case of diol sulfoxide 130 (trioxygenation 
product), neither the relative nor the absolute configurations were determined 
(Scheme 3.13.).  
 
 
 
 
Scheme 3.13. Biotransformation of 2-phenyl-1,3-dithiane 110. 
 
The monooxygenation product, trans-(1S,2S)-2-phenyl-1,3-dithiane-1-oxide 
128, was produced as the minor metabolite (7% yield). The diol sulfide, cis-(1S,2R)-
3-(1!,3!-dithian-2!-yl)cyclohexa-3,5-diene-1,2-diol 129, proved to be the major 
metabolite (18% yield) and the diol sulfoxide, (1!,3!-dithan-2!-yl-1!-oxy)cyclohexa-
3,5-diene-1,2-diol 130, was also produced in significant amount as a single 
diastereoisomer  (12% yield). These results appeared to be similar to those obtained in 
the preliminary work carried out earlier in these laboratories,
99
 with slight differences 
in the relative yields. This variation was not unexpected since the proportions of 
metabolites have been found to change in a rational manner during  time-course 
studies. 
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3.4.3. Determination of relative and absolute configurations and enantiopurity 
values of the metabolites 128-130. 
3.4.3.1. Enantiopurity determination of sulfoxide 128. 
 The enantiopurity of trans-2-phenyl-1,3-dithiane-1-oxide 128, obtained earlier 
from the metabolism of 2-phenyl-1,3-dithiane 110 with P. putida UV4, was 
determined by CSP HPLC (Chiralcel OD column, 50% IPA/hex, 1.0 cm
3
/min, ! 2.70) 
and 
1
H-NMR analysis using  ‘Pirkle solvent’. Both methods showed the sulfoxide to 
be a single enantiomer ([!]D + 94, CHCl3). The enantiopurity of the sulfoxide 
metabolite formed during the present research programme was determined by 
comparison with the earlier [!]D value obtained ([!]D + 91, CHCl3) In both cases, the 
dialkyl sulfoxide 128 was assumed to be enantiopure (> 98% ee).  
 
3.4.3.2. Absolute configuration determination of the sulfoxide 128. 
The absolute configuration of sulfoxide 128 was previously determined by X-
ray crystallography
99
 using the anomalous dispersion method (Fig 3.3.).  
 
 
Fig 3.3. X-ray crystal structure of (+)-trans-(1S,2S)-2-phenyl-1,3-dithiane-1-oxide 
128 (Dr J. F. Malone). 
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This provided an unequivocal assignment of the relative (trans) and absolute (1S,2S) 
configurations of (+)-(1S,2S)-2-phenyl-1,3-dithiane-1-oxide 128. In this case the 
reported NMR method suggested that the relative stereochemistry at the 1,2-position 
was cis. Chemically synthesised samples of the trans sulfoxide 128 and the 
corresponding cis isomer showed the 2!-H proton "cis (4.78 ppm, 300MHz, CDCl3) to 
be downfield from "trans (4.57 ppm, 300MHz, CDCl3) This anomaly may be explained 
by the phenyl group having an additional anisotropic interaction superimposed on that 
of the sulfoxide group, thus affecting the 2!-H proton. 
 
3.4.3.3. Enantiopurity determination of the diol sulfide 129. 
 The absolute configuration and enantiopurity of the diol sulfide cis-(1S,2R)-3-
(1!,3!-dithan-2!-yl)cyclohexa-3,5-diene-1,2-diol 129 had been determined 
previously.
99
 The ee value was determined by formation of the ‘Cookson cycloadduct’ 
131 using 4-phenyl-1,2,4-triazoline-3,5-dione 53 (Cooksons reagent) as dienophile, 
followed by formation of a mono (+)-(R)-MTPA ester 132 using (+)-(R)-2-methoxy-
2-phenyl-2-trifluoromethylacetic acid 51 (Moshers acid) (Scheme 3.14.). Study of the 
1
H- and 
19
F-NMR spectra, for the presence of more that one diastereoisomer, 
indicated that the cis-dihydrodiol 129 was enantiopure. Formation of the mono-
MTPA ester rather than the expected diMTPA ester was assumed to be the result of 
steric hindrance between the proximate 1,3-dithianyl and hydroxyl groups. 
 
 
Scheme 3.14. Determination of enantiopurity of cis-dihydrodiol 127. 
 
From a comparison of the specific optical rotation of the parent diol 129, obtained 
from the previous preliminary study
99
 ([!]D + 66, CHCl3) with the value obtained 
from the present research programme ([!]D + 82, CHCl3), the bioproduct was taken to 
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be enantiomerically homogeneous. Although the [!]D values were of different 
magnitude, the higher value obtained for diol 129 during the later experiment was 
probably the result of having more metabolite which could be obtained in a higher 
state of purity. 
 
3.4.3.4.  Absolute configuration determination of the diol sulfide 129. 
 The absolute configuration of the diol sulfide metabolite 129 was previously 
established
99
 by hydrogenolysis of the carbon-sulfur bonds, using Raney nickel. This 
produced cis-(1S,2R)-3-methylcyclohexa-3,5-diene-1,2-diol 133 (Scheme 3.15.), a 
cis-dihydrodiol of known configuration.  
 
 
Scheme 3.15. Determination of enantiopurity of cis-dihydrodiol 127. 
 
From a comparison of previous ([!]D values
99
 with those obtained during the 
present research programme, metabolite 129 was again found to be an enantiopure 
sample of (+)-cis-(1S,2R)-3-(1!,3!-dithian-2!-yl)cyclohexa-3,5-diene-1,2-diol 129.  
    
3.4.3.5. Absolute configuration and enantiopurity determination of the cis-diol 
sulfoxide 130. 
 In common with the biotransformation of benzylmethyl sulfide 81 using P. 
putida UV4, a diol sulfoxide diastereoisomer  was again isolated from 2-phenyl-1,3-
dithiane 110. The absolute configuration of the diol sulfoxide diastereomer 130 
isolated from the biotransformation of the parent dithiane 110, was determined by 
oxidation of the diol sulfide 129 with DMD. Two diastereoisomers were produced in 
the reaction, one of which was spectrally indistinguishable from the diol sulfoxide 
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metabolite 130. The [!]D values of the compound 130 obtained by dioxygenase-
catalysed oxidation (+ 49, CHCl3) and by the chemoenzymatic method (+ 47, CHCl3) 
were comparable. This confirmed that the metabolite was enantiopure and of the same 
configuration. 
 The absolute configuration of the diol sulfoxide metabolite 130 was then 
determined as (+)-cis-(1S,2R)-3-(trans-(1!S,2!S)-1!,3!-dithan-2!-yl-1!-oxy)cyclohexa-
3,5-diene-1,2-diol by X-ray crystallography using the anomalous dispersion method 
(Fig 3.4.). The sulfoxide stereocentre of metabolite 130 was found to be of the same 
configuration (2’S) as the sulfoxide metabolite 128. In the crystalline state the diol 
sulfoxide 130 adopted a conformation where the sulfoxide oxygen atom and the group 
at C-2#  were trans diequatorial. The –OH group at  C-1 was pseudo-equatorial while 
the –OH group at C-2 was pseudo-axial due to steric interactions between it and the 
1,3-dithian–1-oxide group. There was also some evidence of hydrogen bonding 
between the sulfoxide oxygen atom  and–OH group at C-2. 
 
 
 
 
 
Fig 3.4. X-ray structure of (+)-cis-(1S,2R)-3-(cis-(1!S,2!S)-1!,3!-dithan-2!-yl-1!-
oxy)cyclohexa-3,5-diene-1,2-diol 130 (Dr J. F. Malone). 
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3.4.4. Biotransformation of 2-phenyl-1,3-dithiolane 111 with P. putida UV4. 
 A preliminary small-scale biotransformation of 2-phenyl-1,3-dithiolane 111 by 
P. putida UV4,
99
 gave two bioproducts, which were identified as the sulfoxide, trans-
(1S,2S)-2-phenyl-1,3-dithiolane-1-oxide 134 (monooxygenation product), and the diol 
cis-(1S,2R)-3-(1!,3!-dithiolan-2!-yl)cyclohexa-3,5-diene-1,2-diol 135 (dioxygenation 
product). During the present research programme, this experiment was repeated on a 
larger scale with a longer biotransformation period. Under these conditions a  
trioxygenation product, the diol sulfoxide  3-(1!,3!-dithiolan-2!-yl-1!-oxy)cyclohexa-
3,5-diene-1,2-diol 136, was found to be the major product. Based upon 
1
H-NMR 
analysis of the crude product mixture, which showed mainly metabolite 136, there 
was no longer any evidence of sulfoxide 134 (Scheme 3.16.) and only traces of diol 
sulfide 135.  
 
 
Scheme 3.16. Biotransformation of 2-phenyl-1,3-dithiolane 111. 
 
The sulfoxide, trans-(1S,2S)-2-phenyl-1,3-dithiolane-1-oxide 134, was earlier 
produced as a minor metabolite (3 % yield), while the diol sulfide cis-(1S,2R)-3-(1!,3!-
dithiolan-2!-yl)cyclohexa-3,5-diene-1,2-diol 135 was obtained as the major metabolite 
(15% yield). The diol sulfoxide 3-(1!,3!-dithiolan-2!-yl-1!-oxy)cyclohexa-3,5-diene-
1,2-diol 136 was observed after an extended period of biotransformation (8% yield). 
The diol sulfoxide metabolite 136 was separated from the other metabolites by 
column chromatrography. The sample obtained was sufficiently pure to allow [!]D  
measurements and spectral analysis (NMR, MS and CD). However it proved to be 
relatively unstable during attempted purification decomposing to give a white solid 
which was insoluble in common organic solvents. In view of this instability no further 
work was carried out on diol sulfoxide 136. 
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3.4.5. Determination of the absolute configuration and enantiopurity of the 
metabolites 134-136. 
3.4.5.1. Absolute configuration and enantiopurity determination of the sulfoxide 
134. 
 The enantiopurity of trans-(1S,2S)-2-phenyl-1,3-dithiolane-1-oxide 134 was 
determined during the preliminary small-scale study.
99
 CSP HPLC analysis (Chiralcel 
OD column, ! 1.14) showed the sulfoxide bioproduct 134 to have an ee value of 72% 
([!]D – 95, CHCl3). the metabolite obtained during the current work gave a similar 
[!]D value ([!]D – 103, CHCl3). The sample was recrystallised to obtain an 
enantiopure sample (> 98% ee) with a higher [!]D value (– 128.9, CHCl3). The ee 
value of the initial bioproduct was thus determined to be 80%, a slight increase on the 
earlier small scale biotransformation. From X-ray crystallography, using the 
anomalous dispersion method, the absolute configuration of the sulfoxide 134 was 
determined to be (-)-(1S,2S)-2-phenyl-1,3-dithiolane-1-oxide 134 (Fig 3.5.).  
From the X-ray structure it is evident that the phenyl ring is trans to the 
sulfoxide oxygen atom which appeared to be in a pseudo-axial conformation. The 
1
H-
NMR evidence was consistent with this configuration. The 
1
H-NMR spectrum 
indicated a downfield "(2-H) value of 5.40 ppm compared to "(2-H) 5.29 ppm, associated 
with a sulfoxide was of cis configuration, due to the anisotropic effect of the sulfoxide 
on the 2-H proton. 
 
3.4.5.2. Enantiopurity determination of the diol sulfide 135. 
 The enantiopurity of the diol sulfide metabolite cis-(1S,2R)-3-(1!,3!-dithiolan-
2!-yl)cyclohexa-3,5-diene-1,2-diol 135 was determined earlier,
99
 by formation of the 
‘Cookson cycloadduct’ and then formation of  a mono (+)-(R)-MTPA ester derivative 
of the diol sulfide metabolite 135 obtained from the biotransformation of the 1,3-
dithiolane 111 (Scheme 3.17.).  
Comparison of the earlier optical rotation ([!]D + 60, CHCl3) recorded for diol 
sulfide 135 with the current value ([!]D + 33, CHCl3)  raised the question of diol 
sulfide 135 enantiopurity. In order to determine the enantiopurity, chiral boronate  
derivatives were synthesised using racemic and optically pure 2-(1-
methoxyethyl)benzene boronic acid (MBBA) 54 and 2-
(methoxyphenylmethyl)benzene boronic acid (MPBBA) 57. 
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Fig 3.5. X-ray structure of (-)-trans-(1S,2S)-2-phenyl-1,3-dithiolane-1-oxide 134 (Dr 
J. F. Malone). 
 
 
 
Scheme 3.17. Determination of enantiopurity of  cis-dihydrodiol 133. 
 
The mixture of diastereoisomers formed with MBBA showed  an insufficient degree 
of signal separation in the 
1
H-NMR spectrum for a reliable  ee determination , 
However by studying the 
1
H-NMR spectra of the MPBBA diastereoisomer mixtures, 
it was confirmed that the diol sulfide 133 was enantiopure. It was thus concluded that 
the earlier [!]D value obtained from the small-scale experiment was lower than it 
should have been due to the presence of an impurity. 
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3.4.5.3. Absolute configuration determination of the diol sulfide 135. 
 Using the chiral boronate method the absolute configuration of diol 135, was 
determined as (1S,2R) by 
1
H-NMR analysis which showed "OMe to be upfield  and "Me 
to be downfield using the (-)-MPBBA ("OMe 3.349 ppm) in comparison to the values 
of the alternative diastereomer obtained using (+)-MPBBA ("OMe 3.354 ppm). 
The absolute configuration of the diol sulfide 135 was confirmed  by hydrogenolysis 
of the carbon-sulfur bonds using Raney nickel to yield cis-(1S,2R)-3-
methylcyclohexa-3,5-diene-1,2-diol 133 of known configuration (Scheme 3.18.). 
 
 
 
Scheme 3.18. Determination of absolute configuration of  cis-dihydrodiol 135. 
 
3.4.5.4. Absolute configuration and enantiopurity determination of the diol 
sulfoxide 136. 
 The biotransformation that was left for an extended period, produced mainly 
the diol sulfoxide diastereoisomer 136. As yet the ee value and absolute 
stereochemistrry of metabolite 136 has not been unequivocally determined due to its 
instability during further purification and attempted formation of derivatives. It is 
however likely that the cis-dihydrodiol 135 was the immediate precursor of diol 
sulfoxide 136 ([!]D – 48, CHCl3) and on this basis it was assumed that metabolite 136  
was also a single enantiomer. Furthermore,  a comparison of the CD spectra of the 
diol sulfoxide  metabolite 130 and the diol sulfoxide metabolite 136 indicates a 
similarity between their absolute configurations (Fig 3.6.). Both CD spectra show 
negative absorptions at ca: 220-230nm followed by strong positive absorption at ca : 
260-280-nm. While there are similarities between these CD spectra, it does not 
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provide unequivocal evidence of identical configurations due to the possible influence 
of further chiral centres.  
The 
1
H-NMR signal for 2!-H in compound 136  which is shifted downfield, (> 
5 ppm),  suggested a trans- configuration between the sulfoxide oxygen atom and the 
substituent at a C-2! of the dithiolane ring. Based on the configurations of the other 
bioproducts obtained from benzylmethyl sulfide 81, 2-phenyl-1,3-dithiane 110 and 2-
phenyl-1,3-dithiolane 111 as substrates for biotransformations with P. putida UV4, 
where any sulfoxides or diol sulfoxides produced had the same absolute 
configurations at the sulfoxide centres (Fig 3.7.), it is a possibility that the sulfoxide 
centre in metabolite 136 is identical, i.e. (-)-cis-(1S,2R)-3-(trans-(1!S,2!S)-1!,3!-
dithiolan-2!-yl-1!-oxy)cyclohexa-3,5-diene-1,2-diol 136. 
 
3.5. Conclusion. 
Preliminary results obtained from small-scale biotransformations of 
compounds 81, 110 and 111, have now been repeated and confirmed  using a larger 
scale. This has allowed both the structure and stereochemistry of sulfoxides (128 and 
134), and cis-dihydrodiol metabolites ( 85, 129 and 135), to be fully elucidated. In 
addition the absolute configurations of the new cis-dihydrodiol metabolites 123 and 
124 isolated from the biotransformation of substrates 87 and 88 respectively have 
been determined. A new cis-diol sulfoxide metabolite 136, arising from  
trioxygenation of substrate 111, has been identified. From the metabolism studies  of  
sulfides 81, 110 and 111, evidence of a tandem oxidation process involving both 
sulfoxidation and cis-dihydroxylation in an unusual sequence has been found. 
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Fig 3.6. CD spectra of the two diol sufoxide 130 and 136 obtained from P. putida 
UV4. 
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Fig 3.7. Sulfoxide configurations of bioproducts 122, 128, 130, 134 and 136. 
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Chapter 4. Synthesis of chiral hydroxylated sulfoxides from cis-dihydrodiol  
bioproducts. 
 
 As discussed in Chapter 3, the possibility of obtaining chiral sulfoxides as 
bioproducts from the dioxygenase-mediated metabolism of a range of alkylbenzyl 
sulfides (81, 87-89, 110 and 111) has been examined. A limited degree of success, 
especially with the thioacetals 110 and 111, giving sulfoxides 134 and 128  (80% and 
> 98% ee values respectively) was observed. It was also noted that the dioxygenase 
enzymes have the ability to produce other types of bioproduct, e.g. cis-dihydrodiol 
sulfides from diooxygenation and cis-diol sulfoxides from trioxygenation. It is the 
aim of this chapter to investigate chemoenzymatic methods for the synthesis of further 
types of stable functionalised sulfoxides, i.e. phenolic sulfoxides, from existing 
bioproducts, for possible use as chiral synthons.  
 
4.1. Synthesis using bioproducts from the metabolism of alkylbenzyl sulfides    
81,  87 and 88, and thioacetal 110 with P. putida UV4. 
 A new method of producing stable functionalised single enantiomer sulfoxides 
was examined  involving oxidation of  the diol sulfide metabolites 85, 123, 124, 129 
and 135 where two chiral centres already existed. The chirality could in principle  be 
transferred to the exocyclic sulfur centres, by sulfoxidation followed by separation of 
the resulting diol sulfoxide diastereoisomers. Furthermore,  the introduction of a 
sulfoxide group would be expected to confer increased stability upon the new cis-
dihydrodiol. 
The three diol sulfides 85, 123 and 124, obtained from alkylbenzyl sulfide 
metabolism using P. putida UV4, were oxidised using DMD to give mixtures of 
diastereoisomers in almost equal proportions (Scheme 4.1.). The diastereoisomeric 
pairs 122, 125 and 140-143 were separated by PLC giving ca: 45 % yields for each. 
The lack of diastereoselectivity during this sulfoxidation suggests that neither of the 
lone pairs on the sulfur atom were able to exercise stereocontrol due to preferential 
hydrogen-bonding with the proximate –OH group. 
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Scheme 4.1. Synthesis of diol sulfoxide diastereoisomers 122, 125 and 140-143. 
 
Since the cis-dihydrodiol precursors 85, 123 and 124 were enantiopure, the resulting 
diastereoisomers 122, 125 and 140-143 were also single enantiomers. Only one of the 
six diol sulfoxide compounds 122, 125 or 140-143 was crystalline, which allowed a 
crystal structure analysis to be undertaken (Fig 3.2.). The relative stereochemistry of 
each member of the remaining diastereoisomeric pairs was suggested by their relative 
polarity on TLC analysis (the (S)-sulfoxide diastereoisomer was consistently found to 
be more polar i.e. lower Rf). These tentative assignments   were confirmed by CD 
spectral comparison  (Fig 4.1. and 4.2.), and anchored by the application of  X-ray 
crystallography.  
The CD spectra for the less polar (R)-sulfoxide diastereoisomers consistently 
showed weak positive CD absorptions at ~ 225nm,. The CD spectra contained a slight 
trough, reaching the baseline, followed by a stronger positive absorption at ~ 275nm. 
The CD spectra for the more polar (S)-sulfoxide diastereoisomers consistently showed 
a negative absorption at ~ 205nm rising to the baseline, followed by a strong negative 
absorption at ~ 240nm rising to a stronger positive absorption at ~ 270nm. The less 
polar cis-diol sulfoxides were then identified as (+)-cis-(1S,2R)-3-(R-
methylsulfinylmethyl)cyclohexa-3,5-diene-1,2-diol 125, (+)-cis-(1S,2R)-3-(R-
ethylsulfinylmethyl)cyclohexa-3,5-diene-1,2-diol 140 and  (+)-cis-(1S,2R)-3-(R-
propylsulfinylmethyl)cyclohexa-3,5-diene-1,2-diol 142. The more polar 
diastereoisomers were found to be (+)-cis-(1S,2R)-3-(S-
methylsulfinylmethyl)cyclohexa-3,5-diene-1,2-diol 122, (+)-cis-(1S,2R)-3-(S-
ethylsulfinylmethyl)cyclohexa-3,5-diene-1,2-diol 141 and (+)-cis-(1S,2R)-3-(S-
propylsulfinylmethyl)cyclohexa-3,5-diene-1,2-diol 143. 
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Fig 4.1. CD correlation of diol sulfoxide diastereoisomers 125, 140 and 142. 
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Fig 4.2. CD correlation of diol sufoxide diastereoisomers 122, 141 and 143. 
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The X-ray crystal structure  (Fig 3.2.) also allowed the determination of the 
stereochemistry of the diol sulfoxide 122, obtained from the P. putida UV4 
biotransformation of benzylmethyl sulfide 81, as discussed in Chapter 3. 
 Upon  DMD oxidation the cis-diol sulfide 129, obtained from the metabolism 
of  2-phenyl-1,3-dithiane 110 yielded  two of the four possible diastereoisomers. The 
less polar sulfoxidation product was found to be (+)-cis-(1S,2R)-3-(trans-(1!S,2!S)-
1!,3!-dithan-2!-yl-1!-oxy)cyclohexa-3,5-diene-1,2-diol 130, as it was spectrally 
indistinguishable from the diol sulfoxide metabolite 130 obtained from the 
biotransformation of the parent 1,3-dithiane 110. The absolute configuration of 
compound 130 had been determined by X-ray crystallography (Fig 3.4.). The second 
diastereoisomer was identified as (-)-cis-(1S,2R)-3-(trans-(1!R,2!R)-1!,3!-dithan-2!-yl-
1!-oxy)cyclohexa-3,5-diene-1,2-diol 144 (Scheme 4.2.). When similar oxidations 
were carried out on the parent 1,3-dithiane 110 with several oxidants  (DMD, NaIO4 
and MCPBA), the major product was always found to be the trans- sulfoxide. As 
there were only two cis-diol sulfoxide diastereoisomeric products from oxidation the  
cis-diol sulfide 129, it was assumed  that the second cis-diol sulfoxide diastereoisomer 
144 had a trans-configuration. 
 
 
Scheme 4.2. Synthesis of diol sulfoxide diastereoisomers 130 and 144. 
 
 Unfortunately due to the instability of the dithiolane diol sulfoxide 
bioproducts 136 and 137, the chemical sulfoxidation and separation of 
diastereoisomers was abandoned after the initial attempts. Efforts to isolate the 
products from this sulfoxidation via, cycloadduct formation, were similarly 
unsuccessful. 
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4.2. Aromatisation of chemoenzymatically synthesised cis-diol sulfoxides to 
yield phenols and catechols.  
 One limitation of the cis-dihydrodiols 122, 125 and 140-143 proved to be their 
instability. They have the potential to dehydrate, the driving force of this reaction 
being the aromatisation of the cis-diol ring. Aromatisation was found to occur under 
conditions of high temperature and low pH. Unfortunately some sulfoxides are also 
prone to racemisation under acidic conditions and high temperatures. The 
aromatisation of cis-dihydrodiol sulfoxides may in principle be used in the synthesis 
of chiral sulfoxides containing a phenol or catechol group. 
 
4.2.1. Phenol formation. 
 The crystalline diol sulfoxide 125 synthesised from the parent cis-diol sulfide 
85 was reacted under a range of conditions, in an attempt to aromatise the 
diastereoisomer. Methods studied included heating solutions with p-TSA in CHCl3, , 
NH3 in MeOH, Et3N in CHCl3, pH 7 aqueous buffer solution in water . Samples were 
also absorbed on to silica gel  or heated in the neat state in an effort to promote 
aromatisation. The progress of the reactions were monitored by TLC over an extended 
period of time. In each case evidence of isomerisation to a mixture of 
diastereoisomers 125 and 122 was observed in the presence ofphenolic products. 
Fortunately slight one set of reaction conditions was found to give enantiopure phenol 
sulfoxide 74. Thus a small sample of 125 in 5% TFA / CHCl3 solution was heated  
(45
o
C for 1.5h)  giving the phenolic sulfoxide 74 in a 90% yield, with only a trace of 
compound  84. Sulfoxide 74 was produced with a > 98% ee by CSP HPLC analysis 
(Chiralcel OB column, 10% IPA/Hex, Fig 4.3 and Scheme 4.3.). The CSP HPLC 
trace was compared with that the racemic mixture of enantiomers of 74 (! 1.13, 
Appendix 2.5.). 
 
Chapter 4.  99 
 
Fig 4.3. CSP HPLC trace of enantiopure phenol sulfoxide 74. 
 
 
 
 
Scheme 4.3. Synthesis of enantiopure phenol sulfoxide 74. 
 
 Attempts were made to carry out this aromatisation reaction with crystalline 
diol sulfoxide 130 (p-TSA/CHCl3).  Due to the electron withdrawing nature of the 
sulfoxidised 1,3-dithiane ring, the aromatisation of the cis-dihydrodiol was relatively 
slow and only occurred when the solution was heated (70
o
C). This increased stability 
had earler been observed for aromatisation of othersimilar arene cis-dihydrodiols, 
containing electron withdrawing substitutents.
121
 Under these conditions the rate of 
epimerisation appeared to be much higher than the rate of aromatisation, compared 
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with the relative rates observed for diol sulfoxide 125. The reaction gave four 
phenolic products (
1
H-NMR analysis), only one of which (145) could be fully 
characterised. The product was found to be racemic 2-(trans-1!-3!-dithian-2!-yl-1!-
oxy)phenol 145 by X-ray crystallography (see Fig 4.4.). In the crystalline state the 
1,3-dithiane ring adopted a conformation where the sulfoxide oxygen atom was 
equatorial, with no evidence of hydrogen bonding between the neighbouring hydroxyl 
and sulfoxide groups. The trans-diequatorial relationship between the phenyl and the 
sulfoxide groups was also evident (Fig 4.4.). 
 
 
 
 
 
Fig 4.4. X-ray crystal structure of (±)-2-(trans-1!,3!-dithian-2!-yl-1!-oxy)phenol 145 
(Dr J. F. Malone). 
 
 
 
NMR analysis and optical rotation measurements of the crude product mixture 
suggested that the other compounds were racemic cis / trans isomers of the ortho and 
meta phenols (Scheme 4.4.). The structure of the phenol sulfoxide 145 and 
racemisation was confirmed by X-ray crystallography. 
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Scheme 4.4. Aromatisation and epimerisation of  diol sulfoxide 130. 
 
It is difficult to provide a rational mechanism to account for the racemisation of four 
chiral centres in the cis-diol sulfoxide 130. The conversion of the cis-diol sulfoxide 
130 to the phenolic sulfoxide 145 reduces the number of chiral centres from four to 
two. The possibility of protonation of the sulfoxide group to yield a sulfonium salt 
could facilitate epimerisation of either the phenol or cis-diol sulfoxides as sulfonium 
salts have a much lower barrier to racemisation than the parent sulfoxides. This would 
explain racemisation at the sulfoxide centres, although a significant contributor from a 
ketodiene resonance structure, in the phenol products, may result in epimerisation, 
essentially racemising both the remaining chiral centres (Scheme 4.5.). This could 
occur due to formation of a planar resonance structure involving a carbon-sulfur 
double bond between  the C-2 carbon and the sulfonium sulfur atoms.  
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Scheme 4.5. Total racemisation of chiral centres in phenolic sulfoxide 145. 
 
This racemisation would not occur at the same rate using a diol sulfoxide derivative 
122 or 125 from benzylmethyl sulfide 81 due to the greater difficulty of formation of 
a carbanion intermediate on the benzylic carbon. 
The diol sulfoxide diastereomer 136 obtained from the metabolism of 1,3-
dithiolane 111, showed a similar tendency to epimerise yielding multiple products 
when analysed by TLC and NMR.  
 It was observed that when the reactions were carried out at lower temperatures 
and with lower catalyst concentrations, epimerisation appeared to be faster than 
aromatisation.  
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4.2.2. Catechol formation. 
 An alternative method of aromatising the arene cis-dihydrodiols to yield stable 
chiral sulfoxides, could involve oxidation of one of the allylic hydroxyl groups to a 
ketone, which would tautomerise to an enol. In the case of cis-dihydrodiol metabolites 
obtained from substituted benzene substrates, the enol (catechol) was the only 
observable tautomer due to resonance stabilisation (Scheme 4.6.). 
 
 
Scheme 4.6. Oxidation of a benzene cis-dihydrodiol to a catechol. 
      
A reagent commonly used in dehydrogenation reactions is Pd/C, but the relatively 
high temperatures are required to carry out the oxidation and such conditions may be 
too harsh for sulfoxides and arene cis-dihydrodiols. Arene cis-dihydrodiols are more 
likely to dehydrate to phenols using Pd/C. Other oxidation methods such as CrO3 or 
PCC may be too acidic or may require heating, and for similar reasons cannot be 
used. A milder enzyme-catalysed method for this reaction was examined. An E. coli 
recombinant strain
31
 containing the narB gene encoding a naphthalene cis-dihydrodiol 
dehydrogenase (NDD) was available in our laboratories. This strain was tested using 
the synthesised diol sulfoxide diastereoisomers in order to produce enantiopure 
catechol sulfoxides. 
 The diastereoisomeric pairs of diol sulfoxides 122, 125 and 140, 141 and a 
mixture of 142 and 143 (produced from DMD oxidation of the corresponding cis-diol 
bioproducts 85, 123 and 124), were added to cultures of E. coli narB and yielded 
catechol sulfoxides in some cases. As the configurations of the diastereoisomeric cis-
diol sulfoxides were known, the configurations and enantiopurity values of the 
derived catechol sulfoxide bioproducts were readily deduced. The diol sulfoxides 125 
and 122 gave (-)-3-(R-methylsulfinylmethyl)benzene-1,2-diol (R)-146 and (+)-3-(S-
methylsulfinylmethyl)benzene-1,2-diol (S)-146 with equal and opposite specific 
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optical rotations of  ([!]D - 70.9 (CHCl3) and + 69.5 (CHCl3) respectively. This 
experiment indicated that the cis-diol sulfoxide diastereoisomers were both substrates 
for the NDD enzyme. Similarly the diol sulfoxides 140 and 141 gave (-)-3-(R-
ethylsulfinylmethyl)benzene-1,2-diol (R)-147 and (+)-3-(R-
ethylsulfinylmethyl)benzene-1,2-diol (S)-147 with equal and opposite optical 
rotations ([!]D  - 53 and + 54, CHCl3) respectively (Scheme 4.7.). The inseparable 
equal mixture of diol sulfoxide diastereoisomers 142 and 143 as expected gave 3-
(propylsulfinylmethyl)benzene-1,2-diol 148 as aracemate. From these results is would 
appear that the NDD enzyme is unable to stereodifferentiate between diol sulfoxide 
diastereoisomers. The best yields of catechols were obtained for the crystalline diol 
sulfoxide 125 (71%). When diol sulfoxides 130 and 136 from the P. putida UV4 
metabolism of 1,3-dithiane 110 and 1,3-dithiolane 111 were added as substrates for 
NDD, no catechols were produced and the substrates were recovered unchanged. This 
could be due to the small size of the active site of the NDD enzyme. . 
 
 
 
Scheme 4.7. Catechol formation from diol sulfoxide diastereoisomer pairs 122, 125 
and 140-143 using E. coli narB. 
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4.3. Synthesis of cis-tetrahydrodiol sulfoxide diastereoisomers from the cis-
dihydrodiol metabolite of bromobenzene. 
 Among the substituted benzene substrates that were studied with P. putida 
UV4 were fluoro-, chloro-, bromo- and iodo- benzenes.
122
 The bioproducts were the 
corresponding cis-dihydrodiols i.e. cis-(1S,2R)-3-fluorocyclohexa-3,5-diene-1,2-diol 
147, cis-(1S,2S)-3-chlorocyclohexa-3,5-diene-1,2-diol 150, cis-(1S,2S)-3-
bromocyclohexa-3,5-diene-1,2-diol 34 and cis-(1S,2S)-3-iodocyclohexa-3,5-diene-
1,2-diol 151. With the exception of the fluorobenzene cis-dihydrodiol 149, all other 
cis-diols were enantiopure and were obtained in excellent yields from the 
biotransformations. For these reasons the cis-dihydrodiols  have proved to be very 
useful in chemoenzymatic synthesis (Chapter 1). One of the main reasons that these 
arene cis-dihydrodiols have been so useful in synthesis is the presence of the halides 
(e.g. Br- and I-) which can be interconverted into other functional groups. This halide 
substitution procedure increases the number and types of enantiopure cis-dihydrodiols 
that can be synthesised and subsequently used as chiral synthons. 
 Monooxygenases have earlier been shown to catalyse the oxidation of arenes 
into arene oxides that are in turn converted to trans-dihydrodiols via hydrolysis using 
epoxide hydrolase enzymes (Scheme 4.8.).  
 
 
 
Scheme 4.8. Conversion of monocyclic arenes to arene oxides and trans-
dihydrodiols. 
 
These arene oxides and trans-dihydrodiols have been implicated as the initial 
metabolites formed during the metabolism of carcinogenic PAHs. For this reason 
there has been much interest in studying their synthesis and their physical and 
chemical properties. During the latter studies it was found that arene oxides of 
monosubstituted benzenes have a low barrier to racemisation.
7
 This is due to the arene 
oxide being spontaneously isomerised to the corresponding oxepine via an 
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electrocyclic rearrangment involving cleavage of the epoxide C-C bond (Scheme 
4.9.). 
 
 
 
Scheme 4.9. Spontaneous racemisation of substituted benzene oxide enantiomers via 
oxepine valence tautomers. 
 
Earlier work carried out in these laboratories
7
 has involved the synthesis and 
racemisation of both arene oxides and arene dioxides. It has also been shown that 
arene trans-dioxides can be converted into trans-dihydrodiols.  
In this study, the synthesis of possible synthetic precursors to arene oxides and 
trans-dihydrodiols containing exocyclic sulfoxide centres has been attempted. 
 The first factor was the choice of starting material. The cis-dihydrodiol 
metabolite 34 obtained from the metabolism of bromobenzene 22 with P. putida UV4 
was selected as it was relatively stable and the bromine atom was readily replaceable. 
It was also available in higher yields compared with less the stable iodo-substututed 
bioproduct 151. In a preliminary experiment, cis-diol 34 was partially hydrogenated 
using H2/Rh-Al2O3 in THF at 15-20 psi and two products were isolated. cis-(1S,2S)-3-
Bromocyclohex-3-ene-1,2-diol 152 was obtained in a 40% yield and 2-bromophenol 
153 in a 35% yield (see Scheme 4.10.). Clearly the presence of the phenolic product 
was due to dehydration of the cis-dihydrodiol under the reaction conditions. When 
this reaction was repeated on a larger scale, but using a more dilute solution, the 
yields of the tetrahydrodiol 152 were found to be higher (~ 80% yield), and phenol 
153 was obtained as a very minor product.  
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Scheme 4.10. Partial hydrogenation of  cis-dihydrodiol 34. 
 
Protection of the cis-dihydrodiol 152 as an acetonide derivative was found to facilitate 
substitution of the bromine with a thiophenoxide group (Scheme 4.11.). 
 
 
 
Scheme 4.11. Protection of cis-tetrahydrodiol 152 by formation of an acetonide. 
 
The cis-diol 152 was converted to the acetonide cis- (3aS,7aS)-7-bromo-2,2-dimethyl-
3a,4,5,7a-tetrahydro-1,3-benzodioxole 154 (65% yield) by reacting with dimethoxy 
propoane (DMP) in the presence of an acid catalyst. This acetonide 154 was in turn 
reacted with Bu
t
Li in THF at – 70
o
C followed by the addition of Ph2S2 and allowed to 
warm to – 40
o
C giving the thioether product 155 (93% yield, Scheme 4.12.). Isolation 
and purification of the thioether 155 by PLC was aided by the presence of the benzene 
chromophore. 
 
Scheme 4.12. Substitution of the vinylic bromine with a sulfanyl group. 
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 In the next step the sulfur atom was oxidised using either DMD or MCPBA. 
The DMD oxidation was monitored by TLC and gave only sulfoxide products. These 
sulfoxides were separated by PLC. On the basis of NMR and MS data the sulfoxides 
were identified as the cis-tetrahydrodiol sulfoxides cis-(3aS,7aS)-2,2-dimethyl-7-(R-
phenylsulfinyl)-3a,4,5,7a-tetrahydro-1,3-benzodioxole 156 and cis-(3aS,7aS)-2,2-
dimethyl-7-(S-phenylsulfinyl)-3a,4,5,7a-tetrahydro-1,3-benzodioxole 157 (Scheme 
4.13.).  
 
 
 
Scheme 4.13. MCPBA oxidation of a sulfide 155 and separation of the sulfoxide 
diastereoisomers 156 and 157. 
 
The MCPBA oxidation was carried out in CHCl3 at room temperature and yielded 
three products, the first two products being spectrally identical to the sulfoxide 
diastereoisomers 156 and 157. The third very minor product appeared to be the 
sulfone cis-(3aS,7aS)-2,2-dimethyl-7-(phenylsulfonyl)-3a,4,5,7a-tetrahydro-1,3-
benzodioxole 158 (Scheme 4.14.). This was confirmed by addition of a large excess 
of oxidant that gave one product, sulfone 158 (96% yield). No evidence of an epoxide 
product was observed. Over-oxidation with DMD also yielded a spectrally similar 
compound, without epoxide formation. This observation is consistent with the 
electron withdrawing nature of the sulfone group which prevented epoxidation. 
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Scheme 4.14. Oxidation of sulfide 155 to sulfone 158. 
     
 The final step in the synthesis involved removal of the acetonide protecting 
group from the diastereoisomeric mixture. This was achieved by heating a mixture of 
the sulfoxide diastereoisomers 156 and 157 at 40
o
C in a solution of 1 :2 :8 
TFA/H2O/THF and separation  by PLC giving the diol sulfoxide products (-)-cis-
(1S,2S)-3-(R-phenylsulfinyl)cyclohex-3-ene-1,2-diol 159 and (-)-cis-(1S,2S)-3-(S-
phenylsulfinyl)cyclohex-3-ene-1,2-diol 160 in 70% overall yield. A specific optical 
rotation values ([!]D) of  – 7 (CHCl3) and – 89 (CHCl3) were found for the less polar 
crystalline metabolite for the more polar metabolites respectively (Scheme 4.15.). 
 
 
 
 
 
Scheme 4.15. Deprotection of sulfoxide and separation of the resulting 
diastereoisomers 159 and 160. 
 
 The absolute configurations of the cis-tetrahydrodiol sulfoxide product   160 
was determined by X-ray crystal structure analysis, using the anomalous dispersion 
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method, on the less polar crystalline product (Fig 4.5.). In the crystalline state 
diastereoisomer 160 adopted a conformation where the sulfoxide group was 
equatorial, with the hydroxyl group on C-1 in a pseudo-equatorial position and C-2 –
hydroxyl group in a pseudo-axial position. There is also some evidence of hydrogen-
bonding between hydroxyl at C-2 and and the sulfoxide oxygen atom. The absolute 
configuration at the sulfoxide centre was found to be (S). This identified the product  
(-)-cis-(1S,2S)-3-(S-phenylsulfinyl)cyclohex-3-ene-1,2-diol 160. The configuration of 
the other diastereoisomer was thus deduced to be  (-)-cis-(1S,2S)-3-(R-
phenylsulfinyl)cyclohex-3-ene-1,2-diol 159. 
 
 
 
Fig 4.5. X-ray crystal structure of (-)-cis-(1S,2S)-3-((S)-phenylsulfinyl)cyclohex-3-
ene-1,2-diol 160 (Dr J. F. Malone). 
 
 
 
 
 
 
Chapter 4.  111 
 
 The dihydroxylated sulfoxides 159 and 160 provide the first examples of 
chemoenzymatically synthesised cis-tetrahydrodiol sulfoxides, derived from the 
dioxygenase-mediated metabolism of monosubstuted arenes. As cis-tetrahydrodiol 
sulfoxides these compounds 159 and 160 were found to be much more stable than the 
corresponding cis-dihydrodiols. They also provide a new type of hydroxy sulfoxide 
with potential as chiral ligands for asymmetric asymmetric alkylation reactions using 
diethylzinc. The cis-tetrahydrodiol could also as synthetic precursors of arene oxides 
and trans-dihydrodiols each containing chiral sulfoxide groups. The potential 
relevance of these intermediates in synthesis will discussed briefly. 
As discussed in Chapter 2, diethylzinc reactions with aldehydes may be 
catalysed by chiral alcohol sulfoxides. Previously it has been possible to substitute 
one of the less hindered hydroxyl groups on cis-dihydrodiols and cis-tetrahydrodiols 
with methoxyl groups or silyl ether groups. The X-ray crystal structure of the cis-diol 
sulfoxide 160 also shows possible hydrogen bonding between the hydroxyl group on 
C-2 and the sulfoxide. It should be simple to selectively protect the -OH group on C-1 
leaving the C-2 -OH group free to form intramolecular hydrogen-bonds, or to form a 
chiral complex with diethylzinc. 
It should also be possible to synthesise and study the physical and chemical 
properties of arene oxides derived from diastereoisomers 159 and 160. In previous 
studies on the synthesis of arene oxides and their racemisation through oxepine 
formation the synthetic route involved formation of a tetrahydrodiol similar to 
compound 159 and 160. This approach may also be applied to the synthesis of arene 
oxides containing sulfoxide groups (Scheme 4.16.). This synthetic scheme could 
involve formation of a bromoacetate by reacting the diol with AcOCMe2COBr, 
followed by conversion to the epoxide using NaOMe. The epoxide could be 
brominated with NBS, and HBr removed with NaOMe giving an arene oxide. This 
technique has been successfully applied to other tetrahydrodiols in these laboratories. 
The inclusion of the fixed sulfoxide chiral centre in this scheme could aide the study 
of the epimerisation of the arene oxide by techniques such as 
1
H-NMR spectroscopy 
as the diastereoisomers would have different chemical and physical properties. 
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Scheme 4.16. Application of a cis-tetrahydrodiol sulfoxide diastereoisomer in the 
synthesis of epimerising arene oxide/oxepine sulfoxide diastereoisomers. 
 
From the diastereoisomers 159 and 160 it should also be possible to synthesise the 
corresponding trans-dihydrodiol sulfoxides. One of the well-known methods in 
synthetic organic chemistry of inverting the stereochemistry of an alcohol is the 
‘Mitsunobo inversion’. Theoretically, using this method, it is possible to synthesise 
arene trans-dihydrodiols from arene cis-dihydrodiols by inverting the stereochemistry 
of the 2-hydroxyl. It has been demonstrated by Hudlicky et al
123
 that the direct 
inversion of the C-2 chiral centre bearing a hydroxyl group in cis-dihydrodiols is not 
possible due to the unstable nature of arene cis-dihydrodiols. It is however possible to 
synthesise trans-dihydrodiols via a Mitsunobo inversion on the cis-tetrahydrodiol, 
followed by bromination and dehydrobromination to give the arene cis-dihydrodiol.
7
 
This technique may be applied to diol sulfoxides similar to 159 and 160 (Scheme 
4.17.). This could allow the study of the physical and chemical properties of the 
potential carcinogenic trans-dihydrodiol metabolites derived from organosulfur 
compounds. 
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Scheme 4.17. Synthesis of trans-dihydrodiols  from a cis-tetrahydrodiols. 
 
4.4. Synthesis of potential hydroxy sulfoxide ligands from an optically pure 
benzyl sulfoxide derived from the ‘Andersen method’. 
 As briefly discussed in Chapter 1, chemoenzymatically synthesised 
enantiopure sulfoxide (S)-77 was used in the enantioselective addition of diethylzinc 
to benzaldehyde 101. The results seemed promising even though reaction conditions 
had not yet been optimised. In previous sections, a range of hydroxylated sulfoxides 
have been synthesised chemoenzymatically, including studies into the dioxygenase-
mediated metabolism of dialkyl sulfides, containing benzylic carbon atoms, in an 
attempt to synthesise enantioenriched dialkyl sulfoxides using an enzyme-catalysed 
asymmetric synthesis. In this section it will be demonstrated how functionalised 
sulfoxides, with potential as chiral ligands, can be synthesised from an optically pure 
benzyl sulfoxide, benzyl-p-tolyl sulfoxide 91. 
 This sulfoxide 91 was chosen as it was a benzylic sulfoxide and this sulfoxide 
type may be functionalised at the benzylic carbon atom, due to the ease of formation 
of stabilised carbanions. The inclusion of the second aromatic ring avoided the 
possibility of any side reactions with stabilised alkyl groups as the second sulfoxide 
substituent.  
 Benzylphenyl sulfoxide 161, a sulfoxide similar in structure to sulfoxide 91 
has been produced in an enantioenriched form by the dioxygenase-mediated 
metabolism of the parent sulfide 162 using P. putida UV4 (see Scheme 4.18.).
99
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Scheme 4.18. Dioxygenase-mediated metabolism of sulfide 162 using P. putida UV4. 
 
Although the sulfoxide (S)-161 was produced with a high ee value, the isolated yield 
is very poor.  
 It was also hoped that the sulfoxide 91 might be a good substrate for the 
DMSO reductase-containing strains of bacteria which would provide enough of an 
enantiopure sample for further synthetic studies. Unfortunately no resolution was 
observed, therefore an optically pure sample of (R)-91 was provided from a previous 
synthesis utilising the ‘Andersen method’. This involved the reaction of commercially 
available (R)-menthyl-p-tolyl sulfinate (R)-163 with benzyl magnesium bromide 
(Grignard reagent, Scheme 4.19.) yielding sulfoxide (R)-91. 
 
 
 
 
 
 
Scheme 4.19. Synthesis of enantiopure sulfoxide (R)-91 using the ‘Andersen method’. 
 
The enantiopure sulfoxide (R)-91 was then reacted with mixtures of Bu
t
Li/THF 
followed by addition acetone or  benzophenone 165 at – 70
o
C (Scheme 4.20.). 
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Scheme 4.20. Functionalisation of sulfoxide (R)-91. 
 
The products from these reactions were both produced as single diastereoisomers, the 
absolute configurations of these were determined by X-ray crystallography, using the 
anomalous dispersion method (Figs 4.6. and 4.7.). The X-ray crystal structure of 
crystalline 166 ([!]D + 372, CHCl3) showed the aromatic substituents facing each 
other, with no evidence of hydrogen-bonding, due to steric interaction. The X-ray 
analysis confirmed the structure absolute configuration of sulfoxide 166 to be (+)-
(1S)-2-methyl-1-(R-4-methylphenylsulfinyl)-1-phenylpropan-2-ol. 
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Fig 4.6. X-ray crystal structure of (+)-(1S)-2-methyl-1-(R-4-methylphenylsulfinyl)-1-
phenylpropan-2-ol 166 (Dr J. F. Malone). 
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Fig 4.7. X-ray crystal structure of (+)-(2S)-2-(R-4-methylphenylsulfinyl)-1,1,2-
triphenylethan-1-ol 167 (Dr J. F. Malone). 
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The X-ray structure of compound 167 ([!]D + 137, CHCl3) showed the aromatic 
substituents cis to each other, with evidence of hydrogen-bonding between the 
hydroxyl group and the sulfoxide oxygen atom. The X-ray analysis confirmed the 
structure and configuration of sulfoxide 167 to be (+)-(2S)-2-(R-4-
methylphenylsulfinyl)-1,1,2-triphenylethan-1-ol. 
 Hydroxy sulfoxide 167 was then tested under the same conditions as for 
sulfoxide (S)-77, (Chapter 2) for applicability as a ligand in asymmetric Et2Zn 
reactions. The results are presented in Table 4.1. 
 
 
Isolated Yield (%) Ligand Ee (%) of 
105 107 108 104 109 
 
167 
 
 
16.3 
 
 
56 
 
 
15 
 
 
15 
 
 
7 
 
(S)-77 
 
 
27.0 
 
 
30 
 
 
21 
 
 
17 
 
 
10 
 
(S)-106 
 
 
8.7 
 
 
79 
 
 
8 
 
 
0.5 
 
 
_ 
 
 
 
Table 4.1. Enantioselective addition of Et2Zn to benzaldehyde 104. 
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The results in Table 4.1. showed that the new hydroxy sulfoxide 167 has the ability to 
catalyse the enantioselective addition of Et2Zn to benzaldehyde 101. Although the ee 
values are lower, the yields of the byproducts 108 and 109 have decreased in 
comparison to the overall yield. The ee value is however still higher that that obtained 
by the standard ligand (S)-106, which in the literature gives a higher value than in this 
preliminary study. 
 
4.5. Conclusion. 
 In this and previous chapters it has been shown that a wide range of 
enantioenriched functionalised sulfoxides, such as hydroxylated sulfoxides, can be 
synthesised chemoenzymatically, using combinations of DMSO reductase 
dioxygenase and cis-diol dehydrogenase enzymes allied to chemical syntheses. Some 
of these sulfoxides may have been produced as metabolites, whose structures and 
absolute configurations can tell us more about the chemo-, regio- and 
enantioselectivities of attack of the enzymes under study. Other sulfoxides produced 
have been chemoenzymatically synthesised from these metabolites. Other uses for 
these sulfoxides may be as chiral auxiliaries or ligands in reactions such as the 
asymmetric diethyl zinc reactions. Two such sulfoxides 77 and 167 have already 
shown potential for this type of reaction. 
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Chapter 5. Experimental. 
 
5.1. General experimental details. 
 Equipment used in the characterisation of products is summarised in Table 
5.3., along with explanatory comments. 
 Chromatographic techniques employed in purification are listed below (Table 
5.1.). Visualisation of bands/spots was at 254nm with a Spectroline ENF-260C/F UV 
lamp. 
 
Method Stationary phase 
Analytical TLC Merck Kieselgel 60F254 plates 
Preparative TLC (PLC) Glass plates (20cm x 20cm) coated with Merck Kieselgel Pf254 
(21g in 59ml water) 
Flash Chromatography Merck Kieselgel 60 (230-400 mesh) at a flow rate of c.a. 
2.5cm/minute 
 
Table 5.1. Silica based chromatographic techniques used in analysis and purification 
 
 Solvents for chromatography and recrystallisation were as specified for each 
compound and were distilled before use. When anhydrous solvents were used, the 
following procedures were followed (Table 5.2.). 
 
Acetone Distilled from potassium permanganate and stored over potassium 
carbonate. 
Benzene Stored over sodium wire. 
Dichloromethane Distilled from phosphorous pentoxide and stored over 4A 
molecular sieves. 
DMF Distilled from phosphorous pentoxide and stored over 4A 
molecular sieves. 
Ether Stored over sodium wire. 
Pyridine Stored over potassium hydroxide pellets. 
THF Distillation over sodium/benzophenone. 
 
Table 5.2. Drying procedures for solvents. 
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Analysis Instrument / comment 
Melting points (mp) Reichert block; uncorrected 
1
H-NMR-300 & 
500MHz 
General Electric QE 300 or GN 500, Bruker Avance DPX-300 or 
DRX-500; All coupling constants (J) are measured in Hertz; All 
chemical shifts are reported in ppm from TMS. 
13
C-NMR-125MHz Bruker Avance DRX-500. 
Mass spectra Recorded at 70eV on an AE1-MS902 instrument updated by V. 
G. Autospeck instruments, using a heated inlet system. 
Accurate molecular 
weights 
Recorded on an AE1-MS902 instrument updated by V. G. 
Autospeck instruments by the peak matching method using 
perfluorokerosene as standard and were accurate to within ± 
0.000006 a.m.u. 
Elemental Analyses Perkin-Elmer 2400 CHN microanalyser and compounds quoted 
gave elemental analysis within ± 0.5% of the theoretical values. 
[!]D Perkin-Elmer automatic precision polarimeter Model 241; 
Solvent and concentration (g/100cm
3
) specified for each 
compound. Recorded at the sodium D line (598nm) and at 
ambient temperature. 
Circular Dichroism 
(CD) spectra 
Jasco J-720 instrument; methanol solvent (spectroscopic grade). 
Sample concentration (ca. 0.5mg/cm
3
), "# in cm
2
mmol
-1
. 
HPLC Beckman System gold
®
 128 solvent module and 168 detector, 
Pye Unicam LC-XPD pump and LC-UV detector, Shimadzu LC-
6A connected to a Hewlett Packard Diode Array detector. 
X-ray 
crystallogrophy 
Siemens P3/V2000 diffractometer. 
 
Table 5.3.Equipment used in characterisation. 
 
5.2. General biotransformation procedure. 
 A typical shake flask biotransforamtion procedure for P. putida UV4 is 
detailed below. 
 P. putida UV4 was streaked aseptically on to L-agar plates and incubated for 
15hrs at 30
o
C. Single colonies from the plates were streaked on two minimal salts 
(MS) plates (with paper grids attached and one of them also containing indole) using 
sterile tooth picks. After 24hrs incubation, the indole plate was examined. The relative 
intensities of the indigo spots on the plate indicated the most dioxygenase-active 
colonies and were selected for carrying out the biotransformation. 
 Dioxygenase-active colonies (indole-test positive) were inoculated into 20 
Erlenmeyer flasks (250cm
3
) containing minimal growth medium (50cm
3
) and 12.5% 
w/w sodium pyruvate solution (2cm
3
) followed by incubation on a rotary shaker (250 
rev/min) at 30 °C for 7hrs. The turbid solutions were transferred into 2L Erlenmeyer 
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flasks containing minimal growth medium (375cm
3
) and 12.5% w/w/ sodium 
gluconate solution (15cm
3
) and were incubated on a rotary shaker at 30
o
C overnight. 
Centrifugation of the culture suspensions at 7000 rpm for 15min removed the 
bacterial cells and yielded the aqueous supernatant.  This aqueous  mixture of 
bioproducts was concentrated under reduced pressure at ~ 35 
o
C  and the residue 
repeatedly extracted with ethyl acetate. The extract was dried (Na2SO4) and solvent 
removed under reduced pressure to yield the crude biotransformation products for 
purification. 
 Large scale biotransformations were performed using Electrolab 7- and 10L- 
and LH/Inceltech 20- and 50L-fermenters (Table 5.4.). 
 
Make Volume 
(working 
volume) 
Sterilisation 
method 
Heating method Description 
Electrolab 7L (5L) Autoclave None (used at 
room 
temperature) 
Glass vessel with a 
two step rushden 
turbine, sample port 
and punctured bar 
oxygen inlet. 
Electrolab 10L (7-8L) Autoclave None (used at 
room 
temperature) 
As above but was also 
fitted with pH 
monitor, oxygen 
tension and temp. 
probes. 
LH/Inceltech 20L (18L) Self- 
sterilizing 
External electrical 
heating element. 
As for Electrolab 
(10L). 
LH/Inceltech 50L (33L) Self-
sterilizing 
Steam operated 
heating system. 
As for Electrolab 
(10L). 
 
Table 5.4. Details of fermenters. 
 
 For 10L and smaller biotransformations, batch centrifugation at 7000 rpm for 
15mins was used to remove the cells post biotransformation. For larger volumes, 
continuous centrifugation was employed using a Sharples steam operated continuous 
centrifuge. This consisted of a tube spinning at 45000 rpm through which the cell 
suspension was passed. The bacteria are retained in the spinning tube and the cell free 
supernatant collects at the end. Aqueous extracts were generally stored awaiting 
extraction at 4
o
C for a few weeks, depending on the stability of the bioproducts. 
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5.3. Synthesis of substrates for metabolism with P. putida UV4. 
 
  
Benzylethyl sulfide 87. 
 
Benzyl mercaptan (20g, 0.161mol) was added to a stirred solution of sodium (4.2g, 
0.175mol) dissolved in anhydrous ethanol (150cm
3
). The reaction mixture was stirred 
for a further 20 min under an atmosphere of nitrogen gas. Ethyl iodide (27g, 
0.173mol) was  added and the reaction mixture refluxed (6hr) under anhydrous 
conditions. The solvent was evaporated off, the residue extracted with ether and 
washed with water. The extract was dried (Na2SO4), the solvent removed under 
reduced pressure and the residue was distilled to give sulfide 87 (23.5g, 96%) as a 
colourless oil; bp 155-157 
o
C (lit.
124
 bp 35-36 
o
C /15 mmHg); $H (500 MHz, CDCl3) 
1.23 (3 H, t, J 7.4, Me), 2.43 (2 H, q, J 7.4, CH2Me), 3.72 (2 H, s, ArCH2), 7.22-7.25 
(1 H, m, Ar), 7.28–7.31 (4 H, m, Ar); $C (125 MHz, CDCl3) 14.27, 25.14, 35.81, 
126.77, 128.35, 128.71, 138.52; m/z  (ES) 191 ([M+39]
+
, 100%). 
 
 
 
Benzylpropyl sulfide 88. 
 
Benzyl mercaptan (20g, 0.161 mol) was added to a stirred solution of sodium (4.2g, 
0.175 mol) dissolved in dry ethanol (150 cm
3
). Propyl iodide (29.4g, 0.173mmol) was 
then added to the stirring reaction mixture. After refluxing the reaction mixture (2hr) 
under anhydrous conditions the solvent was evaporated off, the residue extracted with 
ether and washed with water. The extract was dried (Na2SO4) and the solvent 
removed under reduced pressure. The crude product was distilled to yield sulfide 88 
(24.5g, 92%) as a colourless oil; bp 165 
o
C (lit.
125
 bp 112 
o
C /15 mmHg); $H (500 
MHz, CDCl3) 0.95 (3 H, t, J 7.3, Me), 1.57 (2 H, m, CH2Me),  2.39 (2 H, t, J 7.3, 
CH2Et),  3.70 (2 H, s, ArCH2), 7.22–7.25 (1 H, m, Ar),  7.28–7.31 (4 H, m, Ar); $C 
(125 MHz, CDCl3) 16.21, 25.27, 36.15, 38.96, 129.57, 131.15, 131.54, 141.41; m/z 
(ES) 205 ([M+39]
+
, 100%). 
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Benzyl i-propyl sulfide 89. 
 
Benzyl mercaptan (4g, 16mmol) was added to a stirred solution of sodium (0.84g, 
18mmol) dissolved in dry ethanol (50cm
3
). Isopropyl iodide (3g, 17mmol) was then 
added to the stirring reaction mixture. After refluxing the reaction mixture (2hr) under 
anhydrous conditions the solvent was evaporated off, the residue extracted with ether 
and washed with water. The extract was dried (Na2SO4) and the solvent removed 
under reduced pressure. The residue was purified by column chromatography 
(hexane) yielding sulfide 89 (4.8g, 90%) as a colourless oil; bp 65
o
C /2mmHg (lit.
126
 
95-98
o
C 10mmHg); Rf 0.85 (Hexane); $H (500 MHz, CDCl3) 1.25 (6 H, d, J 6.7, Me), 
2.80 (1 H, sept, J 6.7, CH), 3.74 (2 H, s, CH2), 7.22–7.25 (1 H, m, Ar), 7.28–7.34 (4 
H, m, Ar); $C (125 MHz, CDCl3) 22.41, 33.55, 34.45, 126.08, 127.73, 128.04, 138.06; 
m/z (ES) 205 ([M+39]
+
, 100%).  
 
 
 
2-Phenyl-1,3-dithiolane 111. 
 
 
A solution of BF3-Et2O complex (6cm
3
, 0.05mmol) was added, dropwise with 
stirring, to a solution of benzaldehyde (15.93g, 0.15 mmol) and ethane-1,2-dithiol 
(14.10g, 0.15mmol) in CHCl3 (600cm
3
) at 0 
o
C. After leaving the mixture standing at 
0 
o
C for 48hr, it was successively washed with ice cold aqueous KOH solution (7%, 2 
x 200cm
3
) and water (200cm
3
). The extract was dried  (Na2SO4) and the solvent 
distilled off to give dithiolane 111 (24.68g, 90%) as a colourless oil which crystallised 
as a white solid; mp 24 
o
C (from hexane) (lit.
127
 24-26 
o
C); $H (500 MHz, CDCl3) 
3.34-3.37 (2 H, m, CHAHB), 3.49-3.53 (2 H, m, CHAHB), 5.64 (1 H, s, 2-H), 7.25-7.33 
(3 H, m, Ar), 7.52 ( 2 H, d, J 8.5, Ar); $C (125 MHz, CDCl3) 40.23, 56.30, 127.95, 
128.04, 128.49, 140.32; m/z (EI) 182 (M
+
, 100%), 105 (M
+
-C6H5, 24%), 77 (M
+
-
C3H5S2, 43%).  
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5.4. Synthesis and biotransformation of racemic sulfoxides for kinetic 
resolution with DMSO reductases.  
 
 The crude mixture of bioproducts, obtained from each biotransformation, was 
purified by column chromatography and/or PLC. The residues were analysed, to 
determine the ee values of the metabolites, using the CSP HPLC systems mentioned 
in Chapter 2. The absolute configurations of the metabolites were asssigned by 
comparisons of their CSP HPLC profiles and/or optical rotation data with that of the 
enantiomers of known configurations. 
 
5.4.1. Synthesis of dialkyl sulfides. 
 
 
Benzylmethyl sulfoxide 70. 
 
A solution of sodium periodate (9.30g, 43.5mmol) in water (100 cm
3
) was added 
dropwise to a solution of benzyl methyl sulfide 81 (5g, 36.2mmol) in methanol 
(300cm
3
), maintained at 0 
o
C.  After leaving the reaction mixture stirred overnight, 
the solvent was evaporated off and the residue extracted with EtOAc. The extract was 
dried (Na2SO4) and the solvent removed to give the crude sulfoxide 70 (5.07g, 91%), 
which crystallised (from hexane) as colourless crystals; mp 50-54 
o
C (lit.
128
 52-55 
o
C, 
from CHCl3); $H (500 MHz, CDCl3) 2.45 (3 H, s, Me), 3.92 (1 H, d, JA,B 12.9, 
CHAHB), 4.06 (1 H, d, JB,A 12.8, CHAHB), 7.28 (2 H, d, J 7.3, Ar), 7.35-7.39 (3 H, m, 
Ar); $C (125 MHz, CDCl3) 37.33, 60.41, 128.47, 129.01, 129.71, 130.03; m/z (EI) 154 
(M
+
, 25%). 
 
 
Benzylethyl sulfoxide 71. 
 
A solution of sodium periodate (9.30g, 43.5 mmol) in water (100cm
3
) was added 
dropwise to a solution of benzylethyl sulfide 87 (5g, 36.2mmol) in methanol (300cm
3
) 
kept at 0 
o
C.  After leaving the reaction mixture stirred overnight, it was worked up as 
described for sulfoxide 70  to give the crude sulfoxide 71 (5.1g, 84%). It crystallised 
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as colourless crystals; mp 56-58 
o
C (from hexane) (lit.
129
 54-55 
 o
C); $H (500 MHz, 
CDCl3) 1.35 (3 H, t, J 7.5, Me), 2.53-2.68 (2 H, m, CH2Me), 3.94 (1 H, d, JA,B 12.9, 
ArCHAHB), 4.03 (1 H, d, JB,A 12.9, ArCHAHB), 7.27-7.39 (5 H, m, Ar); $C (125 MHz, 
CDCl3) 6.61, 44.06, 57.58, 128.37, 129.01, 129.92, 129.98; m/z (EI) 168 (M
+
, 27%). 
 
 
 
Benzylpropyl sulfoxide 72. 
 
A solution of sodium periodate (1.9g, 9.0mmol) in water (25cm
3
) was added dropwise 
to a solution of benzylpropyl sulfide 88 (1g, 6.0mmol) in methanol (50cm
3
) 
maintained at 0 
o
C. After leaving the reaction mixture stirred overnight, it was worked 
up as described for sulfoxide 70  to give the crude sulfoxide 72 (0.98g, 90%) which 
crystallised  as colourless crystals; mp 45 
o
C (from hexane) (lit.
128
 42-43 
o
C, from 
CHCl3); $H (500 MHz, CDCl3) 1.03 (3 H, t, J 7.4, Me), 1.76-1.83 (2 H, m, CH2Me), 
2.52-2.59 (2 H, m, CH2Et), 3.94 (1 H, d, JA,B 12.9, ArCHAHB), 4.03 (1 H, d, JB,A 12.9, 
ArCHAHB), 7.29 (2 H, d, J 8.1, Ar), 7.34-7.40 (3 H, m, Ar); $C (125 MHz, CDCl3) 
13.38, 16.18, 52.90, 59.57, 128.33, 128.97, 130.00, 130.52; m/z (EI) 182 (M
+
, 28%). 
 
 
 
Benzyl i-propyl sulfoxide 73. 
 
A solution of sodium periodate (1.9g, 8.9mmol) in water (25cm
3
) was added dropwise 
to a solution of benzyl iso-propyl sulfide 89 (1g, 6.0mmol) in methanol (50cm
3
) 
which was maintained at 0 
o
C. After leaving the reaction mixture overnight, it was 
worked up as described for sulfoxide 70 to give the crude sulfoxide 73 (0.93g, 85%) 
as a white crystalline solid; mp 36 
o
C (from hexane) (lit.
129
 25-27 
o
C); $H (500 MHz, 
CDCl3) 1.28 (3 H, d, JCH,MeA 7.0, CMeAMeB), 1.33 (3 H, d, JCH,MeB 6.8, CMeAMeB), 
2.65-2.71 (1 H, m, CH), 3.91 (2 H, m, CH2), 7.30-7.37 (5 H, m, Ar); $C (125 MHz, 
CDCl3) 13.78, 16.70, 48.25, 55.01, 128.20, 128.96, 129.92, 130.58; m/z (EI) 182 M
+
, 
77%). 
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(3-hydroxybenzyl)methyl sulfoxide 74. 
 
Phenol 74  was the major component, obtained as a white crystalline solid (67% 
relative yield), from the decomposition of diol sulfoxide 125, mp 120 
o
C (from 
CHCl3); Rf 0.35 (7% MeOH/CHCl3); (Found: M
+
, 170.0402; C8H10O2S requires 
170.0397); $H (500 MHz, CDCl3) 2.50 (3 H, s, CH3), 3.80 (1 H, d, JA,B 14.2, 
ArCHAHB), 4.46 (1 H, d, JB,A 14.2, ArCHAHB), 6.90 (1 H, m, Ar), 7.01-7.05 (2 H, m, 
Ar), 7.26 (1 H, m, Ar), 9.17 (1 H, s, OH); $C (125 MHz, CDCl3) 35.89, 55.18, 117.73, 
119.33, 120.61, 130.64, 132.22, 156.80; m/z (EI) 170 (M
+
, 35%), 107 (M
+
-CH3SO, 
100%). 
 
 
(2-hydroxybenzyl)methyl sulfoxide 84. 
 
Phenol 84, a white crystalline solid (33% relative yield); was obtained as a minor 
component, from the decomposition of diol sulfoxide 125,  mp 116 
o
C (from EtOAc) 
(lit.
130
 108-110
o
C); $H (500 MHz, CDCl3) 2.52 (3 H, s, Me), 3.93 (1 H, d, JA,B 13.7, 
CHAHB), 4.35 (1 H, d, JB,A 13.7, CHAHB), 6.90 (1 H, m, Ar), 3.99 (1 H, d, J 8.2 Ar), 
7.09 (1 H, d, J 7.5, Ar), 7.23 (1 H, m, Ar), 9.08 (1 H, s, OH); $C (125 MHz, CDCl3) 
36.18, 54.88, 117.09, 118.11, 120.39, 130.40, 132.14, 156.58; m/z (EI) 170 (M
+
, 
20%), 107 (M
+
-CH3SO, 100%). 
 
5.4.2. Synthesis of dialkyl sulfides. 
 
 
 
2-(Methylsulfinyl)phenol 77. 
 
A stirred solution of 2-(methylsulfanyl)phenol (5g, 35.7mmol), in acetone (50cm
3
) 
maintained at 0 
o
C, was oxidised by the dropwise addition of a solution of DMD in 
acetone. The progress of oxidation reaction was followed by TLC analysis of the 
reaction mixture.  After completion of the reaction acetone was evaporated off and the 
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residue dried (vaccum pump). The crude dried sample was crystallised, to furnish 
sulfoxide 77 (5.30g, 95%) as a colourless crystalline solid; mp 123 
o
C (from MeOH) 
(lit.
131
 127-128 
o
C); Rf 0.23 (5% MeOH/CHCl3); $H (500 MHz, CDCl3) 2.96 (3 H, s, 
Me), 6.93 (1 H, m, Ar), 6.97 (1 H, d, J 7.7, Ar), 7.07 (1 H, d, J 7.8, Ar), 7.37 (1 H, m, 
Ar); $C (125 MHz, CDCl3) 41.91, 119.71, 119.86, 123.07, 124.83, 133.05; m/z (EI) 
156 (M
+
, 100%), 141 (M
+
-CH3, 95%). Sulfoxide 77 (0.5g), was used as a substrate 
with Citronella braakwi DMSO-11. The progress of the biotransformation was 
monitored by RP HPLC (30% H2O/MeOH). The biotransformation was terminated 
when 55% of the substrate 77 had metabolised to the corresponding sulfide. The 
aqueous biotransformation solution was concentrated under reduced pressure and the 
residue extracted with EtOAc. The crude material, obtained after removal of the 
solvent, was purified by PLC (5% MeOH/CHCl3)  to yield sulfoxide 77 (135mg, 
27%); ([!]D) of – 189 (c 0.5, CHCl3) (lit.
101
 – 191, CHCl3);The enantiomeric excess ( 
! 98%) was determined by CSP HPLC analysis using a Chiralcel OB column (10% 
IPA/hexane, flow 0.5 cm
3
/min, ! 1.58); CD: % 281nm "# - 5.93, % 236nm "# - 1.50, % 
215nm "# 6.39, % 203nm "# – 6.15. 
 
 
 
Methyl p-tolyl sulfoxide 29. 
 
A solution of sodium periodate (4.65g, 21.7mmol) in water (50cm
3
) was added 
dropwise to a solution of methyl-p-tolyl sulfide 79 (2g, 14.5mmol) in methanol 
(75cm
3
) maintained at 0
o
C; the reaction mixture was left stirring overnight and then 
worked up by the procedure described for sulfoxide 70 to give the crude sulfoxide 29 
(2.01g, 90%) as a white crystalline solid; mp 45-48 
o
C (from hexane) (lit.
132
 41-42 
o
C); Rf 0.24 (Et2O); $H (500MHz, CDCl3) 2.41 (3 H, s, ArMe), 2.71 (3 H, s, SOMe), 
7.33 (2 H, d, J 8.0, Ar), 7.54 (2 H, d, J 8.1, Ar); $C (125 MHz, CDCl3) 21.40, 43.99, 
123.57, 130.06, 141.55, 142.52; m/z (EI) 154 (M
+
, 91%), 139 (M
+
-CH3, 100%), 91 
(M
+
-CH3SO). 
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5.4.3. Synthesis of benzyl para-tolyl sulfoxide 91. 
 
 
 
i-Propyl p-toluene sulfinate 92. 
 
p-Toluenesulfinic acid, sodium salt (4g, 22.5mmol) was suspended in thionyl chloride 
(15cm
3
) and the mixture stirred in a partially stoppered  flask for 30min. Excess of 
thionyl chloride was distilled off and anhydrous iso-propanol (40 cm
3
) was added to 
the residue followed by Et3N (10 cm
3
). Water (75 cm
3
) was then added, the crude 
product extracted with EtOAc from the quenched reaction mixture and dried 
(Na2SO4). The solvent was distilled off leaving sulfinate 92 (4.40g, 98%) as a 
colourless oil which decomposed on distillation; Rf 0.84 (Et2O); $H (500 MHz, 
CDCl3) 1.24 (3 H, d, JCH,MeA 6.3, CHMeAMeB), 1.38 (3 H, d, JCH,MeB 6.2, CHMeAMeB), 
2.42 (3 H, s, ArMe), 4.57-4.62 (1 H, m, CH), 7.32 (2 H, d, J 8.3, Ar), 7.60 (2 H, d, J 
8.2, Ar); $C (125 MHz, CDCl3) 21.50, 23.76, 23.96, 72.65, 125.06, 129.61, 142.47, 
142.79; m/z (EI) 155 (M
+
-C3H7, 13%), 107 (M
+
-C7H7, 77%), 91 (M
+
-C3H7O2S, 82%). 
The spectral data of sulfinate 92 was identical with the literature data.
133 
 
 
 
 
Benzyl p-tolyl sulfoxide 91. 
 
Benzyl bromide 94 (1g, 5.85 mmol) was added to anhydrous ether (20 cm
3
) 
containing dry magnesium turnings (0.2g, 8.33 mmol)  under nitrogen gas 
atmosphere. After initiation of the reaction, the mixture was left stirring for 30 min. at 
ambient temperature. iso-Propyl-4-methyl-1-benzene sulfinate 92 (1.16g, 5.85mmol) 
was  added dropwise into the reaction mixture; it was  stirred for a further 15min. 
before quenching it by the addition of  HCl solution (50 cm
3
, 3M). The crude product 
was extracted with EtOAc dried (Na2SO4) and the solvent evaporated leaving 
sulfoxide 91 (1.14g, 97%) as a white crystalline solid; mp 140 
o
C (from MeOH) 
(lit.
134
 136-137 
o
C); Rf 0.51 (Et2O); $H (500 MHz, CDCl3) 2.40 (3 H, s, Me), 3.97 (1 
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H, d, JA,B 12.6, CHAHB), 4.10 (1 H, d, JB,A 12.6, CHAHB), 6.99 (2 H, d, J 7.6, Ar), 
7.21-7.28 (7 H, m, Ar); $C (125 MHz, CDCl3) 21.46, 63.67, 124.48, 128.19, 128.45, 
129.29, 129.56, 130.37, 139.47, 141.65; m/z (EI) 230 (M
+
, 20%), 214 (M
+
-H2O, 
65%), 139 (M
+
-C7H7, 84%), 91 (M
+
-C7H7OS, 63%), 77 (M
+
-C8H9OS, 100%). 
 
5.4.4. Synthesis of Phenyl o-tolyl sulfoxide 78  for kinetic resolution. 
 
 
 
Phenyl o-tolyl sulfide 83. 
 
The Grignard’s reagent of o-bromo toluene 102 (5g, 29.2mmol) was prepared by its 
slow addition to a mixture of magnesium filings (0.84g, 35mmol) in anhydrous ether 
(100 cm
3
) under an inert atmosphere. Diphenyldisulfide (6.3g, 29mmol), in ether (20 
cm
3
), was added dropwise and the reaction mixture refluxed (1hr) befor quenching 
with the addition of HCl solution (50 cm
3
, 3M). The ether layer was separated, 
washed with potassium carbonate solution (50 cm
3
, 1M), dried (Na2SO4) and 
evaporated to give the crude sulfide product. It was purified by column 
chromatography (hexane) to furnish a pure sample of sulfide 83 (4.99 g, 86%) as a 
colourless oil; bp 86-88
o
C /0.1mmHg (lit.
135
 170
o
C /22mmHg); Rf 0.46 (hexane); $H 
(500 MHz, CDCl3) 2.38 (3 H, s, Me), 7.10-7.27 (9 H, m, Ar); $C (125 MHz, CDCl3) 
20.58, 126.33, 126.71, 127.90, 129.12, 129.64, 130.60, 133.02, 133.77, 136.18, 
140.00; m/z (EI) 200 (M
+
, 100%), 91 (M
+
-C6H6S, 16%).  
 
 
 
Phenyl o-tolyl sulfoxide 78. 
 
Phenyl o-tolyl sulfide (4g, 20mmol) was oxidised, following the procedure described 
for the oxidation of sulfide 81, to give a the crude sulfoxide. It was purified by 
column chromatography (Et2O) to furnish sulfoxide 78 (3.24g, 75%) as a crystalline 
solid; mp 42 
o
C (from MeOH) (lit
136
 42 
o
C); Rf 0.73 (Et2O); $H (500 MHz, CDCl3) 
2.36 (3 H, s, Me), 7.16 (1 H, d, J 7.4, Ar), 7.36-7.44 (5 H, m, Ar), 7.59 (2 H, m, Ar), 
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7.94 (1 H, d, J 7.7, Ar); $C (125 MHz, CDCl3) 18.60, 124.77, 125.87, 125.91, 127.15, 
129.31, 130.99, 131.09, 135.79, 142.98, 144.64; m/z (EI)  216 M
+
, 70%), 91 (M
+
-
C6H6SO, 68%), 77 (M
+
-C7H7SO, 93%) 
 
5.4.5. Synthesis of Ethyl-(2-pyridyl) sulfoxide 75. 
 
 
 
Ethyl-2-pyridyl sulfoxide 75. 
 
Ethyl-2-pyridyl sulfide 80 (3g, 21.6mmol) was oxidised, following the procedure 
described for the oxidation of sulfide 81, to give the crude sulfoxide. It was purified 
by column chromatography (5% MeOH/CHCl3) to yield sulfoxide 75 (2.71g, 81%) as 
a colourless oil; bp 120
o
C /4mmHg (lit.
137
 123
o
C /4mmHg); $H (500 MHz, CDCl3) 
1.21 (3 H, m, Me), 2.90-2.97 (1 H, m, CHAHB), 3.15-3.22 (1 H, m, CHAHB), 7.38 (1 
H, d, J 7.4, Ar), 7.92-8.00 (2 H, m, Ar), 8.63 (1 H, d, J 4.8, Ar); $C (125 MHz, CDCl3) 
5.40, 47.44, 120.40, 124.46, 137.78, 149.62, 164.11. The aqueous mixture of 
bioproducts, obtained when sulfoxide 75 (2.0g) was metabolised with P. vulgaris, 
was extracted with EtOAc after removal of most the water under reduced pressure. 
The  residue, left after removal of the solvent from the extract, was purified by PLC to 
yield (-)-(S)-ethyl-2-pyridyl sulfoxide 75 (0.90g, 45%); [!]D - 157 (c 0.6, CHCl3) 
(lit.
138
 - 168, MeOH). The enantiomeric excess (! 98%) of sulfoxide 75 was 
determined by CSP HPLC analysis using a Chiralcel OB column (10% IPA/hexane, 
flow 0.5 cm
3
/min, ! 1.95). 
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5.5. Synthesis of thiophene sulfoxides and a sulfinate for kinetic resolution 
with DMSO reductases. 
 
5.5.1. Synthesis of Dibenzo[b]thiophene sulfoxide 97. 
 
 
 
Dibenzo[b]thiophene sulfoxide 97. 
 
A solution of MCPBA (0.94g, 5.4mmol) in CH2Cl2 (50 cm
3
) was added dropwise 
(30min.) to a mixture of dibenzothiophene (1g, 5.4mmol) and BF3-Et2O (6.8ml, 
54mmol)  in CH2Cl2 (50 cm
3
) under N2 gas atmosphere at – 20 
o
C. The reaction 
mixture was stirred  (4hr) and then allowed to warm up to room temp; it was washed 
with cold water, a saturated solution of NaHCO3 (50 cm
3
), filtered through celite, 
dried (Na2SO4) and the solvent evaporated off. The crude sulfoxide 97 (1.03g, 96%)  
thus obtained was crystallized as a white solid; mp 190-193 
o
C (from Et2O) (lit.
139
 
189-191 
o
C); $H (500 MHz, CDCl3) 7.51 (2 H, m, Ar), 7.59 (2 H, m, Ar), 7.80 (2 H, d, 
J 7.7, Ar), 7.98 (2 H, d, J 7.6, Ar); $C (125 MHz, CDCl3) 121.91, 127.54, 129.55, 
132.55, 137.10, 145.17; m/z (ES) 223 ([M+23]
+
, 100%), 201 ([M+1]
+
, 73%). 
 
5.5.2. Synthesis of 2-substituted Benzo[b]thiophene sulfoxides. 
 
 
2-Methylbenzo[b]thiophene 98. 
 
t-Butyl lithium in hexane (13.2 cm
3
, 33mmol, 2.5M), was added slowly (0.5hr) to a 
solution of benzo[b]thiophene (4.4g, 33mol) in  dry THF (50 cm
3
) under an argon 
atmosphere at – 70 
o
C.  After stirring (0.5hr) methyl iodide (6.0g, 42.3mmol) was 
added in one portion to the reaction mixture. It was stirred for a further period of one 
hour and then ammonium chloride solution (50 cm
3
, 2M) was added to quench the 
reaction. Most of the THF was removed by distillation under reduced pressure, the 
remaining aqueous portion extracted with ether (2 x 75 cm
3
) and dried (Na2SO4). The 
crude product obtained, after evaporation of ether, was purified by column 
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chromatography (hexane) to yield thiophene 98 (4.8g, 94%) as a white crystalline 
solid.; mp 48
o
C (from hexane) (lit.
140
  51-52
o
C); $H (500 MHz, CDCl3) 2.58 (3 H, s, 
Me), 6.97 (1 H, s, 3-H), 7.23-7.39 (2 H, m, Ar), 7.64 (1 H, d, J 7.7, Ar), 7.73 (1 H, d, 
J 8.0 Ar); $C (125 MHz, CDCl3) 16.14, 121.59, 121.99, 122.52, 123.34, 124.05, 
139.69, 140.47, 140.85; m/z (EI) 148 (M
+
, 85%).  
 
 
 
2-Methylbenzo[b]thiophene-1-oxide 96. 
 
A solution of MCPBA (4.8g, 30.4 mmol) in dry CH2Cl2 (100 cm
3
) was added 
dropwise to a solution of thiophene 98 (4.5g, 30.4mol) in CH2Cl2 (100 cm
3
, dry) and 
BF3-Et2O (40g, 34 cm
3
, 0.28mol), under N2 gas atmosphere, at – 20 
o
C.  The reaction 
mixture was stirred  (4hr) and then allowed to warm up to room temp; it was washed 
with cold water, a saturated solution of NaHCO3 (50 cm
3
), filtered through celite, 
dried (Na2SO4) and the solvent evaporated off. The sulfoxide 96  (4.54g, 91%) was 
obtained a crystalline solid; mp 74-75 
o
C (from Et2O) (lit.
141
 80-81 
o
C); Rf 0.51 (4% 
MeOH/CHCl3); $H (500 MHz, CDCl3) 2.39 (3 H, s, Me), 6.78 (1 H, s, 3-H), 7.36 (2 
H, m, Ar), 7.46 (1 H, m, Ar), 7.58 (1 H, d, J 7.6, Ar); $C (125 MHz, CDCl3) 13.02, 
123.62, 126.25, 127.65, 128.68, 132.02, 138.16, 144.64, 150.51; m/z (EI) 164 (M
+
, 
86%), 149 (M
+
-CH3, 100%). 
 
 
2-Ethylbenzo[b]thiophene 99. 
 
t-Butyl lithium in hexane (13.2 cm
3
, 33mmol, 2.5M), was added slowly (30 min) to a 
solution of benzo[b]thiophene (4.4g, 33mol), in  anhydrous THF (50 cm
3
) under an 
argon atmosphere at – 70 
o
C. It was stirred for a further period of one hour and 
ammonium chloride solution (50 cm
3
, 2M) was then added to quench the reaction. 
Most of the THF was removed by distillation under reduced pressure, the remaining 
aqueous portion extracted with Et2O (2 x 75 cm
3
) and dried (Na2SO4). Purification, of 
the crude product, obtained after removal of Et2O, by column chromatography 
(hexane), gave thiophene 99 (4.8g, 91%) as a colourless oil; bp 130
o
C /15mmHg 
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(lit.
142
 128
o
C /15mmHg); $H (500 MHz, CDCl3) 1.37 (3 H, t, J 7.5, Me), 2.92 (2 H, q, 
J 7.5, CH2), 6.99 (1 H, s, 3-H), 7.21-7.31 (2 H, m, Ar), 7.65 (1 H, d, J 7.8, Ar), 7.75 
(1 H, d, J 8.0 Ar); $C (125 MHz, CDCl3) 15.44, 24.12, 119.66, 122.12, 122.68, 
123.35, 124.03, 139.22, 140.26, 148.32; m/z (EI) 162 (M
+
, 65%), 147 (M
+
-CH3, 
100%).  
 
 
 
2-Ethylbenzo[b]thiophene-1-oxide 95. 
 
The thiophene 98 (4.5g, 27.8mol) was oxidised with  MCPBA (4.8g, 27.8mmol) in 
the presence of BF3-Et2O (4 g, 34 cm
3
, 0.28mol) following the procedure described 
for the oxidation of thiophene 96. Purification of the crude product by column 
chromatography (5% MeOH/CHCl3) gave thiophene oxide 95 (4.55g, 92%) as a 
colourless oil; mp 55
o
C (from hexane); Rf 0.55 (4% MeOH/CHCl3); (Found: M
+
, 
178.2478; C10H10OS requires 178.2481); $H (500 MHz, CDCl3) 1.36 (3 H, t, J 7.4, 
Me), 2.71-2.85 (2 H, m, CH2), 6.76 (1 H, s, 3-H), 7.35-7.38 (2 H, m, Ar), 7.45 (1 H, 
d, J 7.5, Ar), 7.86 (1 H, d, J 4.8, Ar); $C (125 MHz, CDCl3) 13.30, 21.17, 124.14, 
126.66, 127.30, 128.04, 132.41, 138.50, 144.73, 157.12; m/z (EI) 178 M
+
, 74%), 163 
(M
+
-CH3, 96%), 149 (M
+
-C2H5, 92%). 
 
5.6. Synthesis of benzo[d]-1,2-oxathiane-2-oxide 101 for kinetic resolution. 
 
  
Benzo[d]-1,2-oxathiane-2-oxide 101. 
 
Sodium hydroxymethyl sulfinate dihydrate (16.4g, 0.107mol) was added  to an ice 
cold solution of 1,2-di(bromomethyl)benzene (14.0g, 53.2mmol) and tetrabutyl 
ammonium bromide (3.43g) in  dry DMF (110 cm
3
).  After stirring the reaction 
mixture at 0 
o
C for 7hr and at room temp for another 7hr, water (200 cm
3
) was added 
and the mixture extracted with Et2O (4 " 100 cm
3
) and the Et2O extract washed with 
water (2 " 75 cm
3
). Ether was removed from the dried extract (Na2SO4) and the 
residue purified by column chromatography (ether) to yield oxathiane oxide 101 
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(6.0g, 67%) as a white crystalline solid; mp 51-54 
o
C (from EtOAc/hexane); Rf 0.73 
(ether); $H (500 MHz, CDCl3) 3.56 (1 H, d, JA,B 15.4, OCHAHB), 4.43 (1 H, d, JB,A 
15.4, OCHAHB), 4.97 (1 H, d, JA,B 13.7, SOCHAHB), 5.31 (1 H, d, JB,A 13.7, 
SOCHAHB), 7.22-7.27 (2 H, m, Ar), 7.34-7.37 (2 H, m, Ar); $C (125 MHz, CDCl3) 
56.42, 62.44, 125.17, 125.62, 127.33, 128.08, 129.10, 133.19; m/z (EI) 168 (M
+
, 7%), 
104 (M
+
-SO2, 90%), (ES) 191 ([M+23]
+
, 51%), 169 ([M+1]
+
, 100%). The spectral 
data of oxathiane oxide 101 was identical to the literature data
143
 which was reported 
as an oil.  
 
5.7. Biotransformation of benzylmethyl sulfide 81 with P. putida UV4. 
            The biotransformation media, from the  biotransformation of commercially 
available benzylmethylsulfide 81 (5g, 36.23mmol),  was evaporated and the viscous 
concentrate repeatedly extracted with EtOAc. The crude evaporated extract-residue 
was purified by column chromatogrpahy  followed by PLC of the selected column 
fractions; 
the following metabolites were isolated:  
 
 
 
(+)-cis-(1S,2R)-3-(Methylsulfanylmethyl)-3,5-
cyclohexadiene-1,2-diol 85. 
 
Isolated by column chromatogrpahy  (4% MeOH/CHCl3), sulfide diol 85 (2.52g, 
35%) was obtained as a white crystalline solid; mp 67
o
C (from Et2O/hexane, 
decomp.); Rf 0.43 (10% MeOH/CHCl3); [!]D + 131 (c 1.0 in CHCl3); (Found: C, 
56.1; H, 7.1. C8H12O2S requires C, 55.8; H, 7.0 %); $H (500 MHz, CDCl3) 2.03 (3 H, 
s, Me), 2.19 (1 H, d, J 8.1, OH), 2.56 (1 H, d, J 7.2, OH), 3.27 (1 H, d, JA,B 13.5, 
CHAHB), 3.32 (1 H, d, JB,A 13.6, CHAHB), 4.30 (1 H, d, J1,2 6.0, 2-H), 4.34 (1 H, m, 1-
H), 5.78 (1 H, d, J 4.9, 4-H), 5.91 (1 H, dd, J 9.3, 3.1, 6-H), 5.96-5.99 (1 H, m, 5-H); 
$C (125 MHz, CDCl3) 14.52, 37.63, 68.57, 69.64, 122.01, 124.44, 129.30, 136.45; m/z 
(EI) 154 (M
+
-H2O, 19%), (ES) 195 ([M+23]
+
, 100%); CD: # 274nm $% 5.14, # 
238nm  $% 1.35, # 230nm $% 1.82, # 209nm $% -1.75. 
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(+)-cis-(1S,2R)-3-Hydroxymethylcyclohexa-3,5-diene-1,2-diol 
86. 
 
Isolated, by a combination of column chromatography (4% MeOH/CHCl3) and 
multiple elution PLC (7% MeOH/CHCl3) triol 86 (56mg, 0.9%) was found to be a 
colourless oil which decomposed on heating; Rf 0.25 (12% MeOH/CHCl3); [!]D + 
33.6 (c 0.5, MeOH); (Found: M
+
-H2O, 124.0525. C7H8O2 requires 124.0524); $H (500 
MHz, CDCl3) 4.28 (1 H, m, 1-H), 4.31 (2 H, s, CH2), 4.38 (1 H, d, J1,2 6.0, 2-H), 5.93 
(3 H, m, 4- & 6-H), 6.01 (1 H, dd, J 5.1, 9.4, 5-H); $C (125 MHz, CDCl3) 62.55, 
65.94, 67.65, 118.69, 122.97, 126.96, 137.54; m/z (EI) 142 (M
+
, 0.5%), 124 (M
+
-
H2O, 10%). The spectral data of diol 86 was identical to the literature data.
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(+)-cis-(1S,2R)-3-(S-Methylsulfinylmethyl)-3,5-
cyclohexadiene-1,2-diol 122. 
 
Sulfoxide diol 122 (66mg, 0.8%) was isolated as colourless oil; Rf 0.23 (10% 
MeOH/CHCl3); [!]D + 71.8 (c 0.9, CHCl3); (Found: M
+
-H2O, 170.0402. C8H10O2S 
requires 170.0406); $H (500 MHz, CDCl3) 2.58 (3 H, s, Me), 3.53 (1 H, d, JA,B 13.0, 
CHAHB),  3.88 (1 H, d, JB,A 13.0, CHAHB), 4.27 (1 H, d, J1,2 6.6, 2-H), 4.30 (1 H, m, 1-
H), 6.02 (1 H, m, 4-H), 6.07 (2 H, m, 5- & 6-H); $C (125 MHz, CDCl3) 37.65, 57.71, 
67.60, 70.33, 125.04, 126.70, 130.10, 132.18; m/z  (EI) 170 (M
+
-H2O, 37 %); CD: % 
269nm "# 7.82, % 238nm "# - 5.98, % 218nm "# 1.25, % 203nm "# - 4.76. 
 
5.8. Biotransformation of benzylethyl sulfide 87 with P. putida UV4. 
 
 
(+)-cis-(1S,2R)-3-(Ethylsulfanylmethyl)-3,5-
cyclohexadiene-1,2-diol 123. 
 
Biotransformation of a commercially available sample of benzylethyl sulfide 87 (20g, 
131.6mmol), followed by the usual work up of the aqueous biotransformed material 
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and column chromatogrpahy  (4% MeOH/CHCl3) of the crude product, yielded diol 
123 (2.54g, 21%) as a white crystalline solid; mp 48 
o
C (from Et2O/hexane); [!] D + 
69.4 (c 0.5, CHCl3); (Found: C, 58.0. H, 7.7; C9H14O2S requires C, 58.0. H, 7.6%); 
(Found: M
+
, 186.0710. C9H14O2S requires 186.0715); (Found: M
+
-H2O, 168.0601. 
C9H12OS requires 168.0609); $H (500 MHz, CDCl3) 1.24 (3 H, t, J 7.4, Me), 2.48 (2 
H, q, J 7.4, CH2Me), 3.33 (1 H, d, JA,B 13.7, CHAHBSEt), 3.36 (1 H, d, JB,A 13.5, 
CHAHBSEt), 4.30 (1 H, d, J1,2 6.0, 2-H), 4.32 (1 H, m, 1-H), 5.78 (1 H, d, J 5.2, 4-H), 
5.89 (1 H, dd, J 9.6, J 3.1, 6-H), 5.95 (1 H, dd, J 9.6, J 5.2, 5-H); $C (125 MHz, 
CDCl3) 14.69, 25.27, 35.47, 68.97, 69.95, 122.20, 124.80, 129.62, 136.85; m/z (EI) 
186 (M
+
, 6%), 168 (M
+
-H2O, 77%), 29 (M
+
-C7H9O2S, 100%); CD: % 275nm "# 6.51, 
% 229nm "# 2.28. 
 
5.9. Biotransformation of benzylpropyl  sulfide 88 with P. putida UV4. 
 
 
(+)-cis-(1S,2R)-3-(Propylsulfanylmethyl)-3,5-
cyclohexadiene-1,2-diol 124. 
 
Biotransformation of a commercially available benzylpropylsulfide 88 (20g, 
120.5mmol) and purification of the crude bioproduct by column chromatogrpahy  
(4% MeOH/CHCl3) gave diol 124 (1.43g, 10%) as a colourless oil which decomposed 
on heating; [!]D + 72.5 (c 0.4, CHCl3); (Found: M
+
, 200.0871. C10H16O2S requires 
200.0871); $H (500 MHz, CDCl3) 0.97 (3 H, t, J 7.3, Me), 1.55-1.63 (2 H, m, 
CH2Me), 2.43 (2 H, t, J 7.2, CH2Et), 3.31 (1 H, d, JA,B 13.5, CHAHBSPr), 3.35 (1 H, d, 
JB,A 13.5, CHAHBSPr), 4.30 (1 H, d, J1,2 6.1, 2-H), 4.31 (1 H, m, 1-H), 5.78 (1 H, d, J 
5.0, 4-H), 5.88 (1 H, dd, J 9.6, J 2.8, 6-H), 5.95 (1 H, dd, J 9.6, J 5.2, 5-H); $C (125 
MHz, CDCl3) 13.85, 22.85, 33.44, 35.84, 69.05, 122.23, 124.74, 129.62, 136.90; m/z 
(EI) 200 (M
+
, 6%), 182 (M
+
-H2O, 72%); CD: % 272nm "# 2.71, % 237nm "# 0.41, % 
229nm "# 0.71, % 209 "# - 0.38. 
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5.10. Biotransformation of 2-phenyl-1,3-dithiane 110 with P. putida UV4. 
Biotransformation of  the commercially available 129 (7.9g, 40.36mmol) and 
purification of the crude bioproduct mixture, by column chromatogrpahy  (5% 
MeOH/CHCl3), furnished three compounds; diols 129 and 130 and dithiane oxide 
128. 
 
 
 
(+)-cis-(1S,2R)-3-(1',3'-Dithian-2'-yl)-3,5-cyclohexadiene-
1,2-diol 129. 
 
129 (1.67g, 18%) colourless solid; mp 51-53 
o
C (from Et2O/hexane); Rf 0.31 (5% 
MeOH/CHCl3); [!]D + 81.5 (c 0.7, CHCl3); $H (500 MHz, CDCl3) 1.84-1.93 (1 H, m, 
5'-CHAHB), 2.11-2.17 (1 H, m, 5'-CHAHB), 2.82-3.01 (6 H, m, SCH2 + OH), 4.29 (1 
H, d, J1,2 6.4, 2-H), 4.33 (1 H, m, 1-H), 4.88 (1 H, s, 2'-H), 5.90 (1 H, dd, J 9.6, 3.3, 6-
H), 5.99 (1 H, dd, J 9.6, 5.5, 5-H), 6.18 (1 H, d, J 5.3, 4-H); $C (125 MHz, CDCl3) 
25.89, 31.87, 32.01, 49.05, 69.20, 70.10, 124.21, 124.56, 131.11, 138.77; m/z (EI) 
230 M
+
, 94%), 212 (M
+
-H2O, 96%); CD: # 276nm "# 3.55, % 254nm "# 0.94, % 
242nm "# 2.61, % 214nm "# - 3.05. 
 
 
 
(+)-cis-(1S,2R)-3-(trans-(1'S,2'S)-1',3'-Dithan-2'yl-1'-
oxy)cyclohexa-3,5-diene-1,2-diol 130. 
 
130 (1.19g, 12%) white crystalline solid; mp 112 
o
C (from Acetone/ Et2O); Rf 0.17 
(5%MeOH/CHCl3); [!]D + 48.7 (c 1.0, CHCl3), + 150 (c 0.6, H2O); (Found: M
+
 C, 
48.8. H, 5.6. C10H14O3S2 requires C, 48.8. H, 5.7%); (Found: M
+
, 246.0386. 
C10H14O3S2 requires 246.0385); $H (500 MHz, CDCl3) 2.24-2.33 (1 H, m, 5'-CHAHB), 
2.48-2.53 (1 H, m, 5'-CHAHB), 2.65-2.70 (1 H, m, 4'-CHAHB), 2.77-2.86 (2 H, m, 4'-
CHAHB & 6'-CHAHB), 3.29 (1 H, m, 1-OH), 3.52 (1 H, d, J 12.8, 6'-CHAHB), 4.24 (1 
H, d, J1,2 5.5, 2-H), 4.30 (1 H, m, 1-H), 4.43 (1 H, d, J 6.1, 2-OH), 4.61 (1 H, s, 2'-H), 
5.99-6.07 (2 H, m, 5- & 6-H), 6.14 (1 H, d, J 5.2, 4-H); &C (125 MHz, CDCl3) 29.55, 
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31.26, 54.41, 65.63, 67.98, 69.27, 123.32, 125.91, 131.95, 134.33; m/z (EI) 246 (M
+
, 
91%), 228 (M
+
-H2O, 55%); CD: % 280nm "# 4.25, % 227nm "# - 6.37. 
 
 
 
(+)-trans-(1S,2S)-2-Phenyl-1,3-dithiane-1-oxide 128. 
 
 
128 (0.639g, 7%) colourless crystals; mp 155-157 
o
C (from CHCl3) (lit.
137
 145-147
o
C, 
racemic); Rf 0.37 (5%MeOH/CHCl3); [!]D + 90.9 (c 1.2, CHCl3); $H (500 MHz, 
CDCl3) 2.28-2.38 (1 H, m, 5-CHAHB), 2.45-2.50 (1 H, m, 5-CHAHB), 2.62-2.67 (1 H, 
m, 4-CHAHB), 2.70-2.77 (1 H, 6-CHAHB), 2.80-2.88 (1 H, m, 4-CHAHB), 3.50-3.57 (1 
H, m, 6-CHAHB), 4.55 (1 H, s, 2-H), 7.26-7.45 (5 H, m, Ar); $C (125 MHz, CDCl3) 
29.52, 31.41, 54.79, 69.68, 128.75, 129.11, 129.33, 133.39; m/z (EI) 212 (M
+
, 100%), 
135 (M
+
-C6H5, 79%), 77 (M
+
-C4H7OS2, 66%); CD: % 248nm "# 1.60, % 227nm "# 
6.12, % 211nm "# - 3.17. 
 
 
5.11. Biotransformation of 2-phenyl-1,3-dithiolane 111 by P. putida UV4. 
           Biotransformation of the commercially available 111 (14.0g, 76.1mmol) and 
purification of the crude bioproduct mixture, by column chromatogrpahy  (5% 
MeOH/CHCl3), yielded three compounds; diols 135 and 141 and dithiolane oxide 
134: 
 
 
 
(+)-cis-(1S,2R)-3-(1',3'-Dithiolan-2'-yl)cyclohexa-3,5-diene-
1,2-diol 135. 
 
135 (2.49g, 15%), colourless crystals; mp 54-57 
o
C (from Et2O/hexane) 
(5%MeOH/CHCl3); [!]D  + 32.8 (c 0.6, CHCl3); (Found: C, 50.2; H, 5.7, C9H12O2S2 
requires C, 50.0; H, 5.6 %); $H (500 MHz, CDCl3) 3.26-3.37 (4 H, m, CH2), 4.34 (1 
H, d, J1,2 5.7, 2-H), 4.44 (1 H, dd, J2,1 5.7, 3.0, 1-H), 5.37 (1 H, s, 2'-H), 5.85-5.92 (2 
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H, m, , 5- & 6-H), 6.05 (1 H, d, J 5.3, 4-H); $C (125 MHz, CDCl3) 39.61, 39.78, 
55.65, 67.27, 70.19, 122.55, 123.11, 132.01, 138.03; m/z (EI) 216 M
+
, 80%), 198 
(M
+
-H2O, 100%); CD: % 264nm "# 2.01, % 215nm "# - 1.25. 
 
 
(-)-trans-(1S,2S)-2-Phenyl-1,3-dithiolane-1-oxide 134. 
 
 
134 (0.46g, 3%) colourless crystalline solid; mp 85-89 
o
C (from MeOH) (lit.
144
 66-67 
o
C, racemic); [!]D - 102.8 (c 0.8, CHCl3) (- 128.9 enantiopure); $H (500 MHz, CDCl3) 
2.88-2.93 (1 H, m, 5-CHAHB), 3.32-3.36 (1 H, m, 4-CHAHB), 3.62 (1 H, m, 4-
CHAHB), 3.80-3.85 (1 H, m, 5-CHAHB), 5.40 (1 H, s, 2-H), 7.33-7.39 (3 H, m, Ar), 
7.48 (2 H, d, J 6.9, Ar); $C (125 MHz, CDCl3) 32.44, 53.27, 77.99, 128.51, 129.01, 
133.14; m/z (EI) 198 (M
+
, 100%), 121 (M
+
-C6H5, 99%), 77 (M
+
-C3H5OS2, 82%); CD: 
% 228nm "# - 9.43. 
 
 
 
(+)-cis-(1S,2R)-3-(trans-(1'S,2'S)-1',3'-Dithiolan-2'-yl-1'-
oxy)cyclohexa-3,5-diene-1,2-diol 136. 
 
136 (1.02g, 8%), unstable colourless oil; [!]D + 62.0 (c 1.6, CHCl3); (Found: M
+
, 
232.0232. C9H12O3S2 requires 232.0228); $H (500 MHz, CDCl3) 3.12-3.17 (1 H, m, 
4'-CHAHB), 3.39-3.44 (1 H, m, 5'-CHAHB), 3.54-3.59 (1 H, m, 4'-CHAHB), 3.84-3.90 
(1 H, m, 5'-CHAHB), 4.44 (1 H, d, J1,2 6.0, 2-H), 4.47 (1 H, m, 1-H), 5.17 (1 H, s, 2'-
H), 5.94-6.02 (2 H, m, 5- & 6-H), 6.25 (1 H, d, J 5.3, 4-H); $C (125 MHz, CDCl3) 
32.35, 56.74, 65.69, 69.64, 72.84, 122.53, 128.66, 130.70, 133.95; m/z (EI) 232 (M
+
, 
15%), 214 (M
+
-H2O, 35%); CD: % 264nm "# 5.33, % 218nm "# - 1.66. 
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5.12. Sulfoxidation of cis-dihydrodiols 85, 123, 124 and 129 using 
dimethyldioxirane. 
                Dimethyldioxirane (DMD) was prepared as a solution in acetone by 
addition of potassium peroxymonosulfate (oxone) to a mixture of water, acetone and 
sodium hydrogen carbonate in accordance with the literature procedure.
144
  A solution 
of DMD (0.08M) was added, dropwise, to a stirring solution of the diol in acetone 
maintained at  
0 
o
C. The progress of the reaction was constantly monitored by TLC (8% 
MeOH/CHCl3) 
 When all of the diol had oxidised to the diolsulfoxides, the reaction was terminated 
by the removal of the solvent in vacuo to yield a mixture of  diastereoisomers: 
 
The crude mixture, obtained from DMD oxidation of diol 85 (2g, 11.6mmol), was 
separated by column chromatography (8% MeOH/CHCl3) into two diolsulfoxides 125 
and 122. 
 
 
(+)-cis-(1S,2R)-3-(R-Methylsulfinylmethyl]-3,5-
cyclohexadiene-1,2-diol 125. 
 
Diolsulfoxide 125 (0.98g, 45%), colourless crystalline solid; mp 123 
o
C (from 
MeOH/CHCl3); Rf 0.28 (10% MeOH/CHCl3); [!]D + 56.2 (c 2.2, MeOH); (Found: C, 
50.9. H, 6.5; C8H12O3S requires C, 51.1. H, 6.4%); (Found: M
+
, 188.0511. C8H12O3S 
requires 188.0507); (Found: M
+
-H2O, 170.0402. C8H10O2S requires 170.0406); $H 
(500 MHz, CDCl3) 2.59 (3 H, s, Me), 3.25 (1 H, d, JA,B 13.3, CHAHB), 4.08 (1 H, d, 
JB,A 13.3, CHAHB), 4.18 (1 H, d, J1,2 6.0, 2-H), 4.33 (1 H, m, 1-H), 5.94 (1 H, d, J 5.2, 
4-H), 6.02 (1 H, m, 5-H), 6.07 (1 H, m, 6-H); $C (125 MHz, CDCl3) 34.14, 54.78, 
66.22, 67.81, 121.72, 126.20, 128.92, 129.81; m/z (EI) 170 (M
+
-H2O, 7%); CD: % 
303nm "# - 0.49, % 267nm "# 1.49, % 225nm "# 0.80. Diolsulfoxide 122 (0.98g, 
45%); Rf 0.23, was found to have identical physical and spectral characteristics to the 
sample isolated from biotransformation of benzylmethyl sulfide 81.  
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Diol 123 (5g, 26.9mmol), on oxidation with DMD, gave a mixture of two products; 
PLC (8% MeOH/CHCl3) separation yielded two diolsulfoxides 140 and 141: 
 
 
(+)-cis-(1S,2R)-3-(R-Ethylsulfinylethyl)-3,5-
cyclohexadiene-1,2-diol 140. 
 
 
Diolsulfoxide 140 (2.45g, 45%),viscous colourless oil; Rf 0.40 (8% MeOH/CHCl3); 
[!]D + 53.1 (c 0.6, MeOH); (required, M
+
: 202.0664, C9H14O3S: 202.0665); (required, 
M
+
-H2O: 184.0562, C9H12O2S: 184.0558); $H (500 MHz, CDCl3) 1.30 (3 H, t, J 7.5, 
Me), 2.70 (1 H, m, CHAHBMe), 2.82 (1 H, m, CHAHBMe), 3.39 (1 H, d, JA,B 13.2, 
CHAHBSO), 3.89 (1 H, d, JB,A 13.2, CHAHBSO), 4.15 (1 H, d, J1,2 6.0, 2-H), 4.26 (1 H, 
m, 1-H), 5.94-6.05 (3 H, m, 4-,5- & 6-H); $C (125 MHz, CDCl3) 7.11, 43.90, 54.68, 
67.66, 69.67, 123.74, 127.09, 130.98, 131.20; m/z (EI) 184 (M
+
-H2O, 2%), 125 (M
+
-
C2H5OS, 70%), 107 (M
+
-C2H7O2S); CD: % 269nm "# 1.12, % 242nm "# - 0.30, % 
224nm "# 0.59. 
 
 
(+)-cis-(1S,2R)-3-(S-Ethylsulfinylethyl)-3,5-
cyclohexadiene-1,2-diol 141. 
  
 
Diolsufoxide 141 (2.45g, 45%), viscous colourless oil; Rf 0.34 (8% MeOH/CHCl3); 
[!]D + 187 (c 0.7, MeOH); (required, M
+
: 202.0664, C9H14O3S: 202.0665); $H (500 
MHz, CDCl3) 1.34 (3 H, t, J 7.5, Me), 2.72-2.78 (2 H, m, CH2Me), 3.58 (1 H, d, JA,B 
12.9, CHAHBSO), 3.80 (1 H, d, JB,A 12.9, CHAHBSO), 4.26 (1 H, m, 1-H), 4.30 (1 H, 
d, J1,2 6.1, 2-H), 6.01-6.09 (3 H, m, 4-,5- & 6-H); $C (125 MHz, CDCl3) 6.93, 44.96, 
54.57, 66.69, 70.11, 124.73, 125.99, 129.69, 132.57; m/z (EI) 184 (M
+
-H2O, 2%), 125 
(M
+
-C2H5OS, 70%), 107 (M
+
-C2H7O2S); CD: % 270nm "# 6.03, % 234nm "# - 1.13, % 
205nm "# -2.24. 
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Diol 124 (1g, 5.0mmol) was oxidised (DMD) and the product mixture separated by 
PLC (8% MeOH/CHCl3) into diolsulfoxides 142 and 143: 
 
 
 
(+)-cis-(1S,2R)-3-(R-
Propylsulfinylmethyl)cyclohexa-3,5-diene-1,2-
diol a 142. 
Diolsulfoxide 142 (0.49g, 45%), viscous oil; Rf 0.24 (8% MeOH/CHCl3); [!]D + 77.6 
(c 3.0, CHCl3); (Found: M
+
, 216.0818. C10H16O3S requires 216.0820); (Found: M
+
-
H2O, 198.0718. C10H14O2S requires 198.0715); $H (500 MHz, CDCl3) 1.11 (3 H, t, J 
7.2, Me), 1.75-1.83 (2 H, m, CH2Me), 2.59 (1 H, m, CHAHBEt), 2.90 (1 H, m, 
CHAHBEt), 3.32 (1 H, d, JA,B 13.3, CHAHBSOPr), 4.02 (1 H, d, JB,A 13.3, 
CHAHBSOPr), 4.19 (1 H, d, J2,1 5.8, 2-H), 4.33 (1 H, m, 1-H), 5.93 (1 H, d, J 5.1, 4-
H), 6.00 (1 H, dd, J  5.2, 9.7, 5-H), 6.06 (1 H, dd, J 3.5, 9.6, 6-H); $C (125 MHz, 
CDCl3) 13.42, 16.45, 52.02, 54.98, 67.85, 69.58, 123.58, 127.40, 131.19, 131.34; m/z 
(EI) 198 (M
+
-H2O, 2.5%), 125 (M
+
-C3H7OS, 48%), 107 (M
+
-C3H9O2S, 68%); CD: % 
268nm "# 0.94, % 229nm "# 0.33, % 223nm "# 0.21, and compound 143. 
 
 
(+)-cis-(R)-(1S,2R)-3-(S-Propylsulfinylmethyl) 
cyclohexa-3,5-diene-1,2-diol 143. 
 
Diolsulfoxide 143 (0.49g, 45%), a viscous oil; Rf 0.19 (10% MeOH/CHCl3); [!]D + 
60.3 (c 1.5, CHCl3); (Found: M
+
-H2O, 198.0714. C10H16O3S requires 198.0715); $H 
(500 MHz, CDCl3) 1.10 (3 H, t, J 7.4, Me), 1.77-1.84 (2 H, m, CH2Me), 2.63 (1 H, m, 
CHAHBEt), 2.76 (1 H, m, CHAHBEt), 3.57 (1 H, d, JA,B 13.0, CHAHBSOPr), 3.82 (1 H, 
d, JB,A 13.0, CHAHBSOPr), 4.26 (1 H, dd, J1,6 3.8, J1,2 5.8, 1-H), 4.30 (1 H, d, J2,1 5.6, 
2-H), 6.01 (1 H, m, J  4.9, 5-H), 6.07 (1 H, d, J  4.7, 4-H), 6.08 (1 H, m, 6-H); $C (125 
MHz, CDCl3) 13.42, 16.41, 53.42, 54.99, 66.63, 70.19, 124.82, 125.96, 129.66, 
132.54; m/z (EI) 198 (M
+
-H2O, 4%), 125 (M
+
-C3H7OS, 55%), 107 (M
+
-C3H9O2S, 
100%); CD: % 270nm "# 4.47, % 238nm "# - 2.98, % 220nm "# 0.66. 
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(-)-cis-(1S,2R)-3-(trans-1’R,2’R-1’,3’-Dithan-2’-yl-1’-oxy) 
cyclohexa-3,5-diene-1,2-diol 144. 
 
 
Dithiane diol 129 (200mg, 0.87mmol) was oxidised (DMD) and the product mixture 
separated by PLC (5% MeOH/CHCl3) into two dithiane diolsulfoxides 144 and 130. 
Diolsulfoxide 144 (96mg, 45%), viscous oil; Rf 0.14 (5% MeOH/CHCl3); [!]D - 47.8 
(c 1.5, CHCl3); (Found: M
+
, 246.0308. C10H14O3S2 requires 246.0384); $H (500 MHz, 
CDCl3) 2.23-2.38 (1 H, m, R2CHAHB), 2.47-2.51 (1 H, m, R2CHAHB), 2.65-2.70 (1 H, 
m, SCHAHB), 2.75-2.85 (2 H, m, SCHAHB & SOCHAHB), 3.49-3.53 (1 H, m, 
SOCHAHB), 4.31 (1 H, dd, J1,6 3.5, J1,2 6.1, 1-H), 4.39 (1 H, d, J2,1 6.1, 2-H), 4.61 (1 
H, s, SCH), 6.03-6.08 (3 H, m, 4-,5- & 6-H); $C (125 MHz, CDCl3) 29.61, 30.84, 
54.93, 66.53, 67.12, 69.84, 124.39, 125.08, 130.34, 134.57; m/z (EI) 246 (M
+
, 90%), 
228 (M
+
-H2O, 50%); CD: # 270nm "# - 1.14, # 230nm "# 4.06. Diolsulfoxide 130 
(95mg, 45%); Rf 0.17; colourless crystals; mp 155-157 
o
C (CHCl3), was found to 
have identical physical and spectral characteristic to the sample isolated as a 
metabolite of 2-phenyl-1,3-dithiane 110. 
 
  
 
trans-(2-Hydroxyphenyl)-1,3-dithiolane-1-oxide 145.     
 
A solution of diolsulfoxide  130 (100mg, 0.41mmol), in CHCl3 
(5 cm
3
), was heated at 70 
o
C in the presence of p-toluene sulfonic acid (5mg). The 
progress of  reaction was followed by TLC. When all the diol had aromatised, the  
crude reaction mixture was crystallised to yield phenol sulfoxide 145 (25mg, 27%), a 
white crystalline solid; mp 95 
o
C (from CHCl3); Rf 0.49 (7% MeOH/CHCl3); $H (500 
MHz, CDCl3) 2.29-2.39 (1 H, m, R2CHAHB), 2.53-2.58 (1 H, m, R2CHAHB), 2.73-
2.78 (1 H, m, SCHAHB), 2.88-2.96 (2 H, m, SCHAHB & SOCHAHB), 3.61-3.67 (1 H, 
m, SOCHAHB), 5.36 (1 H, s, CH), 6.85 (1 H, d, J 8.1, Ar), 6.94 (1 H, m, Ar), 7.14 (1 
H, m, Ar), 7.20 (1 H, d, J 7.7, Ar), 8.55 (1 H, s, OH); $C (125 MHz, CDCl3) 29.51, 
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31.08, 54.93, 62.99, 118.52, 120.99, 121.12, 127.55, 130.55, 156.06; m/z (EI) 228 
(M
+
, 80%). 
 
 
5.13. Biotransformation of diol sulfoxides with E. coli (narB). 
The biotransformation media, from the  biotransformation of diol sulfoxide (e.g, 122, 
125, 140, 141, 142 and 143) was evaporated and the viscous concentrate repeatedly 
extracted with EtOAc. The crude evaporated extract-residue was purified by PLC:  
 
 
(-)-3-(R-Methylsulfinylmethyl)catechol (R)-146.     
 
 
Enzyme catalysed dehydogenation of diol sulfoxide 125 (200mg, 1.1mmol)  using the 
E. coli (nar B) strain yielded the crude catechol 146 which  was purified by PLC (10%  
MeOH/CHCl3) giving catachol sulfoxide  146 (137mg, 69%) as a light yellow 
coloured semi-solid; Rf 0.28 (10%  MeOH/CHCl3); [!]D – 70.9 (c 2.2, CHCl3); 
(required, M
+
: 186.0351, C8H10O3S: 186.0351); $H (500 MHz, CDCl3) 2.49 (3 H, s, 
Me), 3.80 (1 H, d, JA,B 14.2, CHAHB), 4.44 (1 H, d, JB,A 14.2, CHAHB), 6.56 (1 H, d, J 
7.7, Ar), 6.63 (1 H, s, OH), 6.78 (1 H, m, Ar), 6.89 (1 H, d, J 8.0, Ar), 9.10 (1 H, s, 
OH); $C (125 MHz, CDCl3) 35.66, 54.30, 115.93, 117.53, 121.07, 122.89, 143.59, 
147.03; m/z (EI) 186 (M
+
, 17%), 123 (M
+
-CH3SO, 100%).  
 
 
 
 
(+)-3-(S-Methylsulfinylmethyl)catechol (S)-146.  
 
The title catechol sulfoxide enantiomer (S)-146 (24mg, 24%), semi-solid, [!]D + 69.5 
(c 1.4, CHCl3), was similarly obtained by the enzyme catalysed dehydogenation of 
diol sulfoxide 122 (100mg, 0.55mmol) with the E. coli (nar B) strain.       
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(-)-3-(R-Ethylsulfinylmethyl) catechol (R)-147. 
 
Diol Sulfoxide substrate 140 (100mg, 0.50mmol), on dehydrogenation with E. coli 
(nar B) strain yielded crude catechol 147. Purification  by PLC (10%  MeOH/CHCl3)  
gave catechol sulfoxide 147 (20mg, 20%), a  semi-solid solid; Rf 0.30 (10%  
MeOH/CHCl3); [!]D – 52.2 (c 1.3, CHCl3); $H (500 MHz, CDCl3) 1.30 (3 H, m, Me) 
2.59-2.66 (1 H, m, CHAHBMe), 2.70-2.76 (1 H, m, CHAHBMe), 3.81 (1 H, d, J 14.4, 
ArCHAHB), 4.46 (1 H, d, J 14.4, ArCHAHB), 6.00 (1 H, s, OH), 6.54 (1 H, d, J 7.6, 
Ar), 6.80 (1 H, m, Ar), 6.92 (1 H, d, J 8.0, Ar), 9.78 (1 H, s, OH); $C (125 MHz, 
CDCl3) 6.98, 43.47, 52.38, 155.60, 118.08, 121.18, 122.56, 143.65, 147.57; m/z (EI) 
200 (M
+
, 20%), 123 (M
+
-C2H5SO, 100%).  
 
  
 
(+)-3-(S-Ethylsulfinylmethyl)catechol (S)-147. 
 
The title catechol sulfoxide enantiomer (S)-147 (19mg, 19%), a semi-solid, [!]D + 
53.5 (c 1.0, CHCl3) was similarly obtained from the E. coli (nar B) metabolism of diol 
141 (100mg, 0.55mmol). 
 
 
 
 
3-(Propylsulfinyl)methyl catechol 148. 
 
Enzyme catalysed dehydogenation (nar B) of  a mixture of diol sulfoxides 142 and 
143 (90mg, 0.42mmol), gave a racemic sample of crude catechol 148. Purification by 
PLC (10%  MeOH/CHCl3) furnished a pure racemic sample of catechol sulfoxide 148 
(11mg, 12%),   semi-solid solid; Rf 0.33 (10%  MeOH/CHCl3); $H (500 MHz, CDCl3) 
1.25 (3 H, t, J 7.0, Me), 1.73-1.79 (2 H, m, CH2Me), 2.44-2.49 (1 H, m, SCHAHBEt), 
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2.51-56 (1 H, m, SCHAHBEt), 3.78 (1 H, d, J 14.4, ArCHAHB), 4.48 (1 H, d, J 14.4, 
ArCHAHB), 6.00 (1 H, s, OH), 6.54 (1 H, d, J 7.6, Ar), 6.80 (1 H, m, Ar), 6.91 (1 H, d, 
J 8.0, Ar), 9.80 (1 H, s, OH); $C (125 MHz, CDCl3) 13.37, 16.30, 52.88, 53.58, 
115.58, 118.20, 121.18, 122.59, 143.63, 147.58; m/z (EI) 214 (M
+
, 29%), 123 (M
+
-
C3H7SO, 100%).  
 
5.14. Chemoenzymatic synthesis of diol sulfoxides using bromobenzene cis-
dihydrodiol 34. 
 
 
 
 
(-)-cis-(1S,2S)-1,2-Dihydroxy-3-bromocyclohex-3-ene 152. 
 
A solution of cis-(1S,2S)-1,2-dihydroxy-3-bromocyclohexa-3,5-diene 34 (1g, 
5.24mmol) in THF (15 cm
3
)  was hydrogenated (5hr at 25psi) in the presence of  
rhodium on alumina (500mg, 5%). The catalyst was filtered off, the solvent 
evaporated and the crude hydrogenated product purified by column chromatography 
(5% MeOH/CHCl3) to yield tetrahydrodiol 152 (860mg, 85%) as a white silky 
needles; mp 104-107
o
C (from CH2Cl2) (lit.
145
 105-107
o
C); [!]D – 112 (c 1.2, MeOH) 
(lit.
145
 – 114, MeOH); $H (500 MHz, CDCl3) 1.74-1.88 (2 H, m, 6-H), 2.05-2.14 (1 H, 
m, 5-CHAHB), 2.24-3.32 (1 H, m, 5-CHAHB), 2.59 (1 H, d, J 5.1, OH), 2.68 (1 H, d, J 
3.6, OH), 3.95 (1 H, m, 1-H), 4.21 (1 H, d, J 3.9, 2-H), 6.23 (1 H, m, 4-H); $C (125 
MHz, CDCl3) 25.13, 25.18, 69.03, 71.80, 122.39, 132.81; m/z (EI) 194 (M
+
(
81
Br), 
3%), 192 (M
+
(
79
Br), 3%). 
 
  
(+)-cis-(3aS,7aS)-7-Bromo-2,2-dimethyl-3a,4,5,7a-
tetrahydro-1,3-benzodioxole 154. 
 
A suspension of tetrahydrodiol 152 (1g, 5.18mmol), in 2,2-dimethoxypropane (5cm
3
) 
was   stirred overnight at room temperature in the presence of p-toluenesulfonic acid 
(2mg); the solvent was evaporated off, the residue taken up in Et2O solvent (75 cm
3
), 
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washed with water and dried (Na2SO4). The crude product, obtained after removal of 
Et2O, was purified by column chromatography (25%Et2O/hexane) to yield acetonide 
154 (785mg, 65%) as a crystalline solid; mp 41 
o
C (from Et2O/hexane); [!]D + 80.7 (c 
0.8, CHCl3); (Found: M
+
-CH3, 216.9864. C8H10O2
79
Br requires 216.9867); $H (500 
MHz, CDCl3) 1.41 (3 H, s, CMeAMeB), 1.45 (3 H, s, CMeAMeB), 1.80-1.83 (1 H, m, 
5-CHAHB), 2.03-2.07 (2 H, m, 5-CHAHB & 6-CHAHB), 2.27-2.33 (1 H, m, 6-CHAHB), 
4.41 (1 H, m, 1-H), 4.50 (1 H, d, J 5.3, 2-H), 6.23 (1 H, dd, J 5.7, 2.5, 4-H); $C (125 
MHz, CDCl3) 21.45, 23.41, 25.51, 26.64, 73.26, 75.56, 108.31, 121.34, 131.21; m/z 
(EI) 219 (M
+
(
81
Br)-CH3, 33%), 217 (M
+
(
79
Br)-CH3, 33%). 
 
  
 
(-)-cis-(3aS,7aS)-7-Phenylsulfanyl-2,2-dimethyl-3a,4,5,7a-
tetrahydro-1,3-benzodioxole 155. 
 
 
A solution of acetonide 154 (4g, 17.2mmol) in dry THF (100 cm
3
) was treated with a 
solution of t-butyllithium in hexane (11.5 cm
3
, 17.2mmol, 1.5M) at – 80 
o
C under a 
N2 gas atmosphere.  After stirring the reaction mixture for 1hr, a solution of 
diphenyldisulfide (4.9g, 22.4mmol) in THF (15 cm
3
) was added to it dropwise; it was 
left for stirring at – 80 
o
C for another hour and then at – 41 
o
C overnight. The solvent 
was evaporated off, the crude product was taken up in Et2O (150 cm
3
) and the Et2O 
solution washed with (5%) aqueous K2CO3 solution. The crude mixture, left behind 
after removal of Et2O, was purified by column chromatography (Et2O/hexane) to give 
acetonide sulfide 155 (4.20g, 93%) as a yellow oil, which crystallised on standing; mp 
52 
o
C (from MeOH); Rf 0.45 (25%  Et2O/hexane); [!]D – 28 (c 1.5, CHCl3); (Found: 
M
+
, 262.1015. C15H18O2S requires 262.1028); $H (500 MHz, CDCl3) 1.36 (3 H, s, 
CMeAMeB), 1.44 (3 H, s, CMeAMeB), 1.78 (1 H, m, 5-CHAHB), 1.99 (1 H, m, 5-
CHAHB), 2.07 (1 H, m, 6-CHAHB), 2.32 (1 H, m, 6-CHAHB), 4.38 (2 H, m, 1- & 2-H), 
6.10 (1 H, dd, J 5.3, J 3.1, 4-H), 7.23-7.31 (3 H, m, Ar), 7.40 (2 H, d, J 7.4, Ar); $C 
(125 MHz, CDCl3) 21.95, 25.33, 26.33, 27.75, 73.26, 73.69, 108.92, 127.02, 129.02, 
131.30, 132.34, 134.02, 134.99; m/z (EI) 262 (M
+
, 68%), 247 (M
+
-CH3, 13%).  
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To a solution of acetonide sulfide 155 (1g, 3.8mmol) in CHCl3 (50 cm
3
), maintained 
at 0 
o
C was added dropwise (30 min.) a solution of MCPBA (0.7g, 4.1mmol) in 
CHCl3 (50 cm
3
); the mixture was stirred for 3hr. The organic layer was separated, 
washed with aqueous (5%) K2CO3 solution, dried (Na2SO4) and the solvent 
evaporated off. The crude product was separated by PLC (Et2O) into two acetonide 
sulfoxide 156, 157 and  sulfone 158: 
 
 
 
(-)-cis-(3aS,7aS)-2,2-Dimethyl-7-(phenylsulfinyl)-
3a,4,5,7atetrahydro-1,3-benzodioxole 156. 
 
 
Sulfoxide 156 (0.48g, 45%), a white crystalline solid; mp 87-90 
o
C (from Et2O); Rf 
0.50 (Et2O); [!]D – 48.6 (c 1.5, CHCl3); (Found: M
+
, 278.0982. C15H18O3S requires 
278.0977); (Found: C, 64.3; H, 6.6. C15H18O3S requires C, 64.7; H, 6.52 %); $H (500 
MHz, CDCl3) 1.32 (6 H, s, Me), 1.64 (1 H, m, 6-CHAHB), 2.06 (1 H, m, 6-CHAHB), 
2.23 (1 H, m, 5-CHAHB), 2.45 (1 H, m, 5-CHAHB), 4.17 (1 H, d, J 5.4, 2-H), 4.32 (1 
H, m, 1-H), 6.78 (1 H, dd, J 5.5, J 2.7, 4-H), 7.49 (3 H, m, Ar), 7.69 (2 H, m, Ar); $C 
(125 MHz, CDCl3) 20.58, 24.31, 26.52, 27.57, 69.33, 73.34, 109.90, 125.47, 127.55, 
130.73, 131.31, 142.81, 142.82; m/z (EI) 278 (M
+
, 15%), 263 (M
+
-CH3, 11%), 220 
(M
+
-C3H6O, 100%). 
 
 
 
(+)-cis-(3aS,7aS)-2,2Dimethyl-7-(phenylsulfinyl)-
3a,4,5,7a-tetrahydro-1,3-benzodioxole 157. 
 
 
Sulfoxide 157 (0.48g, 45%), a colourless crystalline solid; mp 80-82
o
C (from Et2O); 
Rf 0.36 (Et2O); [!]D + 121 (c 1.5, CHCl3); (Found: M
+
, 278.0982. C15H18O3S requires 
278.0977); (Found: C, 64.3; H, 6.6. C15H18O3S requires C, 64.7; H, 6.5 %); $H (500 
MHz, CDCl3) 1.05 (3 H, s, CMeAMeB), 1.27 (3 H, s, CMeAMeB), 1.67 (1 H, m, 6-
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CHAHB), 2.02 (1 H, m, 6-CHAHB), 2.20 (1 H, m, 5-CHAHB), 2.40 (1 H, m, 5-CHAHB), 
4.38 (1 H, m, 1-H), 4.68 (1 H, d, J 5.8, 2-H), 6.74 (1 H, dd, J 5.9, J 2.8, 4-H), 7.47 (3 
H, m, Ar), 7.68 (2 H, m, Ar); $C (125 MHz, CDCl3) 20.84, 25.41, 26.09, 26.99, 70.22, 
73.47, 109.40, 125.60, 128.88, 130.97, 135.18, 143.48, 143.73; m/z (EI) 278 (M
+
, 
15%), 263 (M
+
-CH3, 11%), 220 (M
+
-C3H6O, 100%). 
 
 
  
(-)-cis-(3aS,7aS)-2,2-Dimethyl-7-(phenylsulfonyl)-
3a,4,5,7a-tetrahydro-1,3-benzodioxole 158. 
 
 
Sulfone 158 was a minor product (56mg, 5%), white crystalline solid; mp 129
o
C 
(from MeOH); Rf 0.76 (Et2O); [!]D - 154 (c 1, CHCl3) (Found: M
+
, 294.0926. 
C15H18O4S requires 294.0941); (Found: C, 61.1; H, 6.3. C15H18O4S requires C, 61.2; 
H, 6.2 %); $H (500 MHz, CDCl3) 0.69 (3 H, s, CMeAMeB), 1.23 (3 H, s, CMeAMeB), 
1.71 (1 H, m, 6-CHAHB), 2.07 (1 H, m, 6-CHAHB), 2.27 (1 H, m, 5-CHAHB), 2.41 (1 
H, m, 5-CHAHB), 4.42 (1 H, m, 1-H), 4.98 (1 H, d, J 4.7, 2-H), 7.24 (1 H, dd, J 6.0, J 
2.4, 4-H), 7.48 (2 H, m, Ar), 7.57 (1 H, m, Ar), 7.92 (2 H, d, J 7.3, Ar); $H (125 MHz, 
CDCl3) 20.76, 24.21, 26.31, 26.49, 70.26, 72.94, 109.07, 128.57, 128.75, 132.99, 
140.51, 141.35, 142.42; m/z (EI) 295 (M
+•+1, 3%), 279 (M
+•-CH3, 100%). 
 
A solution of unseparated acetonide sulfoxides 156 and 157 (1:1, 400mg, 1.45mmol) 
in TFA/H2O/THF (1:2:8, 30 cm
3
) was kept at 40 
o
C  for 8hr. On completion of the 
deprotection reaction, monitored by TLC, the solvent mixture was evaporated under 
reduced pressure and the residue taken up in EtOAc (50 cm
3
); the EtOAc extract was 
washed with a saturated solution of NaHCO3, dried  (Na2SO4) and the solvent 
removed.  The crude mixture  was separated by PLC into diolsulfoxides 160 and 159: 
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(-)-cis-(1S,2S)-3-(S-Phenylsulfinyl)cyclohex-3-ene-1,2-diol 
160. 
 
 
Diolsulfoxide 160  (120mg, 35%), white crystalline solid; mp 145-150 
o
C (from 
Et2O); Rf 0.35 (8% MeOH/CHCl3); [!]D – 6.6 (c 1, CHCl3); (Found: M
+
,
 
238.0658. 
C12H14O3S requires 238.0664); $H (500 MHz, CDCl3) 1.58 (1 H, m, 6-CHAHB), 1.95 
(1 H, m, 6-CHAHB), 2.19 (1 H, m, 5-CHAHB), 2.58 (1 H, m, 5-CHAHB), 3.65 (1 H, m, 
1-H), 4.29 (1 H, d, J 4.0, 2-H), 6.77 (1 H, dd, J 7.5, J 3.8, 4-H), 7.51-7.63 (5 H, m, 
Ar); $C (125 MHz, CDCl3) 23.80, 25.05, 66.21, 67.87, 124.39, 129.38, 131.06, 
139.03, 141.15, 141.48; m/z (EI) 238 (M
+
, 15%), 220 (M
+
-H2O, 5%).  
 
 
 
 
(-)-cis-(1S,2S)-3-(R-Phenylsulfinyl)cyclohex-3-ene-1,2-diol 
159. 
 
 
Diolsulfoxide 159 (120mg, 35%), a semi-solid; Rf 0.32 (8% MeOH/CHCl3); [!]D – 
88.5 (c 1.0, CHCl3); (Found: M
+
,
 
238.0658. C12H14O3S requires 238.0664); $H (500 
MHz, (CD3)2CO) 1.43-1.49 (1 H, m, 6-CHAHB), 1.66-1.75 (1 H, m, 6-CHAHB), 2.03-
2.13 (1 H, m, 5-CHAHB), 2.28-2.37 (1 H, m, 5-CHAHB), 3.54 (1 H, m, 1-H), 3.71 (2 H, 
m, 2-H & OH), 3.88 (1 H, m, OH), 6.47 (1 H, m, 4-H), 7.41 (3 H, m, Ar), 7.57 (2 H, 
m, Ar); $C (125 MHz, (CD3)2CO) 23.00, 25.39, 64.64, 68.24, 125.10, 128.95, 129.79, 
130.76, 144.39, 144.58; m/z (EI) ) 238 (M
+
, 13%), 220 (M
+
-H2O, 15%). 
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5.15. Synthesis of enantiopure benzyl-para-tolyl sulfoxide 91. 
 
 
 
(+)-(R)-Benzyl-p-tolylsulfoxide (R)-91. 
 
 
Benzyl magnesium bromide solution (4.1cm
3
, 4.1mmol, 1M, Et2O) was added 
(30min), at 0 
o
C, to a solution of (R)-menthyl-p-tolyl sulfinate (R)-163 (1g, 3.4mmol) 
in dry THF (30 cm
3
). After stirring (1hr) the reaction mixture at room temperature the 
solvent was evaporated and EtOAc (75 cm
3
) was added to the residue. The mixture 
was shaken with a solution HCl (50 cm
3
, 3M) until all the solid particles had 
dispersed; the EtOAc layer was separated, washed with water and dried (Na2SO4). 
The  crude product left behind, after removal of solvent, was purified by column 
chromatography (Et2O) to furnish sulfoxide R)-91 (0.78g, 81%) as a white crystalline 
solid; [!]D + 247 (c 0.1, acetone) (lit.
146
 + 228, acetone). 
 
 
   
(+)-(3S)-2-Methyl-1-(R-4-
methylphenylsulfinyl)-1-phenylpropan-2-ol 
166. 
 
Bu
t
Li solution in hexane (0.8 cm
3
, 1.0mmol, 1.3M, hexane) was added to a solution of 
sulfoxide (R)-91 (200mg, 0.87mmol) in anhydrous THF (20 cm
3
) at – 70 
o
C. After 
leaving the reaction mixture stirred (0.5hr) at – 70 
o
C, dry acetone (1 cm
3
) was added 
and the reaction mixture allowed to warm to room temperature; the reaction was 
quenched by the addition of a solution of NH4Cl (25 cm
3
, 10%).  Most of the THF 
was distilled off under reduced pressure and the remaining liquid reaction mixture  
extracted with EtOAc (2 x 30 cm
3
). The extract was dried (Na2SO4), solvent 
evaporated off and the crude product obtained was purified by PLC (CHCl3) to yield 
sulfoxide 166 (165mg, 66%) as a colourless crystalline solid; mp 164 
o
C (from 
MeOH); Rf 0.30 (CHCl3); [!]D +372 (c 0.4, CHCl3) (Found: M
+
-C7H7OS, 149.0965. 
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C10H13O requires 149.0966); $H (500 MHz, CDCl3) 1.29 (3 H, s, CMeAMeB), 1.77 (3 
H, s, CMeAMeB), 2.28 (3 H, s, ArMe), 3.32 (1 H, s, CH), 3.66 (1 H, s, OH), 6.96 (2 H, 
d, J 8.2, Ar), 7.02 (2 H, d, J 8.0, Ar), 7.11 (3 H, m, Ar), 7.19 (2 H, m, Ar); $C (125 
MHz, CDCl3) 20.30, 28.29, 29.56, 73.28, 76.50, 123.17, 126.49, 126.87, 128.13, 
129.69, 130.02, 136.86, 139.93; m/z (EI) 149 (M
+
-C7H7OS, 97%), 139 (M
+
-C10H13O, 
44%), 91 (M
+
-C10H13O2S, 100%). 
 
 
 
(+)-(2S)-2-(R-4-Methylphenylsulfinyl)-1,1,2-
triphenylethan-1-ol 167. 
 
Sulfoxide (R)-91 (200mg, 0.87mmol), Bu
t
Li solution (0.8 cm
3
, 1.0mmol, 1.3M, 
hexane) and benzophenone 165 (230mg, 1.3mmol) were reacted following the 
procedure described for the synthesis of sulfoxide 166 to yield sulfoxide 167 (255mg, 
71%) as  colourless crystalline solid; mp 143 
o
C (from MeOH); Rf 0.45 (Et2O); [!]D 
+137 (c 0.7, CHCl3); (Found: M
+
, 412.1474. C27H24O2S requires 412.1497); $H (500 
MHz, CDCl3) 2.27 (3 H, s, ArMe), 4.48 (1 H, s, CH), 5.86 (1 H, s, OH), 6.90 (2 H, d, 
J 8.2, Ar), 6.95-7.07 (10 H, m, Ar), 7.35 (3 H, m, Ar), 7.49 (2 H, m, Ar), 7.88 (2 H, d, 
J 7.4, Ar); $C (125 MHz, CDCl3) 21.36, 74.79, 81.71, 124.33, 125.46, 126.17, 126.46, 
127.30, 127.48, 127.65, 127.76, 128.70, 129.16, 130.41, 131.36, 137.10, 141.37, 
144.97, 146.15; m/z (EI) 394 (M
+
-H2O, 0.25%), 287 (M
+
-C6H6OS, 31%), 273 (M
+
-
C7H7OS, 22%), 256 (M
+
-C7H8O2S, 100%). 
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